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ABSTRACT
Introduction Staphylococcus aureus bacteraemia (SAB) is increasingly common in both
community and health care settings. Clinical investigations have demonstrated some fun-
damental elements in the management of SAB. Intravenously administered antimicrobial
therapy is indispensable and needs to be initiated without delay. The presence of deep in-
fection foci dictate duration of therapy, and ?-lactam antibiotics are superior in methicillin-
sensitive S. aureus (MSSA) bacteraemia and should be preferred whenever possible. Deep
infection foci, including infected foreign devices (both permanent and non-permanent),
should be meticulously sought and eradicated whenever possible. However, despite the
use of effective antistaphylococcal antibiotics, radiological investigations, intensive care
unit surveillance and invasive or surgical interventions, the overall mortality in SAB has re-
mained high and has ranged from 14% to 32% in recent studies. No substantial reduction
in overall SAB mortality has been observed in the past two decades.
The present studies were performed to evaluate factors that may affect progression and
prognosis in SAB. The following studies were undertaken: 1) evaluation of predisposing
factors, severity of illness, clinical picture and outcome of methicillin-sensitive health care-
associated (HA-) and community-associated (CA-) SAB in disease progression and prog-
nosis, 2) comparison of the prognostic value of cell-free DNA (cf-DNA) and C-reactive pro-
tein as biomarkers among ICU and non-ICU SAB patients, 3) evaluation of the impact of
bedside (formal) infectious disease specialist consultation (IDSC), telephone (informal)
IDSC and no IDSC on disease progression and prognosis, 4) investigation of the impact of
rifampicin (RMP) combination therapy on outcome.
Study population The studies were based on 430 prospectively followed SAB patients in a
nationwide multicentre study in 1999-2002 and retrospectively collected data from all SAB
patients (n=187) in Helsinki University Central Hospital in 2000-2002 and 2006-2007. For
studies on comparison of HA- and CA-SAB and cell-free DNA as a prognostic marker alone
the prospective patient cohort was used. IDSC and RMP combination therapy were ana-
lysed from the retrospective patient cohort.
Main results CA-SAB cases represented 46% of all SAB cases and differed from the HA-
SAB cases in many respects. CA-SAB patients, as compared with HA-SAB cases, were
younger (52.9±19.5 vs. 62.4±15.2 years, ±SD, p <0.0001), had less chronically ill cases
(12% vs. 41% of patients, p <0.0001, in McCabe’s classification) and presented higher
prevalence of deep infection foci within three days of S. aureus-positive blood culture (84%
vs. 69%, p <0.0001). No significant difference in mortality was observed between CA- and
HA-SAB at 28 days (11% vs. 14%), whereas at three months the mortality difference was
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significant (13% vs. 22%, p=0.023). Factors independently predicting outcome were age (p
<0.0001), alcoholism (p=0.020), immunosuppressive treatment (p=0.007), underlying dis-
eases (p=0.002), severe sepsis at positive blood culture (p=0.022), S. aureus pneumonia
(p<0.0001) and endocarditis (p=0.007). High Pitt bacteraemia scores and ICU treatment
presented high cf-DNA values at both days 3 and 5. At day 3, cf-DNA cut-off value >1.99
?g/mL among ICU SAB patients predicted mortality with a sensitivity of 67% and a specific-
ity of 77%. High Pitt bacteraemia scores and day 3 cf-DNA were the strongest factors sig-
nificantly predicting outcome in ICU patients when accounting for all prognostic factors. Cf-
DNA at day 5 was more dependent on patient age and underlying diseases and did not
predict outcome. CRP had no mortality predictive value for either ICU or non-ICU SAB pa-
tients. Most SAB patients received bedside IDSC (72%). Bedside (formal) IDSC, as com-
pared with telephone (informal) IDSC, was associated with more localized deep infection
foci (78% vs. 53%, p<0.0001) and lower mortality at seven days (1% vs. 8%, p=0.001), at
28 days (5% vs. 16%, p=0.002) and at three months (9% vs. 29%, p <0.0001). When all
prognostic factors were controlled, the three-month mortality for telephone IDSC patients
was higher (OR, 2.31) as than that for bedside IDSC patients. Adjunctive rifampicin therapy
for at least 14 days was received by 47% of SAB patients, and among 88% of them the
therapy was initiated within seven days of S. aureus-positive blood culture. Early onset ad-
junctive rifampicin therapy for at least 14 days was linked to significantly reduced risk for fa-
tal outcome (OR 0.38), and the risk was even lower in patients with a deep infection focus
(OR 0.29). Late-onset rifampicin therapy or rifampicin therapy for less than 14 days did not
have any prognostic impact.
Conclusions The overall prevalence of deep foci exceeded those reported in previous
studies. As in many previous reports, CA- and HA-SAB patients differed regarding patient
characteristics, severity of illness, deep infection foci prevalence and outcome. CA- and
HA-SAB should be viewed as two different entities. The prospective study design and IDS
surveillance contributed to a high number of deep infection foci diagnosed already within
three days of S. aureus-positive blood culture and to overall low mortality rates. The prog-
nostic value of cf-DNA in SAB patients with ICU treatment was evident. The study clearly
indicated that cf-DNA was associated with high Pitt bacteraemia scores and ICU treatment,
and ICU non-survivors present high cf-DNA values irrespective of time of death. Bedside
(formal) IDSC appeared to be superior to telephone (informal) IDSC with respect to radio-
logical investigations provided, deep foci localization, appropriate antibiotic therapy and
outcome. SAB cases should be provided with formal bedside IDSC whenever possible.
SAB patients, especially those with deep infection foci, seemed to gain from adjunctive ri-
fampicin therapy initiated within seven days of S. aureus-positive blood culture and contin-
ued for at least 14 days. A positive prognostic impact of early initiation of rifampicin adjunc-
tive therapy on MSSA bacteraemia was demonstrated for the first time.
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1. INTRODUCTION
Staphylococcus aureus is a major pathogen of both community- (CA-) and health care-
associated (HA-) bacteraemias and results in considerable morbidity and mortality [1,2,3].
Throughout the last decades, the incidence of S. aureus bacteraemia (SAB) has increased
both worldwide and in Finland [4,5,6,7]. Today, S. aureus is responsible for 11-20% of bac-
teraemias worldwide [8,9,10,11].
Mortality associated with SAB is remarkably high, ranging from 14% to 32% in recent stud-
ies [2,3,12,13,14,15,16,17,18]. High mortality is encountered despite the availability of an-
tistaphylococcal antimicrobial therapy [19], high-standard radiological investigations such
as transthoracal and transoesophageal echocardiographies [20,21], improved accessibility
to intensive care unit surveillance [3] and better possibilities for surgical interventions and
deep infection foci eradication [22]. Prognosis of SAB is impacted by patient-specific back-
ground characteristics such as age and underlying diseases [22,23], severity of illness at S.
aureus-positive blood culture [24,25], development of complications e.g. endocarditis or
persistent SAB and uneradicated deep infection foci [3,26] and clinical management such
as appropriate antimicrobial therapy [19,22].
Several aspects of SAB have received more attention in recent years. CA- and HA-SAB
are increasingly recognized as completely different entities. CA-SAB patients are younger,
healthier, more often injection drug users (IDUs) and in 20-61% of cases present with no
port of entry or no primary focus (i.e. primary SAB) [2,7,19,27,28,29]. In addition, they have
a high occurrence of deep infection foci and endocarditis [2,3,7,19,28] and an increased
risk for persistent SAB (positive blood cultures subsequent to onset of appropriate antibiotic
therapy) [30]. In HA-SAB, the source of bacteraemia is mostly iatrogenic with catheter-
related aetiology in 21-64% of patients and wound or surgery related infections are com-
mon [2,3,7,19,28,29] and a low occurrence of deep infection foci is observed [2,7,28].
The standard antimicrobial therapy of methicillin-sensitive SAB is a ?-lactam, with semisyn-
thetic penicillin as the drug of choice [15,31,32], whereas first- or second-generation cepha-
losporins or clindamycin are the choice for patients with non-anaphylactic semisynthetic
penicillin allergy [31,33,34]. However, the bacteriostatic nature of clindamycin is associated
with an increased relapse risk, and hence, clindamycin is not recommended for treatment
of endocarditis in SAB [31,34,35]. For SAB patients with severe penicillin-cephalosporin al-
lergy, vancomycin constitutes the standard treatment [36,37], although several reports
connect vancomycin therapy to treatment failures as compared with ?-lactams [22,38,39,
40,41]. For methicillin-resistant SAB, vancomycin is the drug of choice [36]. Short par-
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enteral antibiotic therapy for 10-14 days is usually sufficient for uncomplicated SAB and for
most cases of catheter-related SAB when the catheter has been removed [42,43,44,45],
whereas parenteral therapy for 4 (-6) weeks is the standard practice for patients with deep
or metastatic infection foci, left-sided endocarditis and non-eradicable primary foci. This
expert opinion is, however, backed by only limited scientific evidence [31,46,47,48].
The impact of methicillin-resistant S. aureus (MRSA) bacteraemia, delayed onset of appro-
priate antimicrobial therapy and infectious disease specialist consultation (IDSC) -guided
SAB management are topics intensively debated in recent years [3,49,50]. Several reports
connect MRSA bacteraemia to both poor prognosis and delay in onset of appropriate an-
timicrobial therapy [49,51,52]. Delayed effective antimicrobial therapy is known to be a ma-
jor risk for poor prognosis in SAB [50]. Vancomycin, the first-line therapy for MRSA, results
in a higher risk for persistent and recurrent SAB than the standard staphylococcal penicillin
cloxacillin [53]. However, bacteraemic infections due to MRSA are rare in Finland, with
MRSA prevalence remaining near 3% in SAB [54]. IDSC-guided SAB management has re-
cently been shown to enhance proper antibiotic selection [55] and improve diagnostics [56],
with more deep foci localized [57], reducing mortality [3,57]. The nature of the IDSC are,
however, mostly undescribed [3,16,18,56,58].
The antimicrobial agent rifampicin and its role in invasive and bacteraemic S. aureus infec-
tions have received much attention, as rifampicin possesses potentially valuable antimicro-
bial characteristics, such as bactericidal and high antistaphylococcal activity for both methi-
cillin-sensitive S. aureus (MSSA) and MRSA, biofilm-penetrating features and capability of
achieving high intracellular concentrations [59,60,61,62,63,64,65]. Monotherapy with rifam-
picin results in rapid resistance development, and thus, combination therapy is a prerequi-
site for this agent [36,66,67,68]. However, in vitro studies with rifampicin have presented
conflicting results. In vitro studies on the efficacy and interaction of combining rifampicin
and oxacillin (semisynthetic penicillin) have reported antagonistic or indifferent interactions
[69], no antagonism [70] or antagonism (at high oxacillin concentrations) and synergy (at
low oxacillin concentrations) [71]. A recent review concluded that in vitro studies are heavily
method-dependent and have limited relevance in clinical practice [72]. Animal studies with
rifampicin combination therapy have been more encouraging, with reports of e.g. standard
therapy (nafcillin or vancomycin) and rifampicin in chronic osteomyelitis leading to non-
significantly [73] and significantly [74] improved results compared with monotherapy.
Clinical studies with rifampicin combination therapy in invasive and bacteraemic S. aureus
infections have been small-sized and underpowered [66,75,76,77,78,79], although in two
reports the patient number is considerable (93 and 381) [15,80]. Rifampicin combination
therapy in patient cohorts with low MRSA prevalence have improved clinical progression
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and outcome. However, patient cohorts with high MRSA prevalence have reported pro-
longed SAB [81,82], development of rifampicin resistance [82,83,84] and poorer clinical
outcome [82,83,84]. The optimal time-point for rifampicin adjunctive therapy remains a mat-
ter of debate, as no prospective studies have investigated this topic. However, a retrospec-
tive report [82] and general guidelines [36] for high MRSA prevalence recommend rifam-
picin onset after bacteraemia clearance. These recommendations apply, however, only to
patient populations with a high MRSA prevalence, and no recommendations are available
for low MRSA or solely MSSA bacteraemia. The exact role of rifampicin in SAB manage-
ment remains to be elucidated.
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2. REVIEW OF THE LITERATURE
2.1. Incidence of Staphylococcus aureus bacteraemia
The current, precise incidence of SAB remains a matter of debate, as most SAB studies
are limited to specific hospitals [2,3,19] and few population-based surveillance studies re-
porting incidence trends are available. Several reports indicate increased incidence of SAB
and SAB-related complications, e.g. deep infection foci such as endocarditis, over the past
decades [4,5,6,7]. Countries with low MRSA prevalences, such as Finland, the Scandina-
vian countries and Canada, have generally reported a low annual SAB incidence of 14-28
episodes /100 000 person-years [6,7,29,85,86,87], whereas countries with high MRSA
prevalence, such as England, Wales, Northern Ireland, United States and Australia, have
reported much higher SAB incidences of 32-39 episodes /100 000 person-years [88,89,
90,91]. Several factors, including advanced age [6,7,85], male gender [6,85,92] and MRSA
[92], have been associated with increased incidence of SAB.
However, a multinational population-based surveillance study from 2012 [93] concluded
that the overall SAB incidence is not increasing, although MRSA bacteraemia incidence is
rising, and a very recent Danish rapport [94] from 2014 observed a decreasing incidence of
SAB, from 30.8 episodes /100 000 person-years in 2000-2002 to 24.4 episodes /100 000
person-years in 2006-2008. Further research is required to establish whether a change in
the incidence trend of SAB is occurring.
2.2. Predisposing factors for Staphylococcus aureus bacteraemia
2.2.1. Microbiology and carriage of Staphylococcus aureus bacteria
2.2.1.1. Microbiological aspects of Staphylococcus aureus
S. aureus is a facultative anaerobic Gram-positive coccal bacterium and the most virulent
among the staphylococci family. S. aureus is visualized as grape-like cocci clusters under
the microscope [1]. Various biochemical characteristics distinguish S. aureus from the other
Gram-positive bacteria. The catalase-positive nature of S. aureus distinguishes staphylo-
cocci from enterococci and streptococci, whereas positive coagulase tests, mannitol-
fermentation and deoxyribonuclease tests separate S. aureus from other staphylococcal
bacteria [1,95]. The production and secretion of enzymes and exotoxins represent essential
virulence factors for S. aureus, e.g. coagulase that enables clotting of plasma and coating
of bacterial cells to prevent phagocytosis, hyaluronidase that breaks hyaluronic acid, facili-
tating spread of S. aureus exotoxins that demonstrate superantigen activity capable of in-
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ducing toxic shock syndrome or exfoliative toxins capable of initiating staphylococ-
cal scalded-skin syndrome [1,95,96,97].
2.2.1.2. Colonization with Staphylococcus aureus
Colonization of skin and mucous membranes with S. aureus is increasingly recognized as
a major predisposing factor for SAB and invasive S. aureus infections (ISA infections). Sev-
eral body areas, such as the perineum or the throat, are viewed as potential colonization
areas, although the anterior nasal region is regarded as the primary ecological and en-
dogenous reservoir site [98]. Within the healthy population, approximately 20% of individu-
als are persistent nasal carriers, whereas 30% are viewed as intermittent carriers and 50%
as non-carriers [99,100,101]. The prevalence of nasal carriage varies according to age,
gender, living habitats and underlying conditions, with higher occurrence associated with
young age [102,103], male gender [102], imprisonment and crowded living conditions [104],
hospitalization [102,103] and chronic diseases such as HIV/AIDS [105] and diabetes melli-
tus [102].
2.2.1.3. Clinical impact of nasal Staphylococcus aureus carriage
Nasal carriage of S. aureus has appeared to be a major predisposing factor for both com-
munity- and health care-associated SAB as well as S. aureus infections related to invasive
or surgical procedures. Nasal S. aureus carriers have a two- to nine-fold higher risk for sur-
gical-site infections as compared with non-carriers [100,106,107,108,109]. The risk for S.
aureus infections concerns persistent carriers. Intermittent carriers have an infection risk
similar to that of non-carriers, and the infection risk is significantly lower than that of persis-
tent carriers [110]. In HA-SAB, up to 80% of S. aureus blood culture isolates have been
identical to the ones from the anterior nasal region of the patient, proclaiming an endoge-
nous origin of SAB [100,108]. In superficial skin infections, up to 100% of the S. aureus
skin culture isolates have matched the anterior nasal S. aureus isolates [109]. However,
among patients with HA-SAB the all-cause mortality and SAB-related mortality have been
significantly lower in S. aureus nasal carriers than in non-carriers [100].
2.2.1.4. Decolonization of Staphylococcus aureus carriage
Eradication and decolonization of nasal S. aureus carriage through the use of an an-
tistaphylococcal agent, usually mupirocin, has been explored as one method of preventing
SAB and ISA infections in various patient populations [98,111,112,113,114]. So far, only
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specific patient groups seem to significantly gain from mupirocin. The most encouraging
results have been achieved among dialysis patients, where mupirocin application reduced
both S. aureus peritonitis in peritoneal dialysis patients and SAB occurrence in haemodi-
alysis [113,114]. However, mupirocin failed to reduce surgical-site S. aureus infections in
general surgical or orthopaedic patients [111], although it significantly reduced overall
health care-associated and endogenous S. aureus infections among carriers [112]. Among
non-surgical patients, no significant impact of mupirocin was observed for health care-
associated S. aureus infections [98]. Two studies from 2007 and 2009 investigated the im-
pact of body washing with the antiseptic chlorhexidine among ICU patients to reduce
MRSA colonization and MRSA bacteraemia and reported significantly reduced MRSA
colonization, whereas no significant change in MRSA bacteraemia occurred [115,116].
2.2.2. Patient-related underlying factors for Staphylococcus aureus bacteraemia
2.2.2.1. Impact of age and gender
High age and male gender are generally viewed as major risk factors for SAB. Patients
younger than 1 year or older than 60 years and males are reported to be at increased risk
for SAB in several recently performed population-based studies [6,29,87,117,118]. Epide-
miological studies have demonstrated a rising incidence of SAB in recent decades in both
Finland [6] and worldwide [7,92], and this increase has occurred predominantly in patients
with higher age and male gender [6,87,92,118].
2.2.2.2. Impact of underlying diseases
The vast majority of SAB patients have some underlying disease such as cardiovascular
disease, chronic pulmonary disease, chronic liver disease, chronic renal failure and dialysis
need, malignancy, diabetes mellitus and autoimmune disease [2,7,14,15,17,19,29,
85,120,121,122,123,124]. In studies from the 1990s, only 3-5% of SAB patients had no un-
derlying diseases [27,119], whereas in the 2000s, almost one-third of SAB patients had no
underlying diseases [120] and over half of SAB patients, depending on SAB acquisition,
had no chronic illnesses [7]. Very recently, 41% of SAB patients were reported to be
healthy [23].
Haemo- and peritoneal dialysis have been observed to increase the risk of SAB (RR 150-
360) along with several other much weaker predisposing factors such as rheumatoid arthri-
tis (RR 2.2-2.6), diabetes (RR 7.0-10.6), malignancy (RR 12.9-13.6) and HIV infection (RR
17.1-23.7) [85,87]. Immunosupression has been shown to be a major predisposing factor
for SAB in connection with radiation therapy or immunosupressive medication, e.g. chemo-
therapy or corticosteroid treatment [14,17,121,123]. The most commonly reported immuno-
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suppressive conditions among SAB patients have been HIV/AIDS (1-5%) [3,12,14,15,122]
and neutropenia (1-16%) [22,40,123].
2.2.2.3. Impact of substance abuse
Among SAB patients, alcohol abuse and alcoholism have been identified in 5-14% and IDU
in 2-31% [2,14,15,19,29,87,120,121,122,123,124]. The alcohol-related increased infection
risk is multifactorial. Several studies associate alcohol abuse with malnutrition, poor dental
hygiene and aspiration risk [125]. Alcoholism is known to impair the immune system
through modifications in macrophage and neutrophil function and to cause dysfunction of
lung surfactant and cilia [125,126]. Alcohol abuse is viewed as a significant risk factor for
severe bacteraemic infections [127], and alcoholism is a risk factor for sepsis among ICU
patients [128]. S. aureus is viewed as the most relevant IDU bacterial pathogen [129,130].
Several factors are proposed to contribute to the high incidence of S. aureus infections in
IDUs such as higher S. aureus colonization rates than in non IDUs [131], increased infec-
tion risk due to poor hygiene and unsterile injection habits [132,133] and S. aureus trans-
mission through sharing of injection equipment [134].
2.2.3. Destruction of skin and mucous membrane
The presence of intact skin provides an excellent defence against S. aureus. However, any
damage, such as trauma, invasive or surgical procedures, implantation of foreign body ma-
terial or injection drug use, enables S. aureus to penetrate the skin barrier and disseminate
to deeper tissues or the bloodstream, with bacteraemia as a consequence [135]. Factors
destroying intact skin and mucous membranes, are well-recognized predisposing factors,
especially among HA-SAB patients [2,12,15,122,123]. Catheter-related SAB is present in
21-64% of HA-SAB patients [2,3,28,29], whereas wounds and surgical infections occur in
6-16% [7,19,28]. Some studies report that 11-23% of SAB patients have undergone sur-
gery in the previous one to three months [15,136]. Chronic dialysis as a predisposing factor
is reported in 7-19% of SAB cases [7,19]. Several studies report trauma as a risk for SAB,
with up to 26% of SAB patients having experienced some trauma two months prior to S.
aureus-positive blood culture [15,87].
2.3. Clinical picture of Staphylococcus aureus bacteraemia
2.3.1. Staphylococcus aureus-positive blood culture
The clinical characteristics and symptoms at SAB presentation may be non-specific, with
the clinical picture varying from afebrile to critically ill with high fever, septic shock, adult
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respiratory distress syndrome (ARDS), disseminated intravascular coagulation (DIC) and
need for ICU treatment [2,3,31,57].
Fever is the most common symptom among 72-96% of patients on or before hospital ad-
mission [19,29]. Fever commonly persists, as 39% of patients have been reported to have
fever 72 hours after onset of appropriate antimicrobial therapy [121]. Among patients with
SAB and endocarditis, up to 100% present with fever [137]. Other common symptoms are
chills, nausea and fatigue [29].
When patients seek medical treatment for SAB, haemodynamic complications, sepsis and
severe organ complications are commonly observed. In SAB, lack of sepsis has been re-
ported in 2% of patients [58], whereas 10-25% of patients may suffer from haemodynamic
instability such as severe sepsis or septic shock [2,3,19,28,58,121,138]. Up to 20% of pa-
tients present with some degree of organ failure [28], with 3% suffering from adult respira-
tory distress syndrome (ARDS) [2,28], 6% needing mechanical ventilation [2], 5-22% hav-
ing acute renal failure [2,3,28,138] and 1-2% having disseminated intravascular coagulation
(DIC) [2,28]. ICU treatment is needed in 16-32% of patients [2,18,57].
Various scoring systems for assessment of severity of illness and outcome prediction have
been developed, e.g. the Acute Physiology and Chronic Health Evaluation II (APACHE II)
or Sequential Organ Failure Assessment (SOFA) score [139,140]. However, although the
APACHE II is efficient in determining the severity of illness among critically ill patients, it is
challenging to apply in clinical practice due to the complex score calculation procedure and
the requirement for altogether 12 parameters, including 6 laboratory tests (arterial pH, se-
rum sodium and potassium, creatinine, haematocrit and white blood cell count) [141]. As
with APACHE II, the SOFA score calculation is complex and requires several laboratory
parameters (platelet count, bilirubin and creatinine) [140]. The Pitt bacteraemia score is,
however, an alternative to APACHE II and SOFA scores, and it requires only 5 clinical pa-
rameters (fever, presence of hypotension, need for mechanical ventilation, cardiac arrest
event and altered mental status) [142]. Among SAB patients, the Pitt bacteraemia score
system reflects severity of illness [13,14] and among ICU patients with sepsis it predicts
mortality better than APACHE II [141].
2.3.2. Methicillin-resistant Staphylococcus aureus bacteraemia
Methicillin, a semisynthetic penicillin derivative, was presented in 1959 against penicillin-
resistant S. aureus strains. However, in 1961 the first MRSA strains emerged in the United
Kingdom [143], after which MRSA has steadily become more common and is now encoun-
tered worldwide [1]. The mechanism for methicillin resistance in S. aureus is  the  mecA
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gene, located on an DNA region named the staphylococcal cassette chromosome mec
(SCCmec element, found also in coagulase-negative staphylococci), encoding the penicil-
lin-binding protein 2a (PBP2a) [144,145]. PBPs are required for bacterial cell wall synthe-
sis. However, PBP2a differs from regular PBPs as it does not bind methicillin or other ?-
lactam antibiotics, hence, PBP2a can function despite the presence of methicillin or other
?-lactam antibiotics. The mechanism for MRSA is the expression of PBP2a, which is not
inhibited by methicillin or other ?-lactam antibiotics at concentrations that inhibit other PBPs
[146,147].
MRSA was for decades regarded as a health care-associated challenge, but in the 1990s
community-associated MRSA spread rapidly [148,149]. During the past decades the overall
incidence of SAB due to MRSA has increased without any corresponding decline in MSSA
bacteraemia [150,151]. Hence, the overall impact of SAB has increased. In the United
States, health care-associated MRSA bacteraemia increased from 35% in 1991 to 45% in
1997-1999 [152,153], whereas the overall MRSA bacteraemia incidence in the United
Kingdom and Wales increased from 4% in 1993 to 43% in 2002 [154]. The aetiology behind
rising MRSA rates is complex and probably multifactorial. However, the increase in MRSA
prevalence is associated with underlying diseases and comorbidity, prolonged hospitaliza-
tion and poor adherence to infection control precautions [5,155].
Patients with MRSA bacteraemia have been reported to be older and to more often have
previous MRSA colonization and a longer duration of hospitalization than patients with
MSSA bacteraemia [156,157,158]. Higher mortality in MRSA relative to MSSA bacteraemia
is a common observation – a topic discussed more in detail in section 2.7.3. As community-
associated MRSA infections emerged in the 1990s, several studies reported that CA-
MRSA frequently causes severe skin and soft tissue infections and severe necrotising
pneumonia linked to Panton-Valentine leukocidin (PVL) toxins [159,160,161,162, 163]. CA-
MRSA bacteraemias are increasing and have been associated with necrotizing pneumonia
and cutaneous abscesses, although no mortality difference relative to MSSA bacteraemias
has been observed [120].
2.3.3. Classification, characteristics and prevalence of infection foci
2.3.3.1. Categorization of infection foci
Infection foci in SAB are mostly defined as primary (i.e. cutaneous or portal of entry) or
secondary (i.e. deep or metastatic) [164,165,166] (see Tables 1 and 2a-b). Moreover, an
unknown portal of entry is defined as primary SAB [27]. Some authors classify SAB simply
as complicated or uncomplicated [21]. Furthermore, some authors have used definitions
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such as deep-seated foci [120], whereas others have only mentioned the foci with most
clinical relevance, e.g. endocarditis [167], and some report infection foci when they are
eradicable and eradicated [19,22,168]. Categorization as primary, secondary, cutaneous,
deep or metastatic foci are the most common categorization types [164,165,166], whereas
complicated and uncomplicated SAB are seldom used [21,30,136]. Many reports list the
occurrence of primary SAB, i.e. cases where the portal of entry or primary source of SAB is
unknown [27] (Table 1). The variable classification of infection foci in the literature makes
comparison of different patient materials cumbersome.
2.3.3.2. Primary infection foci
Various body locations may function as the primary site of infection. The recognition of SAB
foci as either primary or secondary was first introduced in 1976 [164], and SAB patients
were divided according to recognizable primary infection lesions. The primary S. aureus in-
fection focus was viewed as a potential portal of entry for the SAB if the clinical picture of
the primary focus preceded SAB, whereas secondary foci were viewed as metastatic infec-
tions. When no primary focus is found, the presence of an intravascular catheter or a post-
operative wound may be the primary focus [19]. Also the urinary tract may serve as a portal
of entry and a primary focus for SAB. Patients with urological challenges, such as long-
term care patients with frequent urine catheterization, often have S. aureus isolated from
urine samples. However, although the urinary tract may function as a primary focus, in
most cases simultaneous S. aureus bacteruria is a result of haematogenous spread and is
secondary to SAB [169,170,171,172]. The respiratory tract is identified as a primary source
in many reports [12,19,40].
2.3.3.3. Secondary, metastatic or deep infection foci
Due to haematogenous spread in SAB, virtually any organ may be infected [173] and the
infections are defined as secondary, metastatic or deep foci. However, S. aureus infections
are seldom the result of bacterial inoculation due to trauma or an iatrogenic process, e.g.
joint puncture, surgery or arthroscopy [12,44,173,174]. Foreign body infections and deep-
seated abscesses are often of haematogenous origin, although foreign body infections may
be postoperative without a bacteraemia phase [121,136,175,176]. Prosthetic joint infections
are commonly classified as early (i.e. development within 3 months of surgery), as delayed
(i.e. development within 3-24 months of surgery) and as late (i.e. development later than 24
months after surgery) [177,178]. Early and delayed prosthetic joint infections are mostly
achieved during the prosthesis implantation process, whereas late prosthetic joint infec-
tions are commonly of haematogenous origin where the skin, dental region or respiratory or
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urinary tract are frequent sources of SAB [179]. S. aureus pneumonia is predominantly of
haematogenous origin and may be due to release of infected tricuspidal vegetations or re-
lease of infected thrombotic material in the venous system [19,180]. S. aureus meningitis is
most often postoperative and on rare occasions haematogenous (due to massive S. aureus
bacteraemia load and usually a high number of other deep foci present) [181,182]. Most
studies report endocarditis, osteomyelitis, abscesses and pneumonia or respiratory infec-
tion, whereas septic arthritis and foreign body infections are rarely described (Table 2a).
Some report bone and joint infections together (Table 2a), whereas some mention only
specific abscesses, e.g. epidural [29,183], psoas [184] or abdominal abscesses [16].
Table 1. Frequency of Staphylococcus aureus bacteraemia (SAB) with unknown portal of
entry, deep foci, persistent bacteraemia and relapse or recurrence of bacteraemia.
Study Unknown
entry portal 1
Deep foci
(reported) 2
Deep foci
(estimated) 2
Persistent
SAB 3
Recurrent
SAB
Chong et al. 2013
Khatib et al. 2013
Robinson et al. 2012
Choi et al. 2010
Walker et al. 2009
Kim et al. 2008
Ruotsalainen et al. 2006
Kaech et al. 2006
Khatib et al. 2006
Fowler et al. 2003
Chang et al. 2003
Jensen et al. 2002
Blyth et al. 2002
Ringberg et al. 2000
-
17%
24%
16%
8%
31%
-
-
19%
13%
15%
-
26%
33%
19%
13%
13%
-
-
19%
87%
24%
9%
74%
-
16%
26%
53%
-
-
-
66%
32%
-
-
-
-
39%
16%
-
-
-
26%
36%
56% 4
-
-
-
-
-
38%
-
7%
-
-
-
4%
-
-
5%
2%
2%
1%
-
6%
16%
-
12%
6%
-
1 Primary SAB. 2 Reported: Reported in original article. Estimated: Summary of all deep foci. 3 Positive blood
cultures ? 3 days past the onset of antibiotic therapy.  4 Positive blood cultures ? 1 day past the onset of antibi-
otic therapy.
2.3.3.4. Definitions of complicated and uncomplicated bacteraemia
Some reports classify SAB as complicated or uncomplicated, but the definitions used have
not been uniform [21,30,136]. Complicated SAB has been regarded as the presence of
secondary foci or recurrence of SAB within three months. Furthermore, any event requiring
ICU treatment or careful monitoring or follow-up of the SAB patient, e.g. severe sepsis,
septic shock, ARDS, DIC, thromboembolic event or septic embolization, have been re-
garded as complicated SAB [28,121,185,186]. Uncomplicated SAB has been defined as
catheter-related bacteraemia or when there is no suspicion of secondary foci or SAB recur-
rence [121,136]. Furthermore, some have included defervescence within 72 hours of onset
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of appropriate antibiotic therapy in the criteria [30]. A very recent report form 2013 defined
complicated SAB as persistent bacteraemia (duration ? three days), SAB relapse and/or
secondary foci, whereas uncomplicated SAB was defined as bacteraemia duration ? two
days, no foreign device and/or secondary foci [21].
2.3.3.5. Risk factors associated with complicated bacteraemia
Persistent bacteraemia or fever for longer than 72-96 hours have been identified as risk
factors for complicated SAB [14,40,121,187]. Furthermore, CA-SAB, underlying diseases
and especially haemodialysis and unremoved infected catheters have been connected to
complicated SAB [42,136,166]. Several reports have failed in connecting MRSA bacterae-
mia to complicated SAB [121,188], although one report associated intravascular catheter-
related MRSA bacteraemia with complicated SAB [136]. Vancomycin therapy in SAB, re-
gardless of MSSA or MRSA, has been recognized as an independent risk factor for recur-
rence, treatment failure and mortality [37,41,189,190], whereas high vancomycin minimum
inhibitory concentration (MIC) (>1.5 ug/mL) has been presented as an independent predic-
tor for complicated bacteraemia [186]. Some reports associate primary SAB with higher oc-
currence of secondary deep foci [2]. A thorough prospective report from 2003 identified four
risk factors to be significantly associated with the risk for complicated SAB: persistent bac-
teraemia and persistent fever (positive blood cultures > 72-96 hours and fever > 72 hours)
subsequent to onset of appropriate antibiotic therapy, CA-SAB and presence of skin le-
sions suggesting acute systemic infection. The lack of any of these risk factors gave a
probability of 16% for complicated SAB, whereas the presence of three risk factors had a
probability of 70% for complicated SAB [121].
2.3.3.6. Prevalence of infection foci
The prevalence of infection foci in SAB differs widely in studies due to usage of various
definitions and likely underdiagnosis [191] (Table 1).
SAB with unknown portal of entry or unknown primary source (i.e. primary SAB) [27] varies
between 8% and 33% (Table 1), whereas some report up to 50% [192]. The occurrence
among HA-SAB patients is much less frequent [2,192]. A primary focus (i.e. cutaneous or
portal of entry) has been identified in 37-88% of SAB cases [2,3,19,136]. The term secon-
dary foci is used by a few studies, with an occurrence of up to 16% [19,21], whereas the
term metastatic or deep foci is commonly applied (9-87%) (Tables 1 and 2a).
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The occurrence of endocarditis has varied from only 2% to up to 39% (Table 2a). Most
studies present endocarditis en bloc [3,12,21,57,121] and a few specify left- or right-sided
or prosthetic valve endocarditis [2]. Osteomyelitis is often reported and the frequency var-
ies between 2% and 14%. It is noteworthy that many authors present osteomyelitis and
septic arthritis together, whereas deep-seated abscesses have been reported in only a few
studies, with an occurrence of 1-24% in SAB patients. The prevalence of SAB pneumonia
has varied from 5% to 30% (Table 2a).
Table 2a. Frequency of deep infection foci in Staphylococcus aureus bacteraemia (SAB).
Study Endo-
carditis
Osteo-
myelitis
Deep-seated
abscesses
Pneumonia Septic
arthritis
Foreign body
infection
Deep
foci
Robinson et al.
2012
Nagao et al.
2010
Choi et al.
2010
Walker et al.
2009
Lahey et al.
2009
Rieg et al.
2009
Wang et al.
2008
Jacobsson et al.
2008 3
Jacobsson et al.
2007 3
Ruotsalainen et al.
2009
Kaech et al.
2006
Khatib et al.
2006
Fowler et al.
2003
Jensen et al.
2002
Blyth et al.
2002
Mylotte et al.
2000
Ringberg et al.
2000
Fowler et al.
1998
10%
5%
2%
2%
12%
11%
26% 3
-
-
18%
17%
8%
39%
8%
4%
6%
33%
13%
11% 1
5% 7
10% 1
2%
10%
10% 1
20% 1
12%
14%
34%
6% 2
10%
10%
7%
11%
2%
-
6%
-
1%
7%
-
3% 6
15%
24%
1% 4
1% 4
44%
-
-
10%
-
10%
1%
-
2% 5
9%
6%
30%
6%
15%
-
13%
5%
5%
40%
-
5%
-
15%
5%
14%
-
-
-
1%
-
2%
5%
-
-
14%
15%
13%
-
-
24%
-
5%
-
-
6%
-
-
-
-
2%
-
-
-
-
18%
12%
-
-
-
-
-
-
-
13%
10%
-
-
-
36%
-
-
-
87%
24%
9%
74%
16%
26%
15%
53%
-
1 Bone and joint infections together. 2 Endocarditis or mycotic aneurysm. 3 Patients with invasive Staphylococ-
cus aureus infections. 4 Only epidural abscesses. 5 Only psoas abscesses. 6 Abdominal abscesses. 7 Only
vertebral osteomyelitis.
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2.3.4. Characteristics of the most common deep infection foci
2.3.4.1. Endocarditis
Historically, endocarditis has been found predominantly in community-associated bacte-
raemia cases, with rheumatic heart disease as a common predisposing valvular abnormal-
ity, and streptococcal bacteria has accounted for up to 60-80% of the microbiological aeti-
ology [193,194]. However, in recent decades the characteristics of endocarditis have
changed; the prevalence of rheumatic heart disease has decreased and new risk factors,
such as degenerative valve diseases among the elderly population, prosthetic valves, in-
travascular catheters, nosocomial bacteraemia and an increasing IDU incidence, have
emerged [19,195, 196,197]. Moreover, S. aureus is replacing streptococcal bacteria as an
aetiological pathogen in endocarditis [198,199], and several reports indicate increasing in-
cidences of SAB and S. aureus-related endocarditis over the last decades [4,5,7]. A thor-
ough prospective study reported a nearly 7-fold increase in S. aureus-related endocarditis
in the 1990s in the United States [198]. However, the absolute incidence of infective endo-
carditis has not increased [20].
The presence of SAB, in combination with some predisposing cardiac disease, constitutes
the basis for endocarditis development [191]. The combination of improved diagnostics, in-
creasing incidence of nosocomial SAB, the ever-increasing usage of invasive procedures
and intravascular catheters as well as more frequent injection drug abuse are presented as
explanations for the increase of S. aureus endocarditis [5,20,34,199]. Major cardiac risk
factors are degenerative valve sclerosis associated with older age, prosthetic valves, mitral
valve prolapse, valvular diseases in general, previous endocarditis and injection drug
abuse [14,31,166, 191,198,200]. Furthermore, risk factors predisposing to SAB endocardi-
tis are persistent bacteraemia, fever [14,121,200,201] CA-SAB [14,121] and unknown
source of bacteraemia [14,200].
2.3.4.2. Pneumonia
Pneumonia due to S. aureus constitutes 1-10% of cases of community-acquired pneumo-
nia and up to 50% of cases of health care-associated pneumonia [202]. The aetiology of S.
aureus pneumonia may be aspiration or haematogenous spread due to release of infected
thrombotic material from the venous system or from tricuspidal vegetations (tricuspidal en-
docarditis) [19,180]. S. aureus pneumonia may eventually become complicated leading to
lung abscess in 19% [203] or pleural empyema in 11-15% of cases [204,205].
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Community-acquired necrotizing pneumonia due to the Panton-Valentine leukocidin (PVL)
toxin secreted by S. aureus is highly fatal, affecting previously healthy individuals and
young people [163]. The association between PVL toxin secreting S. aureus and necrotiz-
ing pneumonia was demonstrated in 1999 [206], and the clinical picture involves leuko- and
thrombocytopenia, severe respiratory distress, airway haemorrhage, multilobar necrosis
and rapid septic shock development with a high mortality ranging from 40% to 60%
[163,207,208,209,210]. However, two recent studies presented outcome and mortality
rates for health care-associated S. aureus pneumonia that were irrespective of PVL even
after adjusting for confounding factors [211,212]. A recent meta-analysis associated PVL-
positive S. aureus strains more commonly with skin and soft tissue infections than with
pneumonia and demonstrated either no evidence or an uncertain indication (due to con-
founding factors) that PVL-positive S. aureus strains were associated with poorer outcome
[213].
2.3.4.3. Septic arthritis
S. aureus is the most common causative organism, accounting for 40-60% of all cases of
septic arthritis [214,215,216,217]. In specific patient subgroups, e.g. diabetes or rheuma-
toid arthritis, S. aureus is found in as many as 80% of cases [218]. Risk factors for septic
arthritis are rheumatoid arthritis, gout, osteoarthritis and HIV infection [218].
Throughout recent decades, the predominance of S. aureus as the leading cause of septic
arthritis has remained unchanged [219]. In SAB, the occurrence of septic arthritis has been
up to 24% (Table 2a) [2,13,16,121]. A prospective study, including S. aureus as a causa-
tive organism in 44% of cases, investigated the source of infection in septic arthritis and
concluded that 67% were of haematogenous origin and 33% non-haematogenous origin
[220]. Septic arthritis is rarely the result of an iatrogen joint intervention and has been esti-
mated to occur in < 0.5% of arthroscopies [221]. Most septic arthritis affects a single joint,
with 50% afflicting the knee and most of the rest the hip or shoulder [218], whereas the pu-
bic symphysis or sacroiliac joint is affected in only 5% of cases [222]. Septic arthritis due to
S. aureus is an emergency due to the high risk of non-reversible and rapid joint destruction
[223].
2.3.4.4. Osteomyelitis
S. aureus as a causative pathogen accounts for more than 50% of osteomyelitis cases.
The classical picture of osteomyelitis involves infection, destruction and necrosis of bone
and potentially new bone formation [224]. Osteomyelitis is encountered in 2-34% of SAB
patients (Table 2a). Many reports apply the Waldvogel classification of osteomyelitis ac-
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cording to aetiology: 1) haematogenous osteomyelitis (due to haematogenous spread),  2)
contiguous focus osteomyelitis (infection spreading from nearby structures, e.g. joint or soft
tissue infections or infection spread due to S. aureus implantation as a result of trauma or
surgery) and  3) osteomyelitis due to vascular insufficiency (most commonly diabetics or
patients with peripheral vascular disease) [225]. Haematogenous osteomyelitis predomi-
nates among paediatric patients, and 85% of haematogenous osteomyelitis is diagnosed
among children < 17 years of age [226]. A study from 2003 investigating osteomyelitis due
to various pathogens (54% S. aureus) reported 6% haematogenous osteomyelitis, 90%
contiguous osteomyelitis, 2% vascular osteomyelitis and 2% other forms [224]. Some stud-
ies use the categorization of acute and chronic osteomyelitis, but there is no strict time ref-
erence for the separation of these two [227]. The clinical presence of a new bone infection
in combination with the lack of bone necrosis and devascularized bone are viewed as acute
osteomyelitis. Histopathologically, acute osteomyelitis correlates with clinical symptoms
that have been present for less than 10-14 days [228]. Chronic osteomyelitis is defined as
long-term bone infection, including low-grade inflammation in pathological analysis and
possible presence of devascularized necrotic bone and new bone formation [229]. Specific
osteomyelitis sites are associated with certain SAB patient subgroups, e.g. clavicular or
sternal osteomyelitis, and are reported more frequently among IDUs than non-IDUs [230].
S. aureus osteomyelitis of the vertebral column (i.e. spondylitis) with or without interverte-
bral disc space affision (i.e. spondylodiscitis) is a continuous clinical challenge. A thorough
Danish nationwide report concluded that 82% of S. aureus spondylitis patients were related
to CA-SAB. Only 39% of the patients had a diagnosis at admission that suggested an ac-
tive vertebral column process, such as back pain, prolapse suspicion or fracture, and only
5% were admitted due to suspicion of osteomyelitis. Altogether 53% had an unknown por-
tal of entry (primary SAB) for the SAB. The spondylitis in 70% of patients was located in the
lumbar part of the vertebral column [231].
2.3.4.5. Foreign body infection
S. aureus is presently ranked as the second most common causative pathogen after co-
agulase-negative staphylococci in foreign body infections [227], accounting for 12-23% of
prosthetic joint infections [232,233,234]. Patients with foreign body devices are at high risk
of device-related infections in SAB; these are encountered in 2-18% of patients (Table 2a).
Two prospective studies investigating patients with a foreign body device and SAB con-
cluded that over 42% of orthopaedic devices, 34% of prosthetic joints and 45% of cardiac
devices became infected [175,235]. Another prospective study observed that 45% of pa-
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tients with permanent pacemakers or implantable cardioverter-defibrillators developed car-
diac device infections as a result of SAB [236].
During the last decades increasingly more foreign body devices, e.g. orthopaedic or car-
diac devices, are inserted [178,237] and device-related infections are receiving more atten-
tion [168,175,236]. Foreign body infections and especially prosthetic joint infections are
categorized according to the time-point of infection onset after insertion as early, delayed,
late or acute haematogenous [178,238]. However, the exact time references vary in differ-
ent reports. According to Zimmerli et al. [178], early infections develop within 3 months of
surgery, delayed infections within 3-24 months of surgery and late infections 24 months or
more after surgery [178]. The categorization according to Zimmerli et al. is the one most
commonly used in clinical practice (discussion with Dr. Kaisa Huotari, Helsinki University
Central Hospital). Some authors use different time references and define early infections
(onset within one month) and haematogenous infections (rapid onset after one month) as
mostly caused by S. aureus, whereas late infections (onset after one month) are usually
caused by coagulase-negative staphylococci [227,238].
2.3.4.6. Meningitis
S. aureus meningitis as a result of SAB is rare and encountered in 0.1-5% of cases
[21,29,121]. SAB with subsequent meningitis mostly reflects a very complicated situation,
with vast infection spread and high probability of other secondary foci. The prognosis is of-
ten poor [239]; one report states a mortality rate of 56% [181].
2.3.4.7. Role of bacteruria
S. aureus bacteruria is very uncommon among the healthy population, except for patients
with urological challenges, such as catheterization or urologic procedures, and usually rep-
resents secondary haematogenous spreading for patients with bacteraemia symptoms. S.
aureus seldom causes urinary tract infections [240]. S. aureus bacteraemia and bacteruria
are observed in 7-10% of patients [241,242]. A case-controlled study including 58% MSSA
bacteraemia cases found that patients with S. aureus bacteraemia and bacteruria (SABU)
had an almost 3-fold increased mortality risk (OR 2.9) as compared with SAB patients
without bacteruria even after adjusting for factors known to increase the risk for S. aureus-
positive urine cultures (e.g. bladder catheters, recent urologic surgery, urinary tract symp-
toms) [170]. Two retrospective studies, one of which included solely MSSA bacteraemia
cases [171], concluded that SABU was a significant risk factor for ICU admission (OR 2.5)
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and an independent predictor for both in-hospital mortality (OR 2.18) [171] and septic
shock and mortality [172].
2.3.4.8. Time-point for diagnosis of deep infection foci
The time-point for diagnosis of deep foci differs, with some authors reporting 74% of SAB
patients having a complicated infection present at the time of initial hospitalization [121]
and others concluding that 84% of SAB patients have deep foci within one week [15] or
metastatic foci within two weeks of SAB diagnosis [185].
2.3.5. Diagnostics of deep infection foci
2.3.5.1. Clinical examination
The clinical status, physical examination and symptoms of the patient constitute the basis
for the search for deep infection foci in SAB patients. A thorough clinical status may reveal
signs of various deep infection foci.
There are several well-documented clinical signs of endocarditis. New heart murmur is
heard in up to 45% of patients during the initial phase of native valve endocarditis [33]. Sys-
temic thromboembolic events [243] and embolization due to mitral valve endocarditis or
large-sized vegetations (>10 mm) may result in acute neurological symptoms, e.g. hemi-
paresis [236,244], necessitating a search for endocarditis [245]. Peripheral thromboembolic
events and embolizations may present as skin petechiae, Janeway lesions (haemorrhagic
spots on soles and palms) and Roth´s spots (haemorrhagic spots on retina) [246], whereas
endocarditis-related immunological complications may result in renal insufficiency [33] and
Osler´s nodes (nodules in the subcutis of fingers and toes) [246]. Clinical signs lead to di-
agnosis of endocarditis in 7% of cases [247], and radiological methods have been shown to
substantially increase the odds for diagnosis [248].
The diagnostic criteria for endocarditis have been modified repeatedly in recent decades.
Originally, autopsy was a prerequisite for endocarditis diagnosis. However, the first criteria
for prediction of endocarditis in SAB were established in 1976 and these included CA-SAB,
lack of primary focus of infection and presence of metastatic infection [164]. These criteria
were improved in 1981 [249] and the introduction of echocardiography further improved the
diagnostics, with the Duke criteria established in 1994. The Duke criteria take into account
echocardiographic imaging, histopathological findings and microbiology and classify the
probability of endocarditis as definite, possible or rejected [250]. The Duke criteria were fur-
ther developed in 2000 (modified Duke criteria), with proposed modifications to the cate-
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gory ´´possible endocarditis`` [248]. The modified Duke criteria are described in detail in the
´´Definitions`` section (2.3.7.1.).
2.3.5.2. Echocardiography
Transthoracic (TTE) and transoesophageal echocardiography (TEE) are the foremost ra-
diological investigations for diagnosis and follow-up of endocarditis [20,34]. TTE is rapid,
non-invasive, widely available in hospitals and may easily be performed bed side; however,
despite excellent specificity (up to 98%) for infective vegetations, a negative TTE does not
exclude S. aureus endocarditis due to its poor sensitivity (40-80%) [247,251,252].
TEE is invasive and requires a patients complete perfect cooperation. However, TEE is su-
perior to TTE in revealing infective vegetations with a sensitivity of 87-100% and a specific-
ity of 89-100% [251,253,254]. Furthermore, TEE is indispensable for prosthetic valve endo-
carditis [255] and detection of small vegetations [256]. In a thorough prospective study of
patients with definite S. aureus endocarditis (with over 50% of patients having an infected
intravascular device as the source of bacteraemia), TTE revealed findings leading to diag-
nosis of endocarditis in 34% of cases; the corresponding figure for TEE was 94% [137].
Clinical use of TTE is fairly common, with reports of up to 23-60% of SAB patients receiving
TTE [12,19,21,121], whereas 6-42% are provided with TEE [12,21,121] and 13% are inves-
tigated with both TTE and TEE [21]. Moreover, patients receiving an infectious disease
specialist consultation are significantly more often provided with TTE or TEE [3,18,56,257]
than patients managed without an infectious disease specialist consultation.
2.3.5.3. Radiological investigations
Radiological investigations in SAB constitute a cornerstone, alongside clinical physical ex-
amination, for diagnosing deep infection foci [31,34,227]. However, there are no generally
accepted algorithms or guidelines for the use of radiological investigations. The choice and
time-point for radiology and possible subsequent control imaging should be assessed for
each SAB patient individually. The foremost radiological imaging techniques for SAB-
related joint and bone infections, deep-seated abscesses and pneumonia are x-ray, ultra-
sound, magnetic resonance imaging (MRI) and computed tomography (CT) [31,227,258].
In septic arthritis, the specific diagnosis is based on joint fluid aspiration analysis, including
cultures [259]. However, various radiological investigations are occasionally indispensable.
Ultrasound may be needed for demonstrating joint effusion and for guidance of needle as-
piration [260]. Ordinary x-ray, especially in the early phase of septic arthritis, usually shows
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regular bone structures and periarticular soft tissue oedema. However, in septic arthritis of
sternoclavicular or pubic symphysis, x-ray reveals adjacent osteomyelitis in 60-90% of
cases [222,261]. Therefore, MRI may be useful in unclear cases of deep joint septic arthri-
tis, e.g. in the hip region, and MRI may reveal joint changes even within 24 hours of infec-
tion onset [262].
In acute osteomyelitis, ordinary x-ray imaging may reveal bone destruction, periosteal reac-
tions, soft tissue oedema as well as joint alterations (narrowing or widening of joint area).
However, these transformations, including bone destruction, are not visible with ordinary x-
ray until 10-21 days after infection onset [263,264,265]. In chronic osteomyelitis, the typical
features are periosteal new bone formation, bone sclerosis and sequestrae and sinuses
[227]. In osteomyelitis, CT is superior to MRI for detection of sequestrae and intraosseus
gas, whereas MRI is superior in localizing vertebral osteomyelitis and epidural and soft tis-
sue abscesses [227]. Regarding vertebral osteomyelitis, bone scintigraphy, i.e. technetium-
99 (Tc 99), may localize and confirm the infection at an early stage, although the accuracy
of MRI is higher [266]. A thorough nationwide Danish study concluded that within one week
bone scintigraphy results were abnormal in 80% and CT scanning in 50%, whereas MRI
results were abnormal in 100% of cases of S. aureus spondylitis [231]. Compared with
conventional radiography (x-ray), both scintigraphy and CT scanning produced positive ra-
diological results significantly earlier [231]. A study comparing diagnostic methods for os-
teomyelitis demonstrated a sensitivity of 72% for MRI, 68% for bone scans and 45% for
leukocyte scintigraphy [267].
Effective use of traditional radiological imaging techniques, such as x-ray, ultrasound, CT
or MRI, is heavily dependent on guidance provided by of localized symptoms. Recently, it
was proposed that a combination of CT scanning and whole-body positron emission tomo-
graphy (FDG-PET/CT) might be superior in localization of infection foci relative to x-ray, ul-
trasound, CT or MRI [268,269]. FDG-PET/CT effectively localizes infection foci and im-
proves diagnostics in bacteraemia patients and patients with fever of unknown origin
[270,271]. A retrospective study observed that conventional radiological techniques (x-ray,
ultrasound, CT or MRI) localized 75% of infection foci among bacteraemic patients (includ-
ing 35% of SAB). However, subsequent to this, FDG-PET/CT managed to localize clinically
relevant new infection foci in 45% of cases, although a median of four tests had already
been performed [270]. A prospective study from 2012, including altogether 115 Gram-
positive bacteraemic patients (74% of SAB) demonstrated deep foci in 73% of patients with
at least one risk factor for metastatic infection (community acquisition, treatment delay,
persistently positive blood cultures >48 hours and persistent fever >72 hours after initiation
of treatment). However, only in 41% of cases did the infection foci produce local signs or
symptoms, and hence, symptom-guided x-ray, ultrasound, CT or MRI revealed few metas-
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tatic foci. FDG-PET/CT was much better, revealing 69% of all metastatic infection foci.
Moreover, FDG-PET/CT revealed at least one clinically silent metastatic focus in approxi-
mately 30% of patients [203]. The use of FDG-PET/CT has been observed to reduce re-
lapses of SAB compared with conventional radiology [272].
2.3.6. Persistent and recurrent bacteraemia
Persistent bacteraemia
Persistent bacteraemia in SAB is generally defined as ongoing positive blood cultures ?
one day [57], ? three days [40] or ? seven days [84,273,274] after onset of proper antibiotic
therapy. Persistent bacteraemia has varied from 7% to 56% in different studies [14,18,21,
30,40,273,275,276] (Table 1). Methicillin resistance is a major risk factor for persisting bac-
teraemia [276,277], and the inferior capability of vancomycin relative to ?-lactams in eradi-
cating SAB is viewed as one probable explanation [40,53,278]. Infected prosthetic devices
[40] and deep infection foci (especially endocarditis) [199] have been described as other
risk factors for persistent bacteraemia. Two studies have demonstrated a significant asso-
ciation between persistent SAB and development of metastatic foci [40,275].
Recurrent bacteraemia
SAB recurrence is defined as a second episode of SAB subsequent to appropriate an-
tistaphylococcal medication and documentation of negative blood cultures and/or clinical
improvement [41], with some reports subgrouping SAB recurrence as a relapse (i.e. identi-
cal pulsed-field gel electrophoresis, PFGE, pattern) or reinfection (non-identical PFGE pat-
tern) [41]. Recurrent episodes of SAB have ranged from 1% to 16% in published studies
[3,15,19,22,28,30,40,41,58,121,123] (Table 1). Most SAB recurrences are relapses and
several factors are recognized as independent risk factors for SAB recurrence or relapse:
endocarditis [41], vancomycin or other glycopeptide therapy for MSSA [37,41,123], secon-
dary foci [19], a total daily dose of dicloxacillin less than 3 g [19], unremoved infected cen-
tral venous catheter [123] and duration of bacteraemia longer than 3 days [37].
2.3.7. Community- or health care-associated Staphylococcus aureus bacteraemia
2.3.7.1. Definitions
SAB is categorized as community-associated (CA-SAB) or health care-associated (HA-
SAB) according to the time-point of collection of the first positive blood culture [7,15,28], al-
though some reports apply a third category of community-onset health care-associated
SAB (COHA-SAB) [3]. The criteria for CA-, HA- and COHA-SAB are mostly standardized in
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the literature. CA-SAB is defined as the first positive S. aureus blood culture taken within
48 hours of hospital admission without any preceding hospitalization within seven days.
HA-SAB defined as the first positive S. aureus blood culture taken ? 48 hours after admis-
sion to hospital or within two days of admission in cases with a hospital discharge within
the preceding seven days [3,15,19,40]. One report viewed long-term care facility residency
during the previous two months or preceding haemodialysis treatment as HA-SAB [15].
COHA-SAB is defined as the first positive S. aureus blood culture within 48 hours of ad-
mission for outpatients with 1) previous healthcare contact, e.g. wound care, intravenous
therapy or haemodialysis within 30 days, 2) any hospitalization for at least 48 hours within
the past three months or 3) long-term care facility or nursing home residency prior to hospi-
talization [3,279]. However, some reports deviate from the time criteria mentioned above
and categorize CA-SAB and HA-SAB according to whether the first positive blood culture
for S. aureus was obtained within or subsequent to 72 hours of hospital admission
[12,21,37,121].
2.3.7.2. Impact of clinical presentation
For decades, SAB was interpreted primarily as a health care-associated infection [118,136,
280], although in recent years the overall occurrence of both acquisition categories has in-
creased [7,155], with reports of CA-SAB in 11-58% [2,3,6,15,18,21,37], HA-SAB in 30-81%
[2,3,6,15,18,21,37,58] and COHA-SAB in 28-57% of cases [3,18,21].
Evident trends have emerged regarding age, underlying conditions and disease progres-
sion related to SAB acquisition. CA-SAB patients are younger and more often IDUs [2,7],
whereas HA-SAB patients are older [2,7,28] and more often chronically ill [2,7,19]. Most re-
ports present no differences in gender [19]. MRSA bacteraemia has been encountered
more frequently in HA cases [23], with occurrences of 0.4-57% for HA-SAB [3,7,23] 0-18%
for CA-SAB and 16% for COHA-SAB. Severity of illness at S. aureus-positive blood culture
is reported to be more serious among CA-SAB patients with a higher occurrence of septic
shock [2,28], ARDS [2,28], DIC [2,28], ICU treatment [2], mechanical ventilation [2] and re-
nal failure [2,28].
Primary SAB (i.e. unknown portal of entry or unknown focus) is more common among com-
munity-associated cases as compared with HA-SAB, but one report presented the opposite
results, with primary SAB in 12% of CA-SAB cases and 57% of HA-SAB cases [85] (Table
2b). When comparing occurrences of primary foci, CA-SAB presents more often with skin
infections and soft tissue infections and IDU. Skin infections were present as a primary fo-
cus in 13-40% of CA-SAB [2,7,19,28] and in 3-4% of HA-SAB, whereas soft tissue infec-
tions were observed in 53% of CA-SAB and 23% of HA-SAB [29], and catheter-related
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SAB occured in only 1-17% of CA-SAB [2,3,28,29], 21-64% of HA-SAB [2,3,28,29] and
37% of COHA-SAB [3]. The same trend applies to wounds and surgical infections, with oc-
currences of 6-16% for HA-SAB and 0-2% for CA-SAB [7,19,28]. Hence, the primary foci of
HA-SAB are mostly iatrogenic and related to invasive procedures or catheter use, whereas
the primary foci for CA-SAB are often unknown or related to IDU or skin and soft tissue in-
fections.
Metastatic, secondary or deep foci are observed more often in CA-SAB than in HA-SAB
(Table 2b). Generally, all deep foci occur more frequently in CA-SAB, with the exception of
foreign body infections. Endocarditis is diagnosed in 7-29% of CA-SAB, 0-5% of HA-SAB
and 10% of COHA-SAB, and both native and artificial valve endocarditis are more common
in CA-SAB (Table 2b). Moreover, CA-SAB patients have been reported to receive more
echocardiography than HA-SAB patients [21]. The occurrence of osteomyelitis is 13-16%
for CA-SAB and 2-4% for HA-SAB [7,19,28], and many studies report septic arthritis and
osteomyelitis together under the term bone and joint infections, with a presence of 11-47%
in CA-SAB and 0-17% in HA-SAB [2,85]. Pneumonia and respiratory infection are reported
in 4-18% of CA-SAB and 1-16% of HA-SAB [7,12,19,28], whereas some report explicitly
more respiratory infections among HA-SAB [29,85]. Furthermore, deep-seated abscesses,
S. aureus-related meningitis and CNS infections are reported more often among CA-SAB
[7,28,85]. However, foreign body infections occur more frequently in HA cases, with fre-
quencies of 0% for CA-SAB and 11% for HA-SAB [2], whereas surgical site infections with
no foreign body are reported in 0% of CA-SAB and 9-20% of HA-SAB [2,28]. Persistent
SAB is reported more often in CA-SAB [30], whereas recurrent SAB is seen in 5% of CA-
SAB and 11% of HA-SAB [19]. However, no significant difference in recurrence prevalence
with respect to acquisition was seen in one report [40].
Several studies have reported no significant difference in mortality between CA-SAB, HA-
SAB and COHA-SAB at 28-day or 30-day [12,18] or three-month follow-up [3,19]. However,
discrepant results have also been presented, with higher mortality in CA-SAB [2] or HA-
SAB [37]. A thorough Danish study reported overall declined trends in mortality for both
CA- and HA-SAB during the last decades [7]. The impact of SAB acquisition on mortality is
discussed in more detail in Section 2.7.2.
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Table 2b Frequency of Staphylococcus aureus bacteraemia (SAB) with unknown portal of
entry, various primary infection foci and deep foci according to community-associated (CA)
and healthcare-associated (HA) acquisition.
Unknown
portal of entry 1
Primary foci
(reported) 2
Deep foci
(reported) 2
Endocarditis Mortality 3Study
CA    HA CA HA CA HA CA HA CA HA
Laupland et al.
2008
Jacobsson et al.
2007
Benfield et al.
2007
Kaech et al.
2006
Johnson et al.
2003
Jensen et al.
2002
Blyth et al.
2002
Mylotte et al.
2000
12%
44%
61%
52%
-
20%
22%
42%
57%
36%
53%
3% ¤¤
-
4% ¤¤
3%
44%
88%
56%
39%
48%
-
80%
78%
58%
43%
64%
47%
97% ¤¤
-
96% ¤¤
97%
56%
-
-
31%
43%
-
29%
35%
-
-
-
6%
5% ¤¤
-
5% ¤¤
12% ¤
-
-
-
12%
29%
-
14%
7%
-
-
-
2%
5% ¤¤
-
3% ¤¤
0
-
-
-
-
26%
24%
40%
-
23%
-
-
-
13% ¤
43% ¤
29%
-
23%
1 Primary SAB. 2 As reported in the original article. 3 Mortality at 3-month follow-up.  ¤ p<0.05 and ¤¤ p<0.001.
2.4. Treatment of Staphylococcus aureus bacteraemia
2.4.1. Standard antibiotic therapy
Countries with low MRSA prevalence, such as Finland, use semisynthetic penicillin (i.e.
cloxacillin) as the standard antimicrobial therapy in SAB [15] and for patients with penicillin
allergy either clindamycin or first, or second-generation cephalosporins [31,33,34]. Several
older reports observe that semisynthetic penicillin might be superior to cephalosporines
such as cefazolin (first-generation cephalosporin) [281,282], cefonicid (second-generation
cephalosporin) and ceftazidime (third-genertaion cephalosporin) [283,284]. In contrast, a
recent study concluded that cefazolin and cloxacillin therapy did not differ with respect to
outcome in MSSA bacteraemia and both were associated with a lower 30-day mortality
than second- (cefuroxime) and third-generation cephalosporins (ceftriaxone and cefo-
taxime) [285]. However, the bacteriostatic nature of clindamycin may increase the risk for
relapses, and there are recommendations to avoid clindamycin in SAB with endocarditis,
whereas in osteomyelitis clindamycin is often recommended due to its excellent tissue
penetration [35,165,286]. Alternatively, MSSA bacteraemia patients with severe allergy to
penicillins or cephalosporins may be treated with vancomycin [36,37].
For MRSA, vancomycin is viewed as the drug of choice, although newer antibiotics like
daptomycin or linezolid have been presented as alternatives (with the exception of left-
sided endocarditis). Daptomycin has been reported to be non-inferior to standard an-
tistaphylococcal therapy in SAB and in right-sided endocarditis due to MSSA or MRSA
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[276], whereas one meta-analysis found no outcome difference between linezolid and van-
comycin therapy [287] and another meta-analysis showed higher success with linezolid,
ableit without improved survival compared with ?-lactam or glycopeptide therapy [288].
2.4.2. Duration of antimicrobial therapy and aminoglycoside combination
Short duration of therapy
Short parenteral antibiotic therapy (10-14 days) is usually regarded as sufficient for uncom-
plicated SAB and, in particular, for most cases of catheter-related SAB [44]. Several stud-
ies have demonstrated that in uncomplicated catheter-related SAB the risk of secondary
foci is low and 10-14 days of parenteral therapy is sufficient when the catheter is removed
[42,43,44,45], whereas two reports show rising complications among patients receiving
shorter than 14 days parenteral therapy [19,289,290]. However, in catheter-related SAB
with persistent bacteraemia, prolonged fever (> 72 hours), predisposing factors for endo-
carditis, e.g. valvular abnormalities, and in some subgroups of patients e.g. rheumatologic
diseases or malignancies, the risk for complicated SAB is increased and long parenteral
therapy may be needed [121,290,291,292]. For uncomplicated non-catheter-related SAB,
the recommendation has been 14 days of parenteral therapy with subsequent 14 days of
oral therapy [293,294]. Moreover, some reports indicate that 14 days of parenteral therapy
may be sufficient for uncomplicated cases of right-sided endocarditis [295,296,297,298].
Long duration of therapy
Patients with deep or metastatic infection foci, left-sided endocarditis, non-eradicable pri-
mary focus or signs of a complicated catheter-related SAB after catheter removal (e.g. per-
sistent bacteraemia, prolonged fever, predisposing factors for endocarditis and some pa-
tients with severe underlying diseases) are considered to need parenteral therapy for 4 (-6)
weeks [46,47,48]. Most SAB-related deep infection foci (i.e. septic arthritis, osteomyelitis,
deep-seated abscesses and foreign body infections) require at least 4 or even 6 weeks of
standard parenteral antibiotic therapy [299,300,301]. However, there is scant evidence to
support the standard parenteral antibiotic therapy of 4 (-6) weeks.
One randomized controlled trial investigated the impact of 2 versus 4 weeks of intravenous
antimicrobial therapy for adult SAB patients. Endocarditis developed in one patient in the 2-
week group, whereas the 4-week group no endocarditis was observed [294]. Recom-
mended antimicrobial therapy differs considerably for left-sided native valve, prosthetic
valve and right-sided endocarditis. For left-sided native valve endocarditis, standard par-
enteral therapy of (4) -6 weeks in uncomplicated cases [20,48] and 6 weeks in complicated
cases [48] is recommended (IA strength of recommendation according to the Infectious
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Diseases Society of America, IDSA) [48]. In both cases, a combination with the first 3-5
days on an aminoglycoside is suggested in most guidelines [1,20,48], although no recom-
mendation strength has been established according to IDSA [48]. The antimicrobial therapy
for prosthetic valve endocarditis resembles that of left-sided native valve endocarditis, al-
though the standard parenteral therapy is recommended to continue ? 6 weeks (IB strength
of recommendation according to the IDSA) [48] with initial aminoglycoside therapy contin-
ued for 14 days [1,20,48]; no strength of recommendation has been established by to the
IDSA, however [48].
The pathophysiology of right-sided endocarditis differs from other forms of endocarditis and
is frequently encountered among IDUs. The recommendation is a standard antibiotic ther-
apy and aminoglycoside combination, and in uncomplicated right-sided endocarditis 14
days of parenteral therapy may be sufficient [295,296,297,298,301]. However, in compli-
cated right-sided endocarditis, including extracardiac infections, vegetations of consider-
able magnitude (>2 cm), MRSA cases, immunosuppression or slow response to initial ther-
apy, 4 weeks of parenteral therapy is recommended [301,302,303].
The current role of aminoglycosides in SAB endocarditis is controversial. Experimental set-
tings have demonstrated ?-lactam and gentamicin synergy [304], although only one clinical
study has reported reduced defervescence and reduced duration of bacteraemia (by one
day) when 2 weeks of gentamicin was combined with nafcillin in SAB endocarditis [305]. In
2006, a meta-analysis observed no improved treatment success and no mortality reduction
as a result  of ?-lactam and aminoglycoside combination relative to ?-lactam alone for na-
tive valve SAB endocarditis [306]. However, aminoglycoside combination therapy was as-
sociated significantly with nephrotoxicity. In 2009, one study concluded that addition of low-
dose gentamicin in native valve SAB endocarditis is an independent predictor for renal tox-
icity and should not be routinely used [307]. The recommendation not to routinely add gen-
tamicin to SAB endocarditis treatment has been supported by other authors [46].
Continuous debate exists as to whether parenteral and oral therapy are equally sufficient in
some subgroups of SAB patients. Two reports, one comparing per os rifampicin and cipro-
floxacin with standard parenteral therapy for right-sided endocarditis in IDUs [80] and the
other comparing per os rifampicin and fleroxacin with standard parenteral therapy for SAB
patients with bone, joint or catheter-related infections [308] presented equal clinical cure
rates in both groups.
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2.4.3. Role of rifampicin adjunctive therapy
The role of rifampicin in SAB and, in particular, in deep infections has been debated for
decades. Recommendations suggest combining rifampicin with standard therapy in foreign
body infections [178], osteomyelitis [77] and deep-seated abscesses [308]. Rifampicin has
potentially valuable antimicrobial characteristics such as high intracellular concentrations,
bactericidal and high antistaphylococcal activity for MSSA and MRSA, penetration of
biofilms [59,60,61,62,63,64,65] and eradication of S. aureus in both non-phagocytic cells
[309] and cells in sessile and planktonic growth phases [310]. Monotherapy with rifampicin
results in rapid resistance development, and thus, combination therapy is a prerequisite for
rifampicin use [36,66,67,68]. However, the exact role of rifampicin in SAB management
remains to be elucidated.
2.4.3.1. Rifampicin studies in vitro
In vitro studies have investigated the efficacy and interactions of rifampicin combined with
other antimicrobial agents – with contradictory results. Rifampicin combined with oxacillin
has shown antagonistic or indifferent interactions [69], antagonistic (at high oxacillin con-
centrations) and synergistic (at low oxacillin concentrations) interactions [71] or no antago-
nism [70]. Rifampicin and ciprofloxacin in vitro combinations have demonstrated antago-
nism [311], indifference [60,312] or synergistic effects [313]. Corresponding conflicting re-
sults have been presented also for rifampicin and vancomycin combinations, with reported
indifference [314], antagonism [315] or synergy [316]. Several reports have noted that
changes in antibiotic concentrations affected the interaction [70,317,318]. Some reports
have suggested that the interaction between rifampicin and other antimicrobial agents may
be method-dependent, e.g. time-kill curve assay versus checkerboard microdilution assay
[71,319,320,321]. However, contradictory results have been achieved also in cases where
the same research methodology has been applied, e.g. time-kill curve assay (rifampicin-
oxacillin combinations) [69,70,71]. A recent thorough review summarizing the results of al-
together 72 reports concludes that in vitro studies are heavily method-dependent and ques-
tions whether in vitro studies have any relevance in exploring the efficacy of rifampicin
combination therapy for clinical infections [72].
2.4.3.2. Rifampicin studies with animal models
Animal models have investigated monotherapy versus rifampicin combination therapy in
various study settings. Mouse models with penicillin-susceptible SAB have demonstrated
higher (p <0.001) survival rates for rifampicin in combination with penicillin or methicillin
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than for penicillin or methicillin alone [322]. Rat and rabbit models of osteomyelitis have
demonstrated reduced colony-forming units in pefloxacin-rifampicin [73] and clindamycin-
rifampicin [323] and higher sterile bone cultures in vancomycin-rifampicin (p <0.01) [74],
cephalothin-rifampicin (p <0.001) [75] and trimethoprim-rifampicin [324] combinations com-
pared with pefloxacin, clindamycin, vancomycin, cephalothin or trimetophrim alone. Rabbit
and rat models of endocarditis treated with monotherapy versus rifampicin combination
therapy have demonstrated enhanced valve sterilization or reduced colony-forming units as
a result of cloxacillin-rifampicin [325] or vancomycin-rifampicin [326] versus non-rifampicin
monotherapy alone. However, contradicting these are reports of an indifferent impact of
vancomycin-rifampicin therapy versus vancomycin alone in rat endocarditis models
[327,328].
2.4.3.3. Clinical studies with rifampicin combination therapy
During 1983-2011 the clinical effect of rifampicin was evaluated in 16 reports. The vast ma-
jority of these studies were prospective, whereas three of the most recent ones were retro-
spective [82,83,176]. The studies differ widely with respect to MRSA occurrence. Some re-
port no MRSA [15,77], whereas others report high (76-100%) MRSA prevalence
[81,82,83,329,330]. In addition, definitions and inclusions of deep infection foci vary con-
siderably. Some studies report only endocarditis [81] or right-sided endocarditis [80],
whereas others report only osteomyelitis [75,77], and one study presented various deep in-
fection foci [15]. The main results of the clinical rifampicin combination studies are summa-
rized in Table 3. These studies compare the clinical outcome of rifampicin combination
therapy against standard therapy alone. Most studies with low MRSA occurrence report
some degree of improved clinical outcome due to rifampicin combination therapy as com-
pared with standard therapy alone, whereas studies with high MRSA occurrence mostly re-
port adverse effects and negative prognostic impact of rifampicin combination therapy.
Several small prospective studies with 14-65 patients from the 1980s report higher cure
rate or lower mortality with rifampicin combination therapy than with standard therapy
alone, although statistical significance is not achieved in many studies due to small sample
size [66,75,76,77]. The end-points, the MRSA prevalence and the deep focus classification
differ between these studies. One study with right-sided endocarditis among IDUs reported
a 100% cure rate of rifampicin combination therapy among patients who managed to com-
plete the study, but no control group was included [78]. Some studies have either failed to
observe resistance development to rifampicin [75,76] or rifampicin resistance is not men-
tioned [66,77].
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During the 1990s and 2000s several prospective studies of varying size (33-381 patients)
and mostly low MRSA occurrence (0-11%) have reported positive results with rifampicin
combination therapy relative to standard therapy (Table 3). One study of right- sided endo-
carditis among IDUs compared oral rifampicin-ciprofloxacin with intravenous oxacillin or
vancomycin (in addition to gentamicin) and noted no difference in clinical failures in the ri-
fampicin combination group relative to the standard therapy group (5% vs. 12%) [80]. An-
other study compared oral rifampicin-ciprofloxacin with ciprofloxacin-placebo in foreign
body infections and showed significantly higher cure rates among patients with rifampicin
combination therapy (100% vs. 58%, p <0.05) [79].
A post hoc analysis of 331 MSSA bacteraemia patients, including various deep infection
foci patients but no MRSA bacteraemia cases, demonstrated improved three-month out-
come for adjunctive rifampicin therapy [15]. A prospective randomized trial with MSSA bac-
teraemia (2% MRSA) and a high number of various deep infection foci compared fleroxacin
and rifampicin combination against conventional intravenous monotherapy with flucloxacil-
lin or vancomycin [308]. The study observed similar cure rates for both therapies, although
rifampicin therapy resulted in several adverse reactions such as hepatitis. Furthermore, a
retrospective study with 17% MRSA cases concluded that rifampicin-fluoroquinolone ther-
apy, compared with other antimicrobial regimens, was associated with improved outcome
in patients with total hip or knee prosthetic infections, with no differences in outcome be-
tween MSSA and MRSA infections [176]. Altogether, four studies with high (51-100%)
prevalence of MRSA bacteraemia have investigated rifampicin combination therapy in en-
docarditis [81,82], osteomyelitis [331] or various deep infection foci [83] or in persistent
MRSA bacteraemia [329]. Of these studies, one included 10% heteroresistant vancomycin-
intermediate S. aureus (hVISA) cases [83].
Development of rifampicin resistance in S. aureus is a well-known disadvantage [67,68]
and has been observed in studies with high MRSA prevalence [82,83,84,329,331]. These
studies have reported development of rifampicin resistance in 5-56% of cases [82,83,
84,329], whereas one study reported unspecified rifampicin resistance [331]. All of these
studies have reported poorer clinical outcome with rifampicin combination therapy. How-
ever, studies with MSSA cases only [15,75] or low (1-17%) MRSA occurrence [176,308]
have reported no rifampicin resistance. Moreover, one study with mixed MSSA and MRSA
cases (percentages not provided) [76] reported no rifampicin resistance.
Conflicting results have been obtained with rifampicin combination therapy for prolonged
bacteraemia. A prospective randomized study with 42 native valve endocarditis patients
compared vancomycin-rifampicin combination with vancomycin only and observed a non-
significantly prolonged bacteraemia rate due to vancomycin-rifampicin combination therapy
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(7 days vs. 9 days) [81]. In another study, rifampicin combination therapy was observed to
lead more often to prolonged bacteraemia than vancomycin or nafcillin treatment alone
[82]. In the latter study, each rifampicin resistance case was associated with rifampicin ini-
tiation during the bacteraemia phase. A study comparing MRSA and hVISA bacteraemia
treated with a vancomycin-rifampicin combination demonstrated prolonged bacteraemia
and higher rifampicin resistance for hVISA cases [83]. The authors proposed that due to
hVISA the vancomycin serum concentration was below the required hVISA MIC, and
hence, rifampicin therapy might be viewed as monotherapy resulting in rifampicin resis-
tance. In the fourth study, 19 elderly patients with prolonged MRSA bacteraemia were
treated with a glycopeptide-rifampicin combination. Patients who developed rifampicin re-
sistance (30%) showed no higher mortality [329]. A retrospective study from 2009, includ-
ing 35 patients with persistent MRSA bacteraemia and various deep infection foci, com-
pared the effect of linezolid (with or without carbapenem) against vancomycin (with or with-
out aminoglycoside or rifampicin) and reported significantly more rapidly achieved early
microbiological response in the linezolid group than in the vancomycin-rifampicin group.
Moreover, significantly higher (80%) mortality rate for the vancomycin and aminoglycoside-
rifampicin combination therapy as compared with vancomycin alone (40% mortality) or
linezolid alone (0% mortality) or linezolid and carbapenem (22% mortality) was observed
[84].
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Table 3. Impact of standard antimicrobial treatment versus rifampicin combination therapy
on outcome and development of rifampicin resistance in Staphylococcus aureus bacterae-
mia.
Study MSSA/
MRSA
 Infection
foci
Antimicrobial
treatment 1
Cure rate  with
RMP vs. non-RMP
RMP-R
Norden et al. 1983
Van der et al. 1983
Van der et al. 1985
Norden et al. 1986
Levine et al. 1991
Heldman et al.
1996
Zimmerli et al.
1998 8
Ruotsalainen et al.
2006
Schrenzel et al.
2004 9
Daver et al.
2007
Riedel et al.
2008
Jang et al.
2009 11
Maor et al.
2009
Senneville et al.
2011
MSSA
Mixed
Mixed
MSSA
MRSA
5%
MRSA
Mixed
MSSA
<1%
MRSA
51%
MRSA
76%
MRSA
100%
MRSA
10%
hVISA
17%
MRSA
osteomyelitis
various
various
osteomyelitis
endocarditis
endocarditis 6
foreign
body 7
various
various
osteomyelitis
endocarditis
various
various
foreign
body 7
nafcillin
oxacillin 2
oxacillin 2
nafcillin
vancomycin
oxacillin vs.
ciprofloxacin 3
flucloxacillin +
ciprofloxacin4
cloxacillin vs.
cloxacillin+levofloxacin 5
flucloxacillin vs.
 fleroxacin p.o.
vancomycin
nafcillin or
vancomycin
linezolid 12
vancomycin
various
 70% vs. 30% (NS)
67% vs. 41% (p <0.01)
61% vs. 56% (NS)
80% vs. 50% (NS)
90% vs. 82% (NS)
95% vs. 88% (NS)
100% vs. 58% (p <0.05)
  †  17% vs. 38% (p <0.001)
86% vs. 84% (NS)
43% vs. 84% (p <0.02)
† 79% vs 95% (p <0.05)
†  80% vs. 0-43% (p=0.03)
---
75% vs. 47% (p=0.01)
(remission rate)
no
NR
no
NR
NR
NR
no
no
no
yes
56%
9%
5-44%
no
†=Mortality. RMP=Rifampicin. RMP-R=Rifampicin resistance. NR=Not reported. 1 Parenteral if not otherwise
specified.   2 Oxacillin for MSSA and vancomycin for MRSA. 3 Ciprofloxacin orally vs. oxacillin and gentamicin.
4 Ciprofloxacin orally after parenteral therapy.   5 Rifampicin combination for deep foci only. 6 Right-sided endo-
carditis. 7 Foreign body infections.   8 S. aureus 79% and S. epidermidis 21%.  9 S. aureus 82% and S. epider-
midis 18%.   10 Percentages and p-value not available.  11 Persistent MRSA bacteraemia (positive blood cultures
despite appropriate antibiotic therapy ? 7 days). 12 Linezolid ± carbapenem vs. vancomycin.
2.4.4. Drainage or surgical treatment
The importance of deep infection foci localization and eradication is emphasized in several
studies [19,168,173]. Eradication and possible surgical intervention are dictated by the na-
ture and accessibility of the deep focus. Abscesses are mostly eradicated through percuta-
neous or surgical drainage, although small abscesses may be managed with antibiotic
therapy alone [165,258]. However, a recent study of over 120 ileopsoas abscesses with
more than 40% of S. aureus origin did not report an association between abscess drainage
and improved outcome [258]. Both acute and chronic osteomyelitis may require surgical in-
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tervention such as surgical decompression, debridement of the infected area and revascu-
larization [333].
The requirement for surgical intervention is high in endocarditis, with up to 45% of left-sided
native valve and virtually 100% of prosthetic valve endocarditis cases [129,334,335],
whereas only a small proportion of right-sided endocarditis requires surgery [34]. For left-
sided native valve endocarditis, the following conditions are generally considered to require
surgical intervention: valvular regurgitation of haemodynamic significance (New York Heart
Association stage III-IV congestive heart failure), mobile and/or large-sized vegetations,
vegetations > 1 cm on the anterior mitral valve area, vegetation causing mechanical ob-
struction of valves, sinus Valsalva rupture, infection extending to the paravalvular area or
paravalvular abscess formation and persistent SAB (?7 days) despite appropriate antim-
icrobial therapy [336,337]. For right-sided endocarditis, persistent and recurrent SAB or
continuous septic embolic complications are indications for surgical intervention [34].
2.5. Infectious disease specialist consultation (IDSC)
2.5.1. Formal and informal consultations
The role of IDSC-guided management in infectious diseases has received increasing atten-
tion in the last decades. Attempts to evaluate the complexity, prognostic impact, error
avoidance and economic cost of IDSC have been made in several studies [184,338,339,
340,341,342].
IDSC is generally categorized as formal or informal (or ´´curbside``) [338]. In formal consul-
tations, the infectious disease specialist (IDS) makes his decision based on information re-
ceived from communication with the patient and from physical examination of the patient as
well as retrieval of patient records. In informal consultations, the IDS provides information
via telephone or other informal discussion and gives advice on disease management with-
out meeting the patient or retrieving the patient´s medical records [340,343,344]. As a re-
sult of the ever-deepening specialization in clinical medicine, IDS consultations, and espe-
cially informal IDS consultations, have become common [340,345,346,347]. IDSs are
among the physicians most frequently consulted [344]. Already in 1998, a study concluded
that informal IDSC was more common than formal IDSC [344]. Most informal consultations
occur via telephone conversation (30-64%) [338,344,346], whereas a much smaller propor-
tion are made up of informal curbside discussions (19%) [338], or e-mail communication
(5%) [344].
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Potential advantages and disadvantages of formal versus informal consultations have been
investigated in several reports. Many studies view informal curbside consultations as time-
saving [344,348], improving the quality of care and reducing hospital admissions [349].
There are concerns that insufficient information may be provided or important information
missed in informal consultations [344]. A recent study concluded that informal or curbside
consultations are associated significantly more often with inaccurate or incomplete informa-
tion being presented, which may result in inappropriate advice [350]. Potential medicolegal
aspects and risks of informal curbside consultations have also been debated [351], with
one report questioning the overall legality of informal curbside consultations [352].
Regarding IDSC, only two studies have evaluated the impact of formal versus informal
consultations on disease progression and prognosis. A prospective post hoc study, includ-
ing altogether 627 patients with various infections, observed no significant difference be-
tween formal and informal IDSC regarding compliance with recommendations for treat-
ment, performing of diagnostic or monitoring tests, early clinical improvement, in-hospital
mortality or length of hospital stay [343]. However, only 3% of all patients received ICU
treatment and only 7% were defined as bacteraemic or septic. Moreover, no causative
pathogens were reported for bacteraemic or septic patients [343]. Another study that in-
cluded altogether 233 retrospectively followed SAB patients found that informal consulta-
tions were not associated with poorer outcome (i.e. no more SAB relapses). However, im-
proved survival with informal IDSC as compared with formal IDSC was observed, although
very few patients (6/179) received informal IDSC, which almost certainly affected the re-
sults [353].
2.5.2. Impact of IDSC on clinical management
IDSC has been shown to enhance proper antibiotic selection [16,18,55,58,257,342,354],
appropriate duration of therapy [18], proper route of delivery of antibiotic therapy and
proper patient monitoring for minimizing adverse drug reactions [341,355]. A positive im-
pact of IDSC on disease management, progression and prognosis has been established for
a large number of specific infectious diseases and clinical situations. As a result of IDS in-
volvement and following of IDS recommendations, patients receive more often correct di-
agnoses [356], more proper therapies [342,357] and less complications [342]. Improved
clinical outcome as a result of IDS-guided management has been shown in HIV and AIDS
patients [358], in candida bloodstream infection [359] and in community-acquired pneumo-
nia [360] and osteomyelitis [361]. Four studies in the 1990s demonstrated reduced morbid-
ity, mortality and cost as a result of IDSC in management of bacteraemic patients
[184,357,362,363]. A recent study including various infectious diseases reported IDS inter-
vention, compared with non-IDS intervention, to be significantly associated with lower mor-
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tality rates, less readmissions, less ICU treatment and shorter hospital length of stay as
well as reduced payments and costs [364].
2.5.3. IDSC in Staphylococcus aureus bacteraemia
A total of 11 studies during 1998-2012 investigated the impact of IDSC on SAB [2,3,12,16,
18,56,57,58,184,257,353]. Study design, setting and study population differed in these
studies. Most studies were retrospective, two were are prospective [18,184] and one com-
bined prospective and retrospective patient data [3]. The patient number (100-599), MRSA
frequency (2-76%) and the proportion of patients with IDCS (27-82%) also varied widely.
However, common in these studies was a positive impact of IDSC on either disease pro-
gression or prognosis. Altogether, 9 studies reported significantly improved clinical man-
agement comprising 1) an increased number of follow-up blood culture collections
[16,56,257], 2) more radiological investigations, i.e. echocardiography and bone scans
[3,18,56] resulting in more endocarditis and deep infection foci diagnosed [3,56,57,
184,257], 3) more appropriate selection and duration of antibiotic therapy, 4) more appro-
priate timing regarding MRSA therapy as well as use of ?-lactam antibiotic whenever pos-
sible [3,18,56,57,58,257,353], 5) more removal of infected prosthetic devices and intravas-
cular catheters, drainage of pus or infection foci removed [16,257,353] and more admis-
sions to surgical ward [58] and 6) longer hospital treatment duration [57].
As a result of improved clinical management, significant reductions in SAB relapses
[184,353] and in both 28-day and three-month mortality (both SAB-related and in-hospital
mortality) were reported in most studies [2,3,12,16,18,56,57,58] with no significant mortality
reduction described in three studies [184,257,353]. The main results for these studies of
IDSC in SAB are listed in Table 4.
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Table 4. Impact of infectious disease specialist consultation (IDSC) on Staphylococcus
aureus bacteraemia management and mortality.
Study N IDSC 1 TTE
TEE 2
Radio-
logy
Deep
foci
IE 3 Follow-up
cultures
Anti-
biotics 4
Focus
removal
SAB
relapse 5
†
Fowler
et al. 1998
Mylotte
et al. 2000
Kaech
et al. 2006
Jenkins
et al. 2008
Lahey
et al. 2009
Rieg
et al. 2009
Nagao
 et al. 2010
Honda
et al. 2010
Choi
et al. 2010
Robinson
et al. 2012
Pragman
et al. 2012
244
293
308
234
240
521
346
341
100
599
233
45%
36%
82%
53-90%
51%
67%
---
33%
42%
27%
77%
-
-
-
?
-
?
?
?
?
-
-
-
-
-
?
-
?
-
-
-
-
-
?
-
-
?
-
?
?
-
?
?
-
?
-
-
?
-
?
?
-
?
?
-
-
-
-
?
?
-
?
-
?
?
-
-
-
-
?
?
?
?
?
?
?
?
-
-
-
?
?
-
-
-
?
-
?
?
-
-
?
-
?
-
-
-
-
?
?
?
?
?
??
??
?
??
?
?
?
† Mortality. ? Significant increase in univariate analysis.    ? Significant decrease in univariate analysis.    ??
Significant decrease in multivariate analysis.   ? No significant effect.   --- Not reported. 1 Percentage of pa-
tients receiving IDSC. 2 Transthoracic or oesophageal echocardiography. 3 Infective endocarditis. 4 Appro-
priate choice and/or duration. 5 Relapse or recurrence of SAB.
2.6 Biomarkers in Staphylococcus aureus bacteraemia
Symptoms of serious infections such as bacteraemia can be non-specific, resulting in chal-
lenging clinical diagnostics and evaluations of disease severity [365]. Biomarkers have
been explored as a tool for risk stratification or as a surrogate marker for patient outcome,
to identify a patient with increased probability of having a disease or a pathologic process
or to follow the treatment response [366]. Vast numbers of biomarkers, e.g. C-reactive pro-
tein (CRP) or procalcitonin (PCT), have been either used or proposed for clinical practice
[367,368], although the predictive value of both has been questioned [369,370]. A review
from 2010 evaluated altogether 178 different sepsis biomarkers from 3370 studies, reflect-
ing the wide scope of the biomarker field in infectious diseases. The review concluded that
none of these biomarkers demonstrate the sensitivity or specificity required for faultless
routine clinical diagnostics. The most widely used are CRP and PCT, although it is well-
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recognized that these have limited prognostic value and insufficient capability to distinguish
sepsis from various inflammatory conditions [371]. Despite extensive research, the specific
role of biomarkers in infections, bacteraemias and sepsis remains undefined [372].
2.6.1. Biomarker candidates
Serological diagnostic assays
Although S. aureus-positive blood culture is generally a prerequisite for SAB diagnosis,
there are situations with clinical suspicion of SAB when blood cultures are not taken or re-
main negative due to foe example earlier antibiotic therapy. In clinical situations with SAB
suspicion, but unavailable blood cultures, the SAB serological response to S. aureus anti-
gens may be valuable when evaluating the clinical situation and S. aureus as a causative
agent. Furthermore, serology has been suggested as a tool for differentiating between
complicated and uncomplicated SAB [373] and for evaluating the effect of treatment [374].
The healthy adult population presents circulating antibodies for most S. aureus antigens
[375,376], and elevated antibody levels or seroconversion (alteration in antibody titres)
constitutes the basis for serological diagnosis.
Two serological tests, antistaphylolysin, i.e. antibody against staphylolysin (ASTA), and
teichoic acid antibody (TAA), are frequently used in clinical practice. Most studies report a
TAA response to infection within 14-28 days [377], with titer elevations of 1:2 - 1:4 suggest-
ing S. aureus infection [378], 1:4 indicating active S. aureus infection [379] and 1:8 encoun-
tered in SAB patients with endocarditis [379,380]. The predictiveness of TAA varies widely,
with complicated SAB cases presenting TAA response in 80% [381]. One study presented
TAA response in 91% of endocarditis, 86% of complicated SAB and 68% of uncomplicated
SAB [382]. However, other studies have reported elevated TAA levels also in 44% of
healthy controls [383].
ASTA has been more applicable among dermatological patients than among invasive infec-
tions due to its correlation with skin barrier function [384]. High ASTA titers are encoun-
tered among patients with dermatoses and atopic dermatitis [384,385]. However, compli-
cated SAB or endocarditis have presented ASTA responses in only 32-62% of cases
[386,387], and hence, due to low sensitivity the predictiveness of ASTA is regarded as lim-
ited [379]. Although extensive research with TAA, ASTA and other serological parameters
has been performed, no serological diagnostic test alone has managed to present titers
positive for all SAB patients or titer elevations separating uncomplicated and complicated
SAB cases [388].
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A study comparing serological characteristics of S. aureus endocarditis in addicts and non-
addicts concluded that serological tests were not helpful for identification of deep infection
foci. Surprisingly, among addicts with no diagnosed endocarditis, ASTA titers were more
often positive than among addicts with endocarditis [389].
Soluble urokinase plasminogen activator
Soluble urokinase plasminogen activator receptor (suPAR) has been presented as an in-
teresting new biomarker in SAB [390,391,392]. Several cell types, e.g. neutrophils, macro-
phages and monocytes, express on the cell surface suPAR (uPAR/CD87) [393,394]. The
suPAR is encountered in various body fluids, such as plasma and urine [395,396], and ele-
vated suPAR levels manifest in inflammation and immune activation [397]. A prospective
study including 59 SAB patients found that suPAR was prognostic for mortality, with a sen-
sitivity of 79% and a specificity of 68%, although suPAR did not predict the presence of
deep infection foci [390]. SuPAR levels were significantly higher among non-surviving bac-
teraemia patients, with a sensitivity of 83% and a specificity of 76% for fatal outcome [392].
However, a study including 55 patients with bacteraemia due to various pathogens, includ-
ing 18% SAB cases, demonstrated that suPAR was a better predictor for Gram-negative
than Gram-positive bacteraemia [391].
Interleukin-10
The cell wall of S. aureus consists of peptidoglycan, which has the capability of macro-
phage stimulation, cytokine release and endotoxin-like activity [1,398]. It has been sug-
gested that circulating peptidoglycan may elevate interleukin-10 levels [399] and this may
hamper the T-helper adaptive immunity for S. aureus bacteria. Thus, interleukin-10 may
present a potential harmful effect on SAB patients [400]. A prospective study including 59
SAB cases (35% of MRSA) identified elevated interleukin-10 as an independent mortality
predictor, whereas survivors seemed to often have normal interleukin-10 levels [401].
Procalcitonin
Procalcitonin (PCT), the precursor for calcitonin hormone, has been suggested as a bio-
marker for bacteraemia and sepsis [391,402,403,404]. PCT might have a role in distin-
guishing between Gram-positive and Gram-negative bacteraemia among critically ill pa-
tients [405] and in differentiating bacteraemia from contaminated blood cultures [406].
However, no studies have investigated the predictive value of PCT solely among SAB pa-
tients, although SAB patients are included in several reports with PCT [391,403,407].
Moreover, PCT has been proposed as a predictor for endocarditis in general [407] and in
SAB [408]. Two thorough prospective reports including bacteraemic patients with 9-27% of
SAB investigated the relationship between PCT and endocarditis. The first study demon-
strated high PCT levels among SAB patients and significantly higher PCT levels in SAB-
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related endocarditis compared with endocarditis due to other bacteraemias [408]. The sec-
ond study demonstrated high PCT levels in SAB patients relative to patients with bacte-
raemia due to other pathogens and even higher PCT levels in patients with SAB and endo-
carditis. Moreover, the study showed significantly higher PCT levels in patients with con-
firmed endocarditis than in patients with rejected endocarditis [407]. A retrospective report
including 119 Gram-positive (20% of SAB) and 44 Gram-negative bacteraemic patients
concluded that PCT among SAB patients was significantly higher than in patients with bac-
teraemia due to coagulase-negative staphylococci (CoNS). It was postulated that PCT
might be useful in differentiating S. aureus from CoNS [403]. A prospective study, originally
designed to investigate suPAR, included 55 bacteraemic patients fulfilling systemic inflam-
matory response syndrome (SIRS) criteria (18% of SAB) and reported significantly higher
PCT levels among Gram-positive bacteraemia than among Gram-negative bacteraemia.
However, PCT did not predict mortality [391].
2.6.2. Cell-free DNA
Cell-free DNA (cf-DNA) has been viewed as a potential biomarker for bacteraemic and
septic patients as well as critically ill patients [402,409,410,411,412,413,414]. As a result of
necrosis, and due to apoptotic cells, free cellular DNA fragments (i.e. cell-free DNA) are
released into plasma [415]. Among healthy individuals, low levels of plasma cf-DNA are
encountered [416] due to removal of deceased cell debris by phagocytes [417]. Specific
clearance processes of cf-DNA remains unestablished, although experimental studies
indicate that liver and kidneys play a key role [418].
Sepsis in both hospitalized [402] and critically ill patients [409] is reflected by elevated cf-
DNA levels, and sepsis has been reported to amend cell necrosis [419] and apoptosis [420]
and result in rising cf-DNA levels [417,421]. Cf-DNA is known to independently predict mor-
tality in patients with bacteraemia due to S. aureus, Streptococcus pneumoniae, ß-
haemolytic streptococcae or Escherichia coli [412]. In patients with severe sepsis and sep-
tic shock, the plasma cf-DNA demonstrates an independent correlation with serum lactate
elevation at ICU admission. This is suggested to demonstrate sepsis-related hypoxaemia in
apoptosis [411]. ICU non-survivors have been shown to present higher cf-DNA levels than
ICU survivors [414,422]. Cf-DNA has been demonstrated to predict mortality among ICU
non-survivors with severe sepsis more accurately than Acute Physiology and Chronic
Health Evaluation (APACHE) II scores, Multiple Organ Dysfunction Syndrome (MODS)
scores, age or gender [414].
Two studies have evaluated the prognostic value of cf-DNA in bacteraemic patients with
positive blood cultures for various bacteraemic pathogens. They demonstrated higher cf-
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DNA levels in ICU patients than in non-ICU patients [412], and in ICU non-surviving pa-
tients with severe sepsis than in those surviving ones [414]. The prognostic use and cut-off
values of cf-DNA regarding bacteraemic ICU patients with only one causative pathogen
have not been studied.
2.7. Prognosis and mortality in Staphylococcus aureus bacteraemia
During the pre-antibiotic era, very high mortality rates of 75-82% in SAB were reported
[423,424]. From the 1950s until the 1980s, much lower mortality rates, varying from 24% to
58% were seen [425,426,427,428,429]. From the 1980s to the beginning of the 2000s, as a
result of improved SAB management, the mortality rates fell significantly from 36% to 21%
from 1981-1985 to 1996-2000 for HA-SAB and from 34% to 26% for CA-SAB during the
corresponding time-period [7]. At the end of the 1990s several studies reported even lower
overall mortality rates of 7-39% [51,137,184]. However, in the 2000s and 2010s the mortal-
ity seems to have stabilized around 14-32% for both in-hospital and SAB-related mortality
[2,3,12,13,14,15,16,17,18]. A vast number of factors may affect the prognosis, and these
may roughly be categorized as host-related, pathogen-related, acquisition-related, clinical
picture (pathogen-host interaction related) -related and treatment-related [430].
2.7.1. Impact of host-related factors
Age
High age is viewed as one of the strongest predictors for both overall and SAB-related mor-
tality. Numerous studies, including both MSSA and MRSA, apply high age, > 60-65 years,
as a statistical parameter and report high age as an independent predictor of fatal outcome
in multivariate analysis for overall mortality at 30 days [12,23,431,432], for 60-day [168] and
three-month SAB-related mortality [156] and for in-hospital mortality related to SAB [22,433]
as well as for overall in-hospital mortality [434]. Recently, also a case-controlled study
where patient characteristics and clinical management were controlled found age over 65
years to be an independent predictor for fatal outcome [435].
Gender
Gender is not viewed as an independent mortality factor in SAB. Although several studies
report higher SAB incidence among males [85,117], a 2-fold higher overall mortality at 30
days was reported in MRSA bacteraemia in females [436,437]. Different hormonal charac-
teristics and health-seeking behaviour have been proposed as explanations for the higher
mortality in women [438]. However, some studies have not identified any significant connec-
tion between SAB outcome and gender [3,7,23]. A large-sized (n > 9000) report of MRSA
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bacteraemic episodes in England presented similar age-adjusted mortality among females
and males, concluding that gender differences may be explained by age differences [439].
Socio-economic status
Although social deprivation and socio-economic status are known to be associated with
higher risk of infection [440], a connection between SAB mortality and socio-economic
status has been reported in only one study and socio-economic status had no impact on
SAB outcome [441].
Underlying diseases
The presence of underlying diseases has a strong impact on SAB outcome. Several stud-
ies have listed cardiac disease [17], chronic liver disease [18,23,442], acute or chronic re-
nal disease [2], dialysis [2,442], malignancy [23,431,442], alcoholism [2], immunosuppres-
sion [2,13], diabetes [12] and multiple comorbidities [7,443] as independent predictors of
mortality. Many studies have applied the McCabe and Jackson criteria to categorize the
severity and prognosis of underlying diseases and comorbidity as healthy, non-fatal, ulti-
mately fatal or rapidly fatal [444]. Ultimately or rapidly fatal underlying diseases have been
shown to predict fatal outcome in many reports [3,22,188]. However, two studies with small
population sizes failed to detect an impact of comorbidities on outcome in SAB [120, 445].
2.7.2. Impact of community or health care acquisition on mortality
The impact of SAB acquisition on outcome has been controversial, with a trend in the last
decade of no significant association with mortality. SAB has traditionally been divided ac-
cording to acquisition into health care- (nosocomial) and community-associated cases.
Several studies in 1970-1990 found HA-SAB to be associated with higher mortality [51,427,
446], and the association of HA-SAB with higher age and comorbidity has been presented
as an explanation for the higher mortality. However, the majority of studies after 2000 have
not managed to detect any significant prognostic impact of SAB acquisition on outcome
[12,17,19,23,183,188,190,447], with the exception of one study connecting HA-SAB to
lower mortality [2]. HA-SAB has been observed to carry higher mortality than CA-SAB in
only two recent studies [442,448]. Hence, it appears that there might be a trend of diminish-
ing impact of SAB acquisition on outcome.
2.7.3. Impact of methicillin resistance on mortality
The relationship between MRSA and SAB prognosis has been thoroughly investigated, but
with conflicting results. Several studies have associated MRSA with a significantly higher
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mortality rate in multivariate analyses [3,23,138,156,431]. Two meta-analyses in 2000 pre-
sented a significantly higher mortality rate in MRSA bacteraemia than in MSSA bacterae-
mia [49,449]. However, some studies have failed to connect MRSA bacteraemia to higher
mortality rates than MSSA bacteremia [12,168,188,450]. Hence, the results of the two
meta-analyses have been questioned due to lack of knowledge of hospital duration prior to
SAB in the original studies; when length of hospital stay was adjusted for, bacteraemias
with MRSA and MSSA presented similar mortality rates [451].
Several factors have been proposed to explain the higher mortality in MRSA bacteraemia.
Some reports have suggested that in patients with MRSA bacteremia higher mortality is
due to higher age [51,157], more severe underlying diseases [188], more severe illness at
bacteraemia onset (e.g. septic shock) and more complications such as pneumonia [51] as
compared with MSSA bacteraemia. One report states that higher mortality in MRSA bacte-
raemia than in MSSA bacteraemia is evident only in critically ill patients after adjustment for
disease severity and acute illness [138]. Various factors in MRSA treatment may be asso-
ciated with poorer outcome. MRSA has been connected to a delay in effective antibiotic
therapy onset [52,157], and vancomycin therapy has been regarded as having weaker effi-
cacy and a less effective blood-sterilizing effect, increasing the risk for persistence of SAB
relative to semi-synthetic penicillin or other ?-lactams [40,53,274,452,453]. Thus, although
vancomycin is the drug of choice, it has repeatedly been connected to treatment failure and
higher mortality than ?-lactams [22,38,39,40,41]. A prospective study of considerable size
(n=1865) presented glycopeptide (mostly vancomycin) therapy as an independent signifi-
cant mortality predictor [190]. Both pro- and retrospective reports have demonstrated a
connection between high vancomycin MIC and worse prognosis in patients with MRSA
bacteraemia [454,455], with MIC values ? 1.5-2 mg/L representing independent parameters
for treatment failure [454] and mortality [455]. Recently, a retrospective study reported high
vancomycin MIC (? 1.5 mg/L) as the only independent risk factor for complicated bacte-
raemia when MSSA bacteraemia patients were treated with vancomycin. However, MIC ?
1.5 mg/L was not associated with higher mortality [186]. Moreover, pathogen-related viru-
lence factors common in MRSA strains have been demonstrated, such as SCCmec type I
or agr (accessory gene regulator) group II polymorphism, which might be associated with
higher mortality or vancomycin treatment failure [456,457].
2.7.4. Impact of clinical manifestations on mortality
Severity of illness at Staphylococcus aureus bacteraemia onset
The severity of illness, particularly the presence of severe sepsis, septic shock or multi or-
gan failure, at onset of SAB are factors strongly predicting mortality [2,19,24,25,183,445].
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Different scoring systems for assessment of severity of illness and outcome prediction have
been developed, e.g. the APACHE II, SOFA and PITT scores [139,140,142]. Severity of ill-
ness at S. aureus-positive blood culture, as evaluated by APACHE-scores [139], has been
shown to be significantly correlated with mortality [12,13,458,459]. However, among ICU
patients with sepsis, the Pitt bacteraemia score system has been observed to predict mor-
tality better than APACHE II with respect to sensitivity-specificity (67% and 74% for
APACHE II versus 68% and 82% for PITT scores) [141]. Other clinical conditions con-
nected to higher mortality have been acute organ dysfunction, need for mechanical ventila-
tion [431], acute renal failure [2], neutropenia [442] and thrombocytopenia [460]. Need for
ICU treatment [3,25,188,436] or ICU admission [3,443] has been observed to independ-
ently predict weaker outcome as compared with non-ICU patients.
Deep infection foci
The prognostic impact of deep infection foci in SAB has varied widely depending on the
type of deep focus. Several studies have presented pneumonia (OR 5.8-17.0) [12,17,51]
and endocarditis (OR 2.8-12.1) [3,24,456] as independent predictors for mortality. How-
ever, among IDUs endocarditis has been associated with significantly better outcome than
among non-IDUs [199]. In native valve infective endocarditis, factors such as age, perian-
nular abscess, heart failure, lack of surgical intervention and thromboembolic central nerv-
ous system event, have been associated with significantly weaker outcome [129]. One
study observed no association between deep infection foci and outcome [2], in contrast to
another that found metastatic foci to lead to weaker outcome [24].
Dosing and onset of antibiotic therapy
Several studies have demonstrated an adverse impact of delayed empiric antibiotic therapy
in both MSSA and MRSA bacteraemia [40,50,188,437]. The delay in time between S.
aureus-positive blood culture and initiation of empiric appropriate antibiotic administration,
after which mortality rises, has varied from 24 to 72 hours [40,50,188,461]. Contrary to this,
there are studies demonstrating a non-significant association between correctly timed ap-
propriate antibiotic therapy and survival rates in both MSSA and MRSA bacteraemia
[24,25,157]. One study concluded that only severely ill SAB patients with APACHE II points
> 15.5 gained from early onset of antibiotic therapy, whereas for SAB patients with
APACHE II < 15.5 delayed antibiotic therapy had no impact on mortality [50]. Some studies
have demonstrated the significance of appropriate dosing of antibiotic therapy. A prospec-
tive study of 278 cases of MSSA bacteraemia, including various deep infection foci, dem-
onstrated that a total daily dose of penicillinase-stable penicillin < 4 g was an independent
predictor for mortality and a total daily dose < 3 g an independent predictor for SAB recur-
rence [19]. Another study that included 87 cases of MRSA bacteraemia demonstrated in-
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creased survival when vancomycin initiation took place within 48 hours of S. aureus-
positive blood culture results and the dose was ? 2.0 g/day [462].
Surgery and focus removal
SAB patients with non-eradicated and non-eradicable foci had higher mortality than pa-
tients who had their focus surgically (or by another intervention) removed (OR 4.17 vs. OR
3.75) [168]. An uneradicated focus was associated with significantly weaker outcome (OR
6.7) also in a study that included only 1% of patients with MRSA bacteraemia [19]. A large
retrospective study comparing vancomycin and ?-lactam therapy on outcome in solely
MSSA bacteraemia patients found eradicated infection foci to be an independent prognos-
tic factor for improved outcome (OR 0.3) [22]. Antibiotic therapy combined with early sur-
gery had significantly better outcome in native valve endocarditis in SAB as compared with
antibiotic therapy alone [463]. A study investigating the prognostic impact of IDS recom-
mendations on outcome of 244 SAB patients found unremoved, infected intravascular de-
vices to be significantly associated with SAB relapse and mortality (OR 6.5) [184]. A very
recent prospective study, including 58% of patients with MRSA bacteraemia, found a three-
day delay in removing eradicable foci to be associated significantly with persistent SAB
(OR 2.18) [30]. However, no direct connection between delayed eradication and mortality
was presented.
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3. AIMS OF THE STUDY
Specific objectives of this study were as follows:
I  To compare predisposing factors, disease progression and outcome of health care-
and community-associated methicillin-sensitive Staphylococcus aureus bacteraemia.
II To evaluate the prognostic value of the biomarker cell-free DNA in methicillin-sensitive
Staphylococcus aureus bacteraemia patients with early intensive care unit treatment.
III To investigate the impact of formal bedside infectious diseases specialist consultation,
informal telephone consultation and no consultation on disease progression and prog-
nosis of methicillin-sensitive Staphylococcus aureus bacteraemia.
IV To evaluate the impact of early and late adjunctive rifampicin therapy onset on disease
 progression and prognosis in methicillin-sensitive Staphylococcus aureus bacteraemia
patients with deep infection foci.
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4. MATERIALS AND METHODS
4.1. Study populations
The study populations consisted of prospectively collected patient data (Studies I and II)
and retrospectively collected data (Studies III and IV).
Study I was a prospective, multicenter study carried out in all five university central hospi-
tals and in seven central hospitals in Finland throughout two time periods: January 1999 to
May 1999 and January 2000 to August 2002. Adult patients with at least one blood culture
positive for Staphylococcus aureus were prospectively followed from a median of three
days after blood culture collection. In total, 1226 SAB patients were identified during the
study period and after controlling for exclusion criteria and excluding patients unable to
provide an informed consent or patients who refused participation, altogether 430 cases
were included. The exclusion criteria were age < 18 years, imprisonment, pregnancy (sus-
pected or proven), breastfeeding, epilepsy, bacteraemia during previous 28 days, po-
lymicrobial bacteraemia (? 3 microbes), history of allergy to any quinolone antibiotic, previ-
ous tendinitis during fluoroquinolone therapy, prior fluoroquinolone use for more than five
days before randomization, positive culture for S. aureus only from a central intravenous
catheter, neutropenia (<0.5 x 10 9/L), patients with bacteraemia due to MRSA (n=6) and a
S. aureus strain resistant to any fluoroquinolone.
Study II included the same prospectively collected patient data as in Study I, although due
to missing study samples (n=12), only 418 SAB cases were included in the analysis.
Study III was retrospective with 342 SAB cases representing all adult patients from Hel-
sinki University Central Hospital in Finland with at least one blood culture positive for
Staphylococcus aureus during two time periods: 2000–2002 and 2006–2007. The earlier
time period 2000-2002 included the patients from Studies I and II. Through the use of a
unique personal number provided to all Finnish residents, S. aureus isolates and patients
were matched. The patient data were collected from written (2000–2002) and electronic
(2006–2007) patient records. Due to missing patient records, 7 patients had to be ex-
cluded. Two time periods were included in order to exclude the possible effect of unidenti-
fied temporal differences regarding personnel, treatment practices or any other factors diffi-
cult to control. All cases with MRSA bacteraemia were excluded (5 cases during 2000-
2002, but none during 2006-2007).
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Study IV included all patient data collected for Studies I and III. Cases with MRSA bacte-
raemia were excluded (n=6)
4.2. Study designs
Data collection included basic patient characteristics: age, gender, underlying diseases and
predisposing factors. SAB acquisition, infection focus and antibiotic treatment were regis-
tered. Surgical procedures, duration of hospitalization and infection foci confirmed through
radiological, bacteriological or pathological research or clinical suspicion only were docu-
mented. Radiological investigations and time to defervescence (axillary temperature < 37.5
oC) were recorded. Laboratory findings included plasma cf-DNA and CRP concentrations at
days three and five from the positive blood culture sampling. IDSC during the first week af-
ter the first blood culture positive for S. aureus was documented. SAB relapse within three
months was documented.
Study I was a prospective study. An IDS followed up each SAB patient for three months.
SAB cases were categorized according to acquisition into CA- and HA-SAB. The differ-
ences of CA- and HA-SAB regarding patient characteristics, underlying conditions, predis-
posing factors and prevalence of deep infection foci within three days and three months
were analysed with univariate analysis. Three-month survival of CA- and HA-SAB were es-
timated with the Kaplan-Meier method and prognostic factors analysed with multivariate
analysis. The primary end-point was case fatality at 28 days and at three months. Secon-
dary end-points were the time to defervescence, decrease in serum CRP concentration
and number of deep infection foci within three days and three months.
Study II was a prospective study. Plasma cf-DNA at days three and five from the positive
blood culture were stratified and compared according to patient demographics, underlying
conditions, severity of illness, deep infection foci, treatment in ICU and mortality for 1) the
whole patient population and 2) patients receiving ICU treatment within seven days of S.
aureus-positive blood culture. Receiver-operating characteristic (ROC) analyses for cf-DNA
and CRP were performed, and cut-off values for day three and five cf-DNA were calcu-
lated. The patient demographics, underlying conditions, severity of illness, deep infection
foci, treatment in ICU and mortality were then stratified and compared according to the cf-
DNA cut-off values of days three and five. Prognostic factors were analysed according to
the Cox regression model. The primary end-point was mortality at seven days, 28 days or
three months, and secondary end-points were deep infection foci localized during the
three-months follow-up.
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Study III was a retrospective study. The SAB cases were categorized according to bedside
(formal), telephone (informal) or no IDSC within one week of S. aureus-positive blood cul-
ture. Patients with fatal outcome within three days after S. aureus-positive blood culture
were excluded to allow for the possibility of death occurring before IDSC, as the mean time
lapse between blood culture collection and IDSC was three days. Patient demographics,
underlying conditions, severity of illness, deep infection foci, treatment in ICU and mortality
were stratified and compared according to IDSC. Multinomial logistic regression analyses
were performed to simultaneously compare the three consultation groups. The Kaplan-
Meier method was used to compare the impact of various IDSC groups on mortality and
defervescence.  Prognostic factors were analysed according to the Cox regression model
in order to determine the prognostic impact of IDSC. The primary end-point was case fatal-
ity at 28 days and three months. Secondary outcome measures were the time to deferves-
cence, any inadequate antibiotic therapy, duration of hospitalization, number of deep infec-
tion foci and any relapse of SAB within three months.
Study IV was a retrospective study. The patient population was categorized according to
whether rifampicin therapy was received, whether it was initiated within seven days (early)
or seven days past (late) positive blood culture and whether it was continued for at least 14
days. The main analyses were performed by excluding cases with a fatal outcome within
three days as well as excluding patients with alcoholism and acute or chronic liver disease
to allow for death before positive blood culture results (the mean time-lapse between blood
culture collection and positive blood culture results was three days) and to account for ri-
fampicin therapy contraindications (alcoholism and liver disease). Moreover, as a parallel
analysis, the patient population was analysed by excluding cases with a fatal outcome
within 14 days of blood culture collection to allow for death before completing 14 days of ri-
fampicin therapy.
Patient demographics, underlying conditions, severity of illness, deep infection foci, treat-
ment in ICU, antibiotic therapy and mortality were stratified and compared according to ri-
fampicin therapy ? 14 days or < 14 days. Cox regression analysis was performed to evalu-
ate the prognostic value of early and late rifampicin therapy for 1) the whole patient popula-
tion, 2) patients with a deep infection foci. The prognostic impact of early and late rifampicin
therapy for ? 14 days or < 14 days in the whole patient population and among patients with
deep infection foci was analysed using the Kaplan-Meier method. The primary end-point
was mortality at three months and the secondary end point deep infection foci during the
three-month follow-up. The rifampicin dose was 450 mg (< 50 kg of body weight) or 600 mg
(> 50 kg of body weight) given once daily.
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4.3. Definitions of terminology
Prognosis or severity of underlying conditions was classified as healthy (no approximated
time period to death), non-fatal (no approximated time period to death), ultimately fatal (ap-
proximated death within 6 months - 5 years) or rapidly fatal (approximated death within 6
months) according to the McCabe and Jackson criteria [444]. SAB was considered HA if
the first positive S. aureus blood culture was received ? 48 hours after admission to hospi-
tal or within two days of admission when the patient had been discharged from a hospital
within seven days precedingly or when the patient was a long-term care facility resident
during the previous two months or was attending haemodialysis. SAB was considered CA
when the first positive S. aureus blood culture was received within 48 hours of hospital ad-
mission without any preceding hospitalization within seven days. Deep infection foci com-
prised deep-seated abscesses, endocarditis, foreign body infection, meningitis, mediastini-
tis, osteomyelitis, pneumonia and septic arthritis. Central venous catheter (CVC) infections
were defined according to the guidelines of the IDSA [42]. The modified Duke criteria were
used to define endocarditis as definite, possible or rejected according to the presence of
major and minor criteria [248]. SAB relapse was defined as the same pattern of resistance
and PFGE typing for the two S. aureus strains. Severe sepsis was regarded as sepsis in-
cluding 1) hypotension, i.e. systolic blood pressure < 90 mmHg, mean arterial blood pres-
sure < 70 mmHg, or a systolic blood pressure decrease > 40 mmHg in adults or < 2 SD be-
low normal for age or 2) hypoperfusion, i.e. hyperlactataemia (>1 mmol/L) or decreased
capillary refill or 3) organ failure, i.e. arterial hypoksaemia Pao2 / F102 < 300, acute oliguria
with urine output < 0.5mL/kg/h, creatinine increase > 0.5 mg/dL, coagulation abnormalities
of INR > 1.5 or APTT > 60, ileus with absent bowel sounds, thrombocytopenia (< 100) or
hyperbilirubinaemia (> 70 mmol/L) [464]. Corticosteroid therapy comprised systemic pred-
nisone at a dose of at least 10 mg/day or the equivalent for at least one month. Immuno-
suppressive treatment was defined as any immunosuppressive treatment received within 6
months of SAB. IDU was considered any information from the patient or the patient records
on injection drug use within 6 months of the first positive S. aureus blood culture. Pitt bacte-
raemia score was calculated based on fever, presence of hypotension, need for mechani-
cal ventilation, cardiac arrest event and altered mental status. The exact criteria are listed
below [142].
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Pitt bacteraemia score criteria.
Criterium               Score
I Mental status
Alert 0
Disoriented 1
Stuporous 2
Comatose 4
II Fever
? 35oC or ? 40oC 2
35.1 - 36.0oC or 39.0 - 39.9oC 1
36.1 - 38.9oC 0
III Hypotension
Systolic blood pressure < 90 mmHg, 2
Intravenous vasopressor requirement, or
acute drop in blood pressure:
> 30 mmHg (systolic), > 20 mmHg (diastolic)
IV Mechanical ventilation requirement 2
V Cardiac arrest 4
Complicated SAB (Study II) was defined as SAB in combination with deep infection foci,
severe sepsis, septic shock or high Pitt bacteraemia score of 4. Hence, the definition of
´´complicated SAB`` (Study II) is not identical to the definition used by other authors who
have defined complicated SAB as the presence of secondary foci, recurrence of SAB within
three months, any event requiring ICU treatment or careful monitoring or follow-up of the
SAB patient for any of the following: severe sepsis, septic shock, ARDS, DIC, thromboem-
bolic event or septic embolization [28,121,185,186].
IDSC were categorized into three groups: bedside (formal) IDSC, telephone (informal)
IDSC or no IDSC. Bedside (formal) IDSC was documented when the IDS had included writ-
ten directives in the patient records regarding patient status based on careful patient record
review and physical investigation. Telephone (informal) IDSC was defined when the treat-
ing physician documented in the patient records the directives given by the IDS and the
name of the IDS. Cases where data or any documentation of IDSC were lacking were
categorized as no consultation. IDSC was considered to have occurred only when it had
taken place within one week after the first positive blood culture of S. aureus. Antibiotic
therapy was regarded as appropriate if administered intravenously for at least 28 days for
deep infection foci and at least 14 days otherwise.
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4.4. Laboratory methods
During 2000-2002 blood cultures were performed with the Bactec system (BD Diagnostic
Systems, Sparks, MD, USA) in five hospitals and the BacT Alert System (Organon-
Teknika, Boxtel, The Netherlands) in seven hospitals, whereas during 2006-2007 the BacT
Alert System was applied. Gram-staining and subculturing on chocolate agar plates were
carried out for aliquots of bottles with a positive signal. Standard laboratory methodology
with Gram-staining, colony morphology, production of urease and DNAase and application
of mannitol and trehalose were used to identify S. aureus isolates. The disk diffusion
method (guidelines of the Clinical and Laboratory Standards Institute, CLSI) was applied
for testing of antimicrobial drug susceptibility. Tested antibiotics were oxacillin, cephalexin,
clindamycin, levofloxacin, rifampicin, and vancomycin. E-test (AB Biodisk, Solna, Sweden)
was applied to determe of MICs of oxacillin (according to manufacturer`s instructions).
Via automatic immunoturbidometric analysis with the 917 analyser or Modular PP-analyser
(Hitachi Ltd, Tokyo, Japan) and Tina-quant CRP reagents (Roche Diagnostics, Tina-quant
CRP), the serum or plasma C-reactive protein (CRP) (Studies I-IV) was determined. CRP
concentration <10 mg/L was defined as normal for both methods. Plasma cf-DNA (Study
III) was analysed with Quant-iTTM high-sensitivity DNA assay kit and QubitH fluorometer
(Invitrogen, Carlsbad, CA, USA). The directives provided by the manufacturer were fol-
lowed during each laboratory analysis step. At mean cf-DNA levels of 0.734 mg/mL, 1.377
mg/mL and 4.954 mg/mL the intra-day variation coefficients were 1.8%, 4.3% and 1.7%,
respectively, and the corresponding inter-day variation coefficients were 3.8%, 5.0% and
3.2% [412].
4.5. Statistical methods
The primary end-point in all statistical analyses was mortality at 28 days or three months. In
Study III, any cases with a fatal outcome within three days of S. aureus-positive blood cul-
ture were excluded from statistical analyses (except cases in Table 1 of Study III) in order
to allow for the possibility of death before any IDSC. In Study IV, for the main analyses,
cases with a fatal outcome within three days of S. aureus-positive blood culture, alcoholism
and acute or chronic liver disease were excluded. As a parallel analysis, cases with a fatal
outcome within 14 days of S. aureus-positive blood culture were excluded.
Data are presented as either absolute values including percentages (Studies I, III and IV)
or medians and interquartile ranges (IQR, 25th and 75th percentiles) (Study II). The Pearson
?2 test to compare categorical variables and Student´s t-test was used for non-categorical
variables. Mann-Whitney U-test was used for non-parametric data (Study II). Odds ratios
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(ORs) with 95% confidence intervals (CIs) were calculated. Univariate factors with p <0.1
were entered into binary logistic regression analysis (multivariate analysis) (Study I) or into
proportional hazards regression (Cox regression model) (Studies II-IV) to estimate factors
predicting three-month mortality. Multinomial logistic regression allowed simultaneous
comparison of the three different IDSC processes (Study III).
Receiver-operating characteristic (ROC) curves were produced for cf-DNA and CRP to es-
timate the discriminative power of these two in predicting three-month mortality. For each
ROC curve, the area under the curve (AUC) was calculated. The Youden index was de-
fined from the ROC curves as either the ROC-curve point maximizing both sensitivity and
specificity values or the sensitivity and specificity sum with the highest value in order to lo-
cate the cut-off point.
Survival estimates and time to defervescence were presented with the Kaplan-Meier
method using the Log-Rank test to compare the graphs (Studies I, III and IV). The Kaplan-
Meier method was used to present survival estimates and time to defervescence (Studies I,
III and IV). The ROC curve cut-off points were used for the Kaplan-Meier survival estima-
tion (Study II). All tests were two-tailed and p <0.05 was considered significant. All analyses
were performed using SPSS software, version 12.0 (SPSS Inc., Chicago, IL, USA).
4.6. Ethical aspects
The study protocols were approved by the ethics committees of all study sites and by the
Institutional Review Board and the Ethics Committee of Helsinki University Central Hospi-
tal. In Study I, patients provided a signed informed consent. Severely ill patients, e.g. pa-
tients in an unconscious state with assisted ventilation, were included as well without a
signed informed consent, as these patients were presumed to gain from the study medica-
tion. A signed informed consent was provided by the patient or a representative as soon as
possible.
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5. RESULTS
5.1. Community- and health care-associated bacteraemia (Study I)
5.1.1. Patient characteristics
The 430 SAB cases included 198 (46%) CA-SAB and 232 (54%) HA-SAB patients.
CA-SAB patients, as compared to HA-SAB patients, were significantly more often HIV-
positive (4% vs. <1%, p=0.018) and had more often chronic alcoholism (16% vs. 7%, p
=0.002), liver disease (25% vs. 7%, p <0.0001) and injection drug abuse (21% vs. 1%, p
<0.0001). HA-SAB patients underwent significantly more frequently a foreign body implan-
tation within one year preceding SAB (41% vs. 9%, p <0.0001), surgical procedures within
three months (44% vs. 8%, p <0.0001) or CVC application (23% vs. 1%, p <0.0001).
Wounds and chronic skin diseases were significantly more common among CA-SAB pa-
tients than among HA-SAB patients (59% vs. 46%, p=0.006) (Study I; Table I).
HA-SAB patients, as compared to HA-SAB patients, were significantly older (62.4 ± 15.2
vs. 52.9 ± 19.5 years, mean ± SD, p <0.0001), had more often an ultimately or rapidly fatal
underlying disease (41% vs. 12%, p <0.0001) and were more chronically ill with cardiovas-
cular disease (55% vs. 27%, p <0.0001), chronic renal failure (24% vs. 3%, p <0.0001), di-
alysis care (20% vs. <1%, p <0.0001), heart valve disease (22% vs. 7%, p <0.0001), ma-
lignancy (21% vs. 7%, p <0.0001), complicated diabetes (21% vs. 11%, p=0.003), haema-
tological malignancy (6% vs. <1%, p=0.001) or connective tissue or rheumatic disease
(15% vs. 8%, p=0.021) and more often received immunosuppressive treatment (19% vs.
7%, p <0.0001).
5.1.2. Clinical aspects
At S. aureus-positive blood culture and within the first week of treatment, no significant dif-
ferences between the patients with CA-SAB or HA-SAB were seen in severe sepsis (7%
vs. 6% at positive blood culture and 13% during the first week for both groups, respectively)
septic shock (3% for both groups and 7% vs. 4%, respectively) or need for ICU treatment
(16% vs. 15% and 23% vs. 21%). During the first three days of SAB, less deep infection
foci were localized among patients with HA-SAB relative to CA-SAB (69% vs. 84%, p
<0.0001), and throughout the three-month follow-up a slight increase was observed in the
number of patients with identified deep foci (80% vs. 87%, p=0.045) (Table 5). HA-SAB pa-
tients presented significantly more often mediastinitis or infection of CVC or peripheral
catheter or permanent foreign bodies, whereas osteomyelitis and deep-seated abscesses
were seen significantly more frequently in CA-SAB. No difference was observed in the oc-
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currence of pneumonia, septic arthritis, endocarditis or cutaneous infections between CA-
and hA-SAB patients. The prevalence of CA- and HA-SAB patients without any diagnosed
infection focus was low at three days (6% vs. 3%) and remained low throughout the three-
month follow-up (5% vs. 2%); however, the difference at both time-points was non-
significant (Table 5).
Table 5. Comparison of infection focus and mortality in community- (CA-) and health care-
(HA) associated Staphylococcus aureus bacteraemia at day three and at three months.
Data are number (%) of patients.
All SAB episodes
(n=430)
HA-SAB
(n=232, 54%)
CA-SAB
(n=198, 46%)
OR
(95%CI)
p-value
From blood culture
to day 3
SAB without foci
Cutaneous foci
Deep foci
Mortality
From blood culture
to 3 months
SAB without foci
Cutaneous foci
Deep foci
Mortality
21 (5)
268 (62)
325 (76)
3 (1)
14 (3)
283 (66)
359 (83)
76 (18)
9 (3)
151 (65)
159 (69)
1 (<1)
5 (2)
160 (69)
186 (80)
50 (22)
12 (6)
117 (59)
166 (84)
2 (1)
9 (5)
123 (62)
173 (87)
26 (13)
0.63 (0.26-1.52)
1.29 (0.87-1.91)
0.42 (0.26-0.67)
0.42 (0.04-4.71)
0.46 (0.15-1.40)
1.36 (0.91-2.02)
0.58 (0.34-0.99)
1.82 (1.08-3.05)
NS
NS
<0.0001
NS
NS
NS
0.045
0.023
OR, odds ratio; CI, confidence interval; NS, non-significant; SAB, Staphylococcus aureus bacteraemia.
5.1.3. Antimicrobial treatment
From the first day of the positive blood culture, all patients with CA- and HA-SAB were
treated with an antibiotic effective against the isolated S. aureus strain. The vast majority of
patients received a ?-lactam antibiotic whereas only 12% were treated with vancomycin.
5.1.4. Outcome
The case fatality at 28 days did not differ between CA- and HA-SAB (11% vs. 14%),
whereas at three months it was significantly higher among the HA-SAB patients (22% vs.
13%, p=0.023). Overall, the case fatality at 28 days was 13% and at three months 18%.
The mortality difference between CA- and HA-SAB remained significant in Kaplan-Meier
analysis. However, no significant difference between CA- and HA-SAB was observed in
time to defervescence (Figure 1). Prognostic factors for a fatal outcome within 28 days ac-
cording to binary logistic regression analysis were age > 60 years, ultimately or rapidly fatal
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disease, immunosuppressive treatment within six months, chronic alcoholism, pneumonia
and endocarditis (Study I; Table III). On the day of S. aureus-positive blood culture, the
mean serum CRP was significantly lower among HA-SAB patients. As described in Section
5.1.2., the overall prevalence of deep infection foci among CA- and HA-SAB differed during
the first three days (84% vs. 69%, p <0.0001) and throughout the three-month follow-up
(87% vs. 80%, p=0.045).
Figure 1. Kaplan-Meier estimation of survival (Log-Rank <0.05) (A) and time to defervescence (Log-
Rank non-significant) (B) for health care-associated (HA) versus community-associated (CA)
Staphylococcus aureus bacteraemias (SAB).
5.2. Cell-free DNA and Staphylococcus aureus bacteraemia (Study II)
5.2.1. Patient characteristics
The study included 418 SAB patients. Initially, 430 SAB cases were identified, but as a re-
sult of missing plasma samples 12 SAB cases were not found. Cf-DNA was determined at
days three and five and the median cf-DNA results were stratified according to patient
characteristics. No significant differences were seen in the day three cf-DNA levels when
stratified and compared according to various underlying factors. At day five, male sex (p
<0.0001), age > 60 years (p <0.05), alcoholism (p <0.05), coronary artery disease (p <0.01)
and complicated diabetes (p <0.05) were associated with significantly higher cf-DNA con-
centrations, whereas McCabe’s healthy and non-fatal classification was associated with
significantly lower (p <0.01) values of cf-DNA (Study II; Table I). Patients with a deep infec-
tion focus (p <0.001), ICU treatment at S. aureus-positive blood culture or within three to
seven days (p <0.0001) or with a fatal outcome irrespective of death time (p <0.0001) pre-
sented significantly higher cf-DNA concentrations at both days three and five (Study II: Ta-
ble I). From the day of positive blood culture onwards, an effective antibiotic against the
cultured S. aureus strain in vitro was provided to all patients. Vancomycin was received by
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a minority (2%) of the patients and vancomycin as the only antibiotic was given to only 1%,
whereas the vast majority of patients were treated with a ?-lactam antibiotic (76%).
5.2.2. Treatment in intensive care unit and cell-free DNA
Within three days of S. aureus-positive blood culture, 87 patients (21%) and within seven
days 99 patients (24%) needed ICU treatment. Regarding demographics and underlying
conditions, the only difference was that ICU patients significantly more often suffered from
alcoholism (p <0.05) than non-ICU patients. However, deep infection foci and mortality at
seven days, 28 days and three months were significantly higher among ICU patients rela-
tive to their non-ICU counterparts. These results were similar when ICU treatment during
the first three days only or during the fiest seven days after positive blood culture were
taken into account (data not shown).
SAB patients who needed ICU treatment within seven days of positive blood culture were
analysed as a subgroup according to three-month survival. At day 3, the non-survivors in
the ICU group presented significantly higher cf-DNA values for age (p <0.01), healthy or
non-fatal disease, alcoholism and cardiovascular disease (p <0.05), ICU-specific character-
istics such as severe sepsis, need for mechanical ventilation or inotropia support or Pitt
bacteraemia scores ? 4 (p <0.05) as well as deep infection foci and complicated SAB (p
<0.01), whereas no difference was seen between CA- and HA-SAB acquisition. However,
at day 5, no significant difference between ICU survivors and non-survivors was observed
(Study II; Table II) and Table 6 (below).
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Table 6. Plasma cf-DNA concentration (?g/mL) at days 3 and 5 from the positive blood cul-
ture in 99 patients with Staphylococcus aureus bacteremia (SAB) in the intensive care unit
(ICU) within 7 days of positive blood culture. Patients are divided according to survivors
and non-survivors at the three-months follow-up. Values are given as median (quartiles).
NS=non significant.
cf-DNA at day 3 cf-DNA at day 5
ICU
survivor
ICU
non-survivor
p-
value X
ICU
survivor
ICU
non-survivor
p-
value X
Demographics
Age >60 years
HA-SAB 1
Underlying
conditions
Healthy or nonfatal 2
Cardiovascular
Alcoholism
ICU characteristics
Severe sepsis
Mechanic ventilation
Inotropic support
Pitt scores ?4
Infection focus
Any deep infection
Complicated SAB 3
1.62(1.37-2.16)
1.60(1.37-2.13)
1.67(1.40-2.12)
1.65(1.38-2.13)
1.68(1.37-2.30)
1.69(1.40-2.11)
1.82(1.43-2.30)
1.77(1.50-2.23)
1.83(1.42-2.42)
1.66(1.40-2.15)
1.66(1.39-2.14)
3.97(2.55-9.46)
2.01(1.59-4.84)
2.37(1.80-7.92)
3.97(2.32-3.63)
5.96(2.37-11.0)
3.94(1.91-7.22)
3.60(1.91-7.22)
3.05(2.01-5.96)
3.05(2.01-5.96)
3.05(2.01-4.84)
3.07(2.09-5.68)
<0.01
NS
<0.05
<0.05
<0.05
<0.05
<0.05
<0.05
<0.05
<0.01
<0.01
1.57(1.31-2.46)
1.53(1.31-1.89)
1.53(1.29-1.93)
1.72(1.38-2.44)
1.81(1.34-1.93)
1.64(1.31-1.88)
1.90(1.48-2.66)
1.63(1.29-1.97)
1.76(1.45-2.45)
1.60(1.29-2.18)
1.59(1.29-2.12)
2.27(1.59-3.01)
2.27(1.14-2.26)
2.27(1.52-3.01)
2.30(1.19-2.26)
2.96(1.70-2.73)
2.66(1.72-3.48)
2.64(1.71-3.48)
2.31(1.89-3.33)
2.31(1.89-3.33)
2.27(1.56-2.66)
2.31(1.89-3.33)
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
X  Mann-Whitney U-test. 1 Health care-associated. 2 Classified according to McCabe and Jackson [444].
3 Defined as SAB and deep infection focus, severe sepsis, septic shock or Pitt bacteraemia scores ? 4.
5.2.3. Sensitivity and specificity of cell-free DNA
Receiver-operating characteristic (ROC) curves were applied to estimate predictive value
of cf-DNA and CRP on the 28-day and three-month outcome in patients treated in the ICU
within 7 days of S. aureus-positive blood culture (n=99) and in non-ICU patients (n=319).
For ICU and non-ICU patients, the ROC analysis revealed that both the 3-day and the 5-
day cf-DNA significantly predicted fatal outcome. This finding held when the data were ana-
lysed separately for the 28-day and the three-month follow-up. CRP, however, had no pre-
dictive value for outcome.
The 3-day AUC for cf-DNA in ICU patients was 0.71 (95% CI 0.57-0.84, p <0.01) with a cut-
off value of 1.99 ?g/mL and a corresponding sensitivity of 67% and specificity of 77% in
predicting fatal outcome within three months. The corresponding 5-day cf-DNA AUC was
0.71 (95% CI 0.58-0.84, p <0.01) with a cut-off value of 1.69 ?g/mL and a sensitivity of 63%
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and a specificity of 60%. For the 28-day mortality, the 3-day cf-DNA AUC was 0.66 (95% CI
0.52-0.81, p <0.05) with a cut-off value of 1.99 ?g/mL and a sensitivity of 60% and a speci-
ficity of 73% (data not shown). For CRP, the 3-day AUC was 0.46 (95% CI 0.32-0.59,
p=0.55) and the 5-day AUC 0.47 (95% CI 0.34-0.61, p=0.67). Among non-ICU patients,
AUC for 3-day cf-DNA was 0.64 (95% CI 0.55-0.74, p <0.01) with a cut-off value of 1.57
ug/mL and a sensitivity of 62% and a specificity of 61% in predicting a fatal outcome in the
three-month follow-up. The corresponding 5-day cf-DNA AUC was 0.68 (95% CI 0.59-0.77,
p <0.01) with a cut-off value of 1.49 ?g/mL and a sensitivity of 65% and a specificity of
61%. For CRP, the 3-day AUC was 0.46 (95% CI 0.36-0.57, p=0.48) and the 5-day AUC
0.51 (95% CI 0.41-0.62, p=0.80) (Study II; Figure 1a-b)
ROC analysis was applied to predict seven days mortality for day three and five cf-DNA in
patients with SAB divided according to Pitt bacteraemia scores and intensive care unit
treatment (see Figure 2a-d below).
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Figure 2.
Receiver-operating characteristic (ROC) curves for cf-DNA predicting 7-day mortality in patients with Staphylo-
coccus aureus bacteraemia (SAB) divided according to Pitt bacteraemia scores and intensive care unit treat-
ment.
A. Pitt bacteraemia score=0. The AUC for day 3 cf-DNA was 0.66 (95% CI 0.40-0.91) (p-value non-significant)
with a cut-off value of 1.59 mg/mL and a sensitivity of 60% and a specificity of 61%. The AUC for day 5 cf-DNA
was 0.69 (95% CI 0.54-0.84) (p-value non-significant) with a cut-off value of 1.49 mg/mL and a sensitivity of
80% and a specificity of 60%.
B. Pitt bacteraemia scores >0. The AUC for day 3 cf-DNA was 0.88 (95% CI 0.77-0.98) (p <0.01) with a cut-off
value of 2.01 mg/mL and a sensitivity of 86% and a specificity of 77%. The AUC for day 5 cf-DNA was 0.76
(95% CI 0.56-0.95) (p <0.05) with a cut-off value of 1.96 mg/mL and a sensitivity of 71% and a specificity of
81%.
C. Pitt bacteraemia score=0 and no intensive care unit. The AUC for day 3 cf-DNA was 0.59 (95% CI 0.34-0.86)
(p-value non-significant) with a cut-off value of 1.45 mg/mL and a sensitivity of 75% and a specificity of 48%.
The AUC for day 5 cf-DNA was 0.72 (95% CI 0.55-0.89) (p-value non-significant) with a cut-off value of 1.49
mg/mL and a sensitivity of 75% and a specificity of 63%.
D. Pitt bacteraemia scores >0 and intensive care unit treatment. The AUC for day 3 cf-DNA was 0.91 (95% CI
0.81-1.00) (p <0.01) with a cut-off value of 2.35 mg/mL and a sensitivity of 80% and a specificity of 91%. The
AUC for day 5 cf-DNA was 0.78 (95% CI 0.58-0.97) (p <0.05) with a cut-off value of 2.14 mg/mL and a
sensitivity of 80% and a specificity of 79%.
70
5.2.4. Prognostic value of cell-free DNA relative to other prognostic factors
The prognostic value of cf-DNA was analysed with proportional hazards regression (Cox
regression model) for ICU and non-ICU patients by applying the cf-DNA cut-off values
(from Study II; Figure 1a-b) as one statistical parameter. In univariate analysis, factors
among ICU patients that were associated with three-month mortality were age > 60 years
(p <0.01), inotropia need (p <0.05), mechanical ventilation (p <0.05), Pitt bacteraemia
scores ? 2-4 (p <0.01) and cf-DNA > 1.99 ?g/mL (at day 3) (p <0.0001), whereas healthy or
non-fatal underlying disease had a protective prognostic impact (p <0.05). For non-ICU pa-
tients, age > 60 years (p <0.01), corticosteroid use (p <0.0001), previous dialysis treatment
(p <0.01), diabetes and complications (p <0.05), haematological malignancy (p <0.05),
chronic pulmonary disease (p <0.01), presence of a deep infection focus (p <0.05) and cf-
DNA > 1.57 ?g/mL (at day 3) (p <0.01) were all associated with fatal outcome within three
months, whereas healthy or non-fatal underlying disease had a protective prognostic im-
pact (p <0.0001) (Table 7).
In the Cox regression model for ICU patients only Pitt bacteraemia scores ? 4 (OR 4.47, CI
1.94-10.3) (p <0.0001) and cf-DNA > 1.99 ?g/mL (at day 3) (OR 3.56, CI 95% 1.69-7.59) (p
<0.001) predicted a fatal outcome whereas, healthy or non-fatal underlying disease (OR
0.34, CI 95% 0.15-0.77) (p <0.05) had a protective prognostic value. Among non-ICU pa-
tients, corticosteroid use (OR 2.89, CI 95% 1.39-6.07) (p <0.01), chronic pulmonary dis-
ease (OR 2.45, CI 95% 1.21-4.96) (p <0.05) and healthy or non-fatal underlying disease
(OR 0.26, CI 95% 0.11-0.63) (p <0.01) had a significant impact on prognosis (Table 7).
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Table 7. Prognostic factors for three-month mortality in Staphylococcus aureus bacterae-
mia patients with (n=99) or without (n=319) intensive care unit treatment within 7 days of S.
aureus-positive blood culture. CI, confidence interval; OR, odds ratio; NS, non-significant.
Univariate
analysis
OR (95% CI)
p-
value
Cox regression
analysis
OR (95% CI)
p-
value
Intensive care unit
Age > 60 years
Healthy or non-fatal A
Chronic alcoholism
Corticosteroid use B
Chronic renal failure C
Dialysis (haemo- or peritoneal)
Diabetes (and complications)
Haematological malignancy
Any deep infection
Endocarditis
Inotropia need
Mechanical ventilation
Pitt bacteraemia scores ? 4
Pitt bacteraemia scores ? 3
Pitt bacteraemia scores ? 2
cf-DNA cut-off 1.99 ?g/mL D
Non-intensive care unit
Age > 60 years
Healthy or non-fatal A
Chronic alcoholism
Corticosteroid use B
Dialysis (haemo- or peritoneal)
Diabetes (and complications)
Haematological malignancy
Chronic pulmonary disease
Any deep infection
Endocarditis
cf-DNA cut-off 1.57 ?g/mL D
3.64 (1.43 - 9.29)
0.33 (0.13 - 0.81)
1.80 (0.64 - 5.06)
3.21 (0.67 - 15.3)
0.71 (0.14 - 3.75)
0.87 (0.16 - 4.75)
1.01 (0.35 - 2.98)
1.10 (0.09 - 12.1)
1.89 (0.20 - 17.5)
1.63 (0.67 - 3.99)
3.19 (1.18 - 8.64)
2.67 (1.04 - 6.86)
3.19 (1.18 - 8.64)
3.14 (1.43 - 9.79)
3.03 (1.29 - 7.58)
5.24 (2.03 - 13.5)
3.04 (1.49 - 6.18)
0.13 (0.06 - 0.26)
1.93 (0.73 - 5.09)
7.91 (3.66 - 17.1)
3.70 (1.70 - 8.07)
2.17 (1.01 – 4.66)
3.54 (1.02 - 12.3)
3.17 (1.58 - 6.39)
3.67 (1.09 - 12.3)
2.24 (0.98 - 5.14)
2.86 (1.45 - 5.64)
<0.01
<0.05
NS
NS
NS
NS
NS
NS
NS
NS
<0.05
<0.05
<0.01
<0.01
<0.01
<0.0001
<0.01
<0.0001
NS
<0.0001
<0.01
<0.05
<0.05
<0.01
<0.05
NS
<0.01
-
0.34 (0.15 - 0.77)
-
-
-
-
-
-
-
-
-
-
4.47 (1.94 - 10.3)
-
-
3.56 (1.69 - 7.59)
-
0.26 (0.11 - 0.63)
-
2.89 (1.39 - 6.07)
-
-
-
2.45 (1.21 - 4.96)
-
-
-
-
<0.05
-
-
-
-
-
-
-
-
-
-
<0.0001
-
-
<0.001
-
<0.01
-
<0.01
-
-
-
<0.05
-
-
-
A  Classified according to McCabe and Jackson [444]. B In the 6 months preceding the positive blood culture.
C  Chronically elevated plasma creatinine (>180 mol/L). D Cut-off value at day 3 as in Figure 1a-b in Study II.
The Cox regression model above was performed using a day 3 cf-DNA cut-off value. When
performed with a day 5 cf-DNA cut-off value of 1.69 ?g/mL for ICU patients or 1.49 ?g/mL
for non-ICU patients, the prognostic value in univariate analysis was significant for both
ICU patients and non-ICU patients (p <0.05). However, in Cox regression model the 5-day
cf-DNA cut-off values had no significant prognostic value for either ICU or non-ICU pa-
tients.
The Kaplan-Meier method was applied to estimate the survival for ICU and non-ICU pa-
tients according to 3-day and 5-day cf-DNA cut-off values. According to the Kaplan-Meier
Log-Rank test, both 3-day and 5-day cf-DNA cut-off values presented significant differ-
ences in three-month survival both for ICU patients at day three (p <0.0001) and at day five
(p <0.05) and for non-ICU patients at days three and five (p <0.01) (data not shown).
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5.3. Impact of infectious disease specialist consultation (IDSC) on Staphylo-
coccus aureus bacteraemia outcome (Study III)
5.3.1. Patient characteristics
The vast majority of the SAB patients received formal bedside IDSC (72%), whereas infor-
mal telephone conversation-based IDSC was given much less often (18%) and a small
proportion of patients had no IDSC (10%). No significant differences emerged in sex, age,
nosocomial acquisition or underlying diseases between patients with formal bedside and in-
formal telephone IDSC. However, significantly more ultimately or rapidly fatal underlying
diseases were seen among SAB patients managed without any IDSC (p=0.008). The mean
time-lapse between blood culture collection and IDSC was 3 days for both formal bedside
and informal telephone groups (Study III; Table I). No significant differences in the occur-
rence of severe sepsis at S. aureus-positive blood culture were seen between the formal
bedside (7%) and the informal telephone consultation (10%) groups, whereas patients
without IDS consultation (31%) suffered from severe sepsis significantly more often than
bedside IDS consultation patients (p <0.0001). The need for ICU treatment among informal
telephone IDSC patients (34%) was more common than among formal bedside IDSC pa-
tients (21%) during the first 3 days after S. aureus-positive blood culture (p=0.037),
whereas within the first week the difference was non-significant (37% for informal tele-
phone IDSC and 29% for formal bedside IDSC, p=0.22) (Study III; Table I).
5.3.2. Impact on radiological diagnostics
The use of echocardiography - transthoracic (TTE) or transoesophageal (TEE) - did not dif-
fer between formal bedside and informal telephone IDSC (77% vs. 71% for TTE and 11%
vs. 3% for TEE). The use of whole-body computed tomography was less common among
informal telephone IDSC (55%) (p=0.049) and no IDSC (29%) (p <0.0001) than among for-
mal bedside IDSC (68%). The use of leukocyte indium-111 scintigraphy was more common
in formal bedside IDSC (43%) than in informal telephone (13%) or no IDSC (9%) (p <0.001)
(Study III; Table I). However, after adjustment for mortality before IDSC, leukocyte indium-
111 scintigraphy was the only radiological investigation provided less often to informal tele-
phone IDSC patients than to formal bedside IDSC patients (p=0.011) (Study III; Table II).
5.3.3. Impact on deep infection focus localization
Formal bedside IDSC resulted significantly more often in identification of a deep infection
focus (78%) than to informal telephone IDSC (53%) or no IDSC (29%), and this was seen
in all deep infection focus types, except endocarditis, for which the difference between for-
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mal bedside (16%) and informal telephone IDSC (7%) was non-significant (p=0.055) (Study
III; Table I). According to multinomial logistic regression analysis, the odds ratio (OR) for
deep infection focus localization was only 0.15 (95% CI 0.06-0.38, p <0.0001) for informal
telephone IDSC and 0.13 (95% CI 0.03-0.54, p=0.005) for no IDSC relative to formal bed-
side IDSC (Study III; Table II).
5.3.4. Impact on antibiotic treatment
From the first day of positive blood culture, each patient received an antibiotic effective
against S. aureus. Most patients received a ?-lactam antibiotic (93%), whereas only 3%
were treated with vancomycin. Patients with formal bedside IDSC (85%) received signifi-
cantly more often proper length of antibiotic therapy relative to informal telephone IDSC
(63%) (p=0.008) or no IDSC patients (54%) (p=0.004) (Study III; Table I). However, after
adjustment for mortality before IDSC, no difference in number of patients with proper antibi-
otic length was observed (Study III: Table II).
5.3.5 Impact on outcome
Formal bedside IDSC resulted in longer mean duration of hospitalization (38.7 ± 21.7 days)
than either informal telephone IDSC (30.6 ± 23.0 days) (p=0.014) or no IDSC (24.9 ± 24.8)
(p=0.001) (Study III; Table I). Mean time to defervescence was shorter for formal bedside
IDSC (6.7 ± 9.7 days) than for informal telephone IDSC (12.6 ± 13.4) (p=0.001) or no IDSC
(13.4 ± 14.7) (p =0.003) (Study III; Table I). Similar results were obtained after early 3-day
mortality was omitted (Figure 3b) (Study III; Table II and Figure 1a). No difference in mor-
tality was seen between formal bedside and informal telephone IDSC within the first 3
days. However, mortality was lower among patients with bedside IDSC at 7 days (1% vs.
8%, p=0.001), at 28 days (5% vs. 16%%, p=0.002), and at three months (9% vs. 29%, p
<0.0001) than among patients treated with informal telephone IDSC (Study III; Table I). Pa-
tients who received no IDSC had a high mortality already at 3 days (26%) and had a higher
mortality throughout the three-month study period than patients receiving formal bedside
IDSC (9% vs 46%%, p <0.001) (Study III; Table I). After adjustment for early death, the 28-
day mortality for formal bedside IDSC (5%) as compared with informal telephone IDSC
(15%) (p=0.08) and no IDSC (12%) (p=0.68) became non-significant. However, the three-
month mortality remained significantly lower for formal bedside IDSC (9%) than for the
other two IDSC groups (28% for informal telephone IDSC and 27% for no IDSC) (Figure
3a) (Study III; Table II and Figure 1b).
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Figure 3. Kaplan-Meier analysis for fatal outcome (3a) and time to defervescence (3b) in patients with Staphy-
lococcus aureus bacteraemia according to telephone (informal) (n=62) or bedside (formal) (n=245) infectious
disease specialist consultation. Log-Rank test for fatal outcome in informal versus formal consultation (p
<0.0001) and for defervescence in informal versus formal consultation (p=0.001). Patients who died during the
first 3 days of S. aureus-positive blood culture (n=11) were excluded.
Prognostic factors for three-month mortality were analysed with proportional hazards re-
gression (Cox regression model). When all prognostic determinants were taken into ac-
count, the factors associated with fatal outcome were informal telephone IDSC (p=0.01), no
IDSC (p=0.002), pneumonia (p=0.001), ICU within three days of S. aureus-positive blood
culture (p =0.012) and corticosteroid therapy (p=0.01), whereas healthy or non-fatal under-
lying disease (p <0.0001), leukocyte indium-111 scintigraphy (p=0.021) and whole-body
computed tomography (p=0.022) had positive prognostic value (Table 8). When compared
with formal bedside IDSC, the odds ratio (OR) for mortality in informal telephone IDSC was
2.31 (95% CI 1.22-4.38) (Study III; Table II).
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Table 8. Prognostic factors for three-month mortality in 331 patients with Staphylococcus
aureus bacteraemia. Patients with a fatal outcome within 3 days of S. aureus-positive blood
culture were excluded. CI, confidence interval; OR, odds ratio.
Univariate
analysis
OR (95% CI)
p-
value
Cox regression
analysis
OR (95% CI)
p-
value
Positive prognostic impact
Healthy or non-fatal disease A
Leukocyte indium-111 scintigraphy
Whole-body computed tomography
Negative prognostic impact
Pneumonia
ICU within 3 days
Corticosteroid therapyB
Telephone IDS within 1 week
No IDS consultation within 1 week
0.11 (0.05 - 0.022)
0.41 (0.19 - 0.87)
0.43 (0.23 - 0.80)
2.31 (1.23 - 4.33)
1.96 (1.00 - 3.83)
5.48 (1.93 - 15.6)
3.21 (1.63 - 6.33)
2.51 (0.99 - 0.37)
<0.0001
0.018
0.007
0.008
0.046
<0.0001
<0.0001
0.045
0.18 (0.09 - 0.35)
0.40 (0.19 - 0.87)
0.49 (0.26 - 0.90)
2.74 (1.49 - 5.05)
2.28 (1.19 - 4.15)
2.98 (1.29 - 6.85)
2.31 (1.22 - 4.38)
3.56 (1.59 - 7.94)
<0.0001
0.021
0.022
0.001
0.012
0.01
0.01
0.002
A Underlying Diseases characterized according to McCabe and Jackson [444]. B Systemic prednisone >10
mg/day or equivalent for >1 month.
During the first 7 days altogether 31% of patients needed ICU treatment. Of these patients
treated in ICU, survivors and non-survivors were compared separately and prognostic fac-
tors for three-month mortality were analysed. Survival was significantly associated with
formal bedside IDSC (p <0.0001), healthy or non-fatal underlying diseases (p=0.003) and
performed whole-body computed tomography (p=0.027). However, ultimately or rapidly fa-
tal diseases (p=0003), informal telephone IDSC (p=0.001) and no IDSC (p=0.008) were
associated with fatal outcome among ICU patients (Study III; Table IV).
Factors difficult to control in retrospective studies are hospital-related temporary differences
in treatment or personnel practices, and thus, in order to exclude the effect of unidentified
differences, two different time periods for data collection were included in Study III.
Moreover, two study periods were regarded as mandatory as most patients from the first
study period had participated in our previous prospective study [15]. This naturally raises
the question of whether any differences are present in the results when the data of the two
time periods are analysed separately. As a parallel investigation (results not mentioned and
data not shown in Study III) the data were analyzed and prognostic factors for the three-
month mortality according to Cox regression were presented I) by including only patients
from the later time period in 2006-2007, II) by including only patients from the earlier time
period in 2000-2002 and III) by excluding the patients from the previous study [15]. Table 9
presents the results.
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Table 9. Prognostic factors for three-month mortality according to Cox regression analysis
in patients with Staphylococcus aureus bacteraemia from different time periods. Patients
with a fatal outcome within 3 days of S. aureus-positive blood culture were excluded. CI,
confidence interval; OR, odds ratio.
n
(342 total)
Cox regression analysis
OR (95% CI)
p-
value
2006 - 2007
Healthy or non-fatal disease A
Corticosteroid therapyB
Telephone IDSC within 1 week C
Whole-body computed tomography
Pneumonia
2000 - 2002
Healthy or non-fatal disease A
Corticosteroid therapyB
Telephone IDSC within 1 week C
Whole-body computed tomography
Pneumonia
2000 - 2002 & 2006 - 2007 X
Healthy or non-fatal disease A
Corticosteroid therapyB
Telephone IDSC within 1 week C
Whole-body computed tomography
Pneumonia
139
48
187
0.35 (0.15 - 0.80)
---
3.33 (1.17 - 9.49)
0.42 (0.18 - 0.96)
2.80 (1.28 - 6.13)
Insufficient
statistical
power
0.24 (0.10 - 0.53)
3.13 (0.99 - 9.89)
3.48 (1.30 - 9.27)
---
---
< 0.05
---
 < 0.05
< 0.05
 =0.01
Insufficient
statistical
power
<0.0001
=0.052
<0.05
---
---
A According to McCabe and Jackson [444]. B Systemic prednisone >10 mg/day or equivalent for >1 month. C
Infectious disease specialist consultation. X Patients from previous prospective study [15] excluded (n=155).
When analysing the earlier time period (2000 – 2002), the statistical power was insufficient
for Cox regression due to the low number of telephone consultations relative to formal bed-
side consultations; however in univariate analysis the factors predicting three-month mor-
tality were McCabe healthy or non-fatal classification (OR 0.09, 95% CI 0.03-0.25, p
<0.0001), pneumonia (OR 2.62, 95% CI 1.08-6.39, p <0.05) and formal bedside IDSC (OR
0.35, 95% CI 0.12-1.07, p=0.057).
By performing separate analyses that take into account only the 2000-2002 or the 2006-
2007 time periods or that exclude data from the earlier study [15], we receive results that
strongly resemble those of Study III. Thus, the two different time periods or the usage of
data from our earlier study [15] do not significantly alter the results.
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5.4. Adjunctive rifampicin treatment in Staphylococcus aureus bacteraemia
(Study IV)
5.4.1. Patient characteristics
Altogether 617 SAB patients were included, 291 (47%) of whom received rifampicin for at
least 14 days, with a mean (± SD) duration of 45.1 ± 24.7. Rifampicin for 1-13 days were
received by 72 patients (12%) and no rifampicin at all by 254 patients (41%).
The main analyses were then performed by excluding patients with a fatal outcome within
three days (n=8) of S. aureus-positive blood culture, alcoholism and acute or chronic liver
disease (n=128). When taking into account these exclusion criteria the patient cohort de-
creased to 475 patients of whom 240 (51%) received rifampicin for at least 14 days, 58
(12%) for 1-13 days and 177 (37%) received no rifampicin therapy. When the two groups
(rifampicin ? 14 days and rifampicin < 14 days) were compared, no difference in age > 60
years, underlying diseases including McCabe´s rapidly fatal disease classification, ICU
treatment or severe sepsis were seen. Male sex, however, associated to longer rifampicin
therapy (p<0.01) (Study IV; Table I).
As a parallel analysis, the patient population was analysed by excluding patients with a fa-
tal outcome within 14 days. When comparing patients with rifampicin ? 14 days and rifam-
picin < 14 days the patients with rifampicin ? 14 days were more likely to be of male gender
(p <0.05) and to be healthier and have less underlying diseases (more McCabe’s healthy or
non-fatal classification) (p <0.01), whereas alcoholism (p <0.01) and dialysis treatment (p
<0.05) were more common among patients with rifampicin < 14 days. No difference in ICU
treatment or severe sepsis was seen between the groups (data not shown in Study IV).
5.4.2. Deep infection foci and Staphylococcus aureus bacteraemia relapse.
Deep infection focus was significantly more often found in patients with rifampicin ? 14
days than in patients with rifampicin < 14 days (88% vs. 62% p <0.0001), and they more of-
ten had various kinds of deep foci visualized e.g. pneumonia (40% vs. 28%, p<0.01) and
endocarditis (18% vs. 9%, p<0.01). However, no difference in SAB relapse within 90 days
follow-up was seen between the two groups (Study IV; Table 1).
5.4.3. Antibiotic therapy
No significant differences were observed in standard background antibiotic therapy for pa-
tients receiving rifampicin ? 14 days or rifampicin < 14 days. The vast majority (99%) were
treated with a standard antibiotic, with in vitro efficacy against the cultured S. aureus strain.
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Most patients received staphylococcal penicillin cloxacillin (52%) or cefuroxime (20%).
Vancomycin was given to only 2% of patients (Study IV; Table 1).
5.4.4. Effect of rifampicin treatment on outcome
The total case fatality at 90 days was 17%. A fatal outcome was significantly lower in pa-
tients who received rifampicin ? 14 days than in patients with rifampicin < 14 days. The
case fatality was at 28 days (6% vs. 15%, p <0.01) and at three months (11% vs. 22%, p
<0.01).
The patient population (n=475) was analysed with proportional hazards regression (Cox
regression model) to address factors predicting three-month mortality. Early rifampicin
therapy onset for at least 14 days associated to improved prognosis (OR 0.38, p<0.01).
Factors connected to poor prognosis were age > 60 years (OR 3.02, p<0.001), rapidly fatal
underlying diseases (OR 6.84, p<0.001), corticosteroid therapy (OR 4.45, p<0.001), severe
sepsis at time of sampling of positive blood culture (OR 2.11, p<0,01), pneumonia (OR
3.13, p<0.001) and endocarditis (OR 2.32, p<0.01) (Study IV; Table 2). When only patients
with a deep infection focus (n=357) were included in the Cox regression model, the factors
associated with prognostic impact were early rifampicin therapy onset for at least 14 days
(OR 0.29, p<0.01), age > 60 years (OR 2.61, p<0.01), rapidly fatal underlying conditions
(OR 4.19, p<0.01), corticosteroid therapy (OR 5.29, p<0.001), severe sepsis at positive
blood culture (OR 2.43, p<0,01), pneumonia (OR 3.44, p<0.001) and endocarditis (OR
2.34, p<0.01) (Study IV; Table 3). Table 10 presents these results of Study IV.
Kaplan-Meier analysis of the effect of onset time point of rifampicin treatment for at least 14
days on outcome demonstrated a significant survival benefit with early onset therapy as
compared to late onset among all SAB patients (Log Rank 0.001) and this difference was
even more accentuated among patients with a deep infection focus (Log-Rank 0.0001)
(Study IV; Figure 2a-b). Figure 4a-b below presents these results.
Lack of rifampicin therapy or rifampicin therapy for 1-7 days or 8-13 days had no positive
prognostic impact in Cox regression analysis. These results were achieved for both the
whole patient cohort and when analysing patients with a deep infection foci separately
(data not shown).
As a parallel analysis, patients with a fatal outcome within 14 days of S. aureus-positive
blood culture (n=49) were excluded, and the patient population (n=568) was analysed with
proportional hazards regression (Cox regression model) to address factors predicting
three-month mortality. In the Cox regression model, a significant positive prognostic impact
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was seen for early onset of rifampicin therapy ? 14 days (OR 0.55, p <0.05) and for
McCabe’s healthy or non-fatal disease (OR 0.29, p <0.0001), whereas pneumonia (OR
3.99, p <0.0001), corticosteroid therapy (OR 2.91, p <0.01) and age > 60 years (OR 1.97, p
<0.05) had a negative prognostic impact. When only patients with a deep infection focus
(n=429) were included in the Cox regression model a positive prognostic impact was seen
for early onset of rifampicin therapy ? 14 days (OR 0.38, p <0.01) and for McCabe’s healthy
or non-fatal disease (OR 0.43, p <0.01), whereas pneumonia (OR 3.88, p <0.0001), corti-
costeroid therapy (OR 3.55, p <0.0001) and age > 60 years (OR 1.94, p <0.05) once again
predicted poor outcome (data not shown).
Table 10. Cox regression analysis for prognostic factors according to three-month mortality
of 475 patients (all patients) and of 357 (patients with a deep infection focus) with Staphy-
lococcus aureus bacteraemia. Patients with a fatal outcome within the first 3 days (n=8), al-
coholism and acute or chronic liver disease (n=128) were excluded. Data are given as
number (%) of patients in each parameter and odds ratio for fatal outcome within three
months. NS, non significant.
Univariate analysis Cox regression
Died Survived OR (95% CI) p-value OR (95% CI) p-value
All patients
Positive prognostic value
Male sex
Rifampicin ?14 days early onset A
Rifampicin ?14 days late onset A
Negative prognostic value
Age > 60 years
Rapidly fatal disease B
Cardiovascular disease
Corticosteroid therapy C
Severe sepsis D
Intensive care unit D
Pneumonia E
Endocarditis E
Patients with a deep focus
Positive prognostic value
Male sex
Rifampicin ?14 days early onset A
Rifampicin ?14 days late onset A
Negative prognostic value
Age > 60 years
Rapidly fatal disease B
Cardiovascular disease
Corticosteroid therapy C
Severe sepsis D
Intensive care unit D
Pneumonia E
Endocarditis E
44(56)
22(28)
4(5)
60(76)
13(16)
23(29)
23(29)
9(11)
20(25)
48(61)
18(23)
37(56)
18(27)
4(6)
49(74)
8(12)
21(32)
22(33)
9(14)
18(27)
48(73)
18(27)
237(60)
188(47)
26(7)
187(47)
3(1)
76(19)
20(5)
16(4)
57(14)
112(28)
44(11)
181(62)
167(57)
22(8)
142(49)
3(1)
60(21)
16(5)
14(5)
42(14)
111(38)
44(15)
0.84(0.52-1.37)
0.43(0.25-0.73)
0.76(0.26-2.28)
3.53(2.03-6.13)
25.8(7.16-93.0)
1.69(0.94-3.05)
7.72(3.98-14.9)
3.05(1.29-7.18)
2.02(1.13-3.59)
3.93(2.38-6.49)
2.36(1.28-4.35)
0.75(0.45-1.33)
0.28(0.15-0.50)
0.79(0.26-2.37)
3.02(1.66-5.49)
13.2(3.41-51.4)
1.63(0.88-3.02)
8.59(4.19-17.6)
3.12(1.29-7.56)
2.22(1.18-4.19)
4.32(2.39-7.81)
2.11(1.12-3.59)
NS
<0.01
NS
<0.0001
<0.0001
NS
<0.0001
<0.01
<0.05
<0.0001
<0.01
NS
<0.01
NS
<0.0001
<0.0001
NS
<0.0001
<0.01
<0.05
<0.0001
<0.05
---
0.38(0.23-0.64)
---
3.02(1.79-5.11)
6.84(3.65-12.8)
---
4.45(2.65-7.48)
2.11(1.24-3.59)
---
3.13(1.98-4.96)
2.32(1.36-3.97)
---
0.29(0.17-0.52)
---
2.61(1.49-4.59)
4.19(1.92-9.16)
---
5.29(3.05-9.19)
2.43(1.37-4.32)
---
3.44(1.98-5.97)
2.34(1.34-4.08)
---
<0.01
---
<0.001
<0.001
---
<0.001
<0.01
---
<0.001
<0.01
---
<0.01
---
<0.01
<0.01
---
<0.001
<0.01
---
<0.001
<0.01
A Rifampicin for at least 14 days initiated early (within 7 days of S. aureus-positive blood culture) or late (7 days
past S. aureus-positive blood culture). B According to McCabe and Jackson [444]. C Systemic prednisone >10
mg/day for > 1 month. D Intensive care unit treatment or severe sepsis at time-point of S. aureus-positive blood
culture. E Pneumonia or endocarditis diagnosed within 90 days follow-up.
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Figure 4. Kaplan-Meier analysis of rifampicin therapy on three-month survival of Staphylococcus aureus bac-
taeremia. Rifampicin therapy was continued ? 14 days and divided according to onset time point: early onset
(i.e. onset within 7 days of positive blood cultures) and late onset (i.e. onset 7 days after positive blood cul-
tures). 4a Including all study patients (N=475). Log-Rank 0.001. 4b Including patients with a deep infection fo-
cus (N=357). Log-Rank 0.0001.
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6. DISCUSSION
6.1. Health care- and community-associated Staphylococcus aureus bacte-
raemia
Disease progression and prognosis of SAB are positively impacted by various factors.
IDSC has been shown to improve identification of deep infection focus and endocarditis
[3,56,57,184,257], resulting in fewer episodes of persistent SAB [18] and reduced probabil-
ity for SAB relapse [184,353]. Some reports have viewed deep focus localization as a pre-
requisite for appropriate management of SAB and improved survival rate [3,16,18,167].
We observed that CA-SAB patients were significantly younger (52 vs. 62 years) and less
often chronically ill with significantly more McCabe’s healthy or non-fatal disease classifica-
tions (88% vs. 59%) than HA-SAB patients. Regarding underlying conditions, only alcohol-
ism, IDU and chronic liver disease were significantly more common among CA-SAB. These
observations are in agreement with previous reports [2,7,19,28]. Also consistent with an
earlier study is the lack of gender difference [19].
In most patients, deep infection foci were evident already within 3 days of positive blood
culture. Deep infection foci were diagnosed more frequently among CA-SAB than among
HA-SAB both within three days (84% vs. 69%) and at three months (87% vs. 80%). In
Study I, each SAB patient was treated and followed up by an IDS, which might explain the
higher number of infection foci localized in our study than in previous studies, but not the
early acquisition. The time-point for deep infection identification has not been reported in
most studies, but one older study observed that metastatic foci were verified within the ini-
tial two weeks of SAB [185], whereas another more recent study concluded that 74% of pa-
tients had a complicated infection (deep infection foci, including septic thrombophlebitis) at
the time of hospitalization [121]. The higher frequency of deep, metastatic or secondary in-
fection foci among CA-SAB than among HA-SAB has been well-documented [2,19,28,29],
with overall deep focus prevalence of 31-43% for CA-SAB and 5-12% for HA-SAB [2,7,28].
Regarding various deep infection foci, the trend with higher prevalence among CA-SAB
than among HA-SAB, was consistent - except for foreign body infections. CA-SAB patients
compared with HA-SAB patients were observed to have significantly more osteomyelitis at
three days (36% vs. 24%) and at three months (41% vs. 28%), both exceeding figures in
previous reports with overall osteomyelitis occurrence of 13-16% in CA-SAB and 2-4% in
HA-SAB [7,19,28]. The frequency of septic arthritis in CA-SAB and HA-SAB patients at
three days was 13% vs. 9% and at three months 17% vs. 11%, respectively, whereas pre-
vious reports have localized septic arthritis in only 5% of CA-SAB and 0% of HA-SAB pa-
tients [28]. Many authors report septic arthritis and osteomyelitis together with an overall
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presence of 11-47% in CA-SAB and 0-17% in HA-SAB [2,85]. Occurrence of pneumonia
among CA-SAB and HA-SAB at three days was 31% and 25% and at three months 38%
and 39% in our patient population, which is more common than reports in earlier studies of
4-18% in CA-SAB and 1-16% in HA-SAB [7,12,19,28]. Endocarditis has been found in 7-
29% in CA-SAB and 0-5% in HA-SAB, with both native and artificial valve endocarditis be-
ing more common in CA-SAB [2,3,7,19,28]. We diagnosed endocarditis within three days in
15% and 11% and at three months in 20% and 15% of CA-SAB and HA-SAB patients, re-
spectively. In conclusion, Study I localized deep infection foci among 83% of patients alto-
gether, which is high considering that some studies report deep or secondary foci in only 5-
6% of HA-SAB and 29-31% of CA-SAB patients [7,19].
In Study I, the CA-SAB patients presented significantly higher mean CRP level on the day
of positive blood culture than HA-SAB patients. A probable explanation for this could be
longer bacteraemia duration, and thus, more time for metastatic spread (as seen in Table
5) and deep infection focus development in CA-SAB patients before arrival to hospital.
We observed that infection foci related to prior surgical interventions, or other invasive pro-
cedures were significantly less common among CA-SAB than among HA-SAB at both three
days and three months (data not shown here). Infections related to a foreign body were
more common in HA-SAB than in CA-SAB at three months for PVCs (peripheral venous
catheters) (2% vs. 14%, p <0.0001), for central venous catheters (0 vs. 19%, p <0.0001)
and for permanent foreign bodies (11% vs. 25%, p <0.0001). Various penetrating foreign
bodies are reported as common predisposing factors for HA-SAB, and catheter-related in-
fection has been reported behind 21-64% of HA-SAB cases [2,3,28,29] and 1-22% of CA-
SAB cases [2,12,19,28]. Surgical infections or infected wounds have been observed in 0-
2% of CA-SAB and 6-16% of HA-SAB patients [7,19,28]. In our study, surgical procedures
during three months preceding SAB were less common in CA-SAB (8%) than in HA-SAB
(44%). A previous study reported 11% of SAB patients have undergone surgery in the pre-
vious month, although a clear division between CA-SAB and HA-SAB was not provided
[136]. The prevalence of permanent foreign body infections was lower for CA-SAB (11%)
than for HA-SAB (25%), but both exceeded an earlier report of 0% for CA-SAB and 11% for
HA-SAB [2].
No difference was seen in the occurrence of cutaneous infection foci throughout the three-
month study period (69% vs. 62%). Skin infections as primary foci have been reported in
earlier studies among 13-40% of CA-SAB and 3-4% of HA-SAB. Hence, Study I presents a
higher prevalence of skin foci in HA- and CA-SAB patients than in previous reports
[7,19,28].
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Prospective studies have reported higher numbers of serious SAB cases [183], and fewer
patients (12-27%) have been classified as pirmary SAB or without infection focus
[19,137,183]. In contrast, retrospective studies have reported 3-61% of SAB patients to
present with primary SAB or without any infection focus [2,7,12,192]. Primary SAB is re-
ported among 20-61% of CA-SAB and 3-53% of HA-SAB cases [2,7,19,28,29]. All patients
in Study I were followed up by an IDS, which have been reported to result in more radio-
logical examinations, more echocardiography and more bone scans [3,18,56,257]. The pa-
tient population in Study I was examined by numerous radiological investigations, e.g.
echocardiography, whole-body computed tomography and leukocyte indium-111 scintigra-
phy. This is demonstrated by Study III, in which up to 45% of the patient population was the
same as in Study I. Thus, the prospective study design and IDS follow-up resulted in more
investigations performed and higher numbers of deep infection focus localization.
In Study I, no difference emerged between HA- and CA-SAB patients suffering from severe
sepsis (13% for both groups), septic shock (4% vs. 7%) or need for intensive care unit sur-
veillance (21% vs. 23%) within one week of S. aureus-positive blood culture. Likewise, no
difference was seen in severity of illnesses on the day of positive blood culture (data not
shown). However, the severity of illness reported here (severe sepsis and septic shock)
was far lower than in previous studies of septic shock (11-24% of CA-SAB and 7-26% of
HA-SAB) [2,19,28] or ICU stay (29% of CA-SAB and 18% of HA-SAB) [2].
Meticulous deep infection search has been shown to result in optimized treatment and im-
proved survival due to deep infection foci often needing eradication and longer antibiotic
treatment [19,22,167]. Our study revealed that most infection foci were present already
early during the first week of SAB and that a thorough search for deep infection foci is war-
ranted in most SAB patients.
The overall mortality of SAB in recent studies has varied between 14% and 32% for both
in-hospital and SAB-related mortality [2,3,12,13,14,15,16,17,18]. The overall mortality in
Study I, 13% at 28 days and 18% at three months, lies within the lower range of previous
findings. The mortality at three months was high for HA-SAB patients, which is in accor-
dance with several previous studies conducted in the 1970s - 1990s [51,427,446].
Due to the prospective nature of Study I, the possibility exists that critically ill patients may
have been missed. Possible reasons for this may be difficult recruitment processes among
very ill patients and severely ill patients with an expected rapid disease progression and fa-
tal outcome may be rejected. Originally, 1226 SAB episodes were identified during the
study period [15], and 430 patients were finally included.
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Studies from the 1970s - 1990s have connected HA-SAB to higher mortality and explained
this link by higher age and more comorbidities in HA-SAB patients than in CA-SAB patients
[51,427,446], whereas more recent reports in the 2000s have failed to detect any signifi-
cant mortality difference between HA- and CA-SAB [12,17,19,23,183,188,190,447]. How-
ever, one study connected HA-SAB to significantly lower mortality [2] and two studies to
higher mortality relative to CA-SAB [442,448]. Higher mortality in CA-SAB has been ex-
plained by earlier detection of bloodstream infections among HA-SAB cases [2]
The higher 28-day mortality rate of HA-SAB than CA-SAB in our patient material was
probably due to severe underlying conditions and higher age among HA-SAB cases. These
factors have outweigted the negative prognostic impact of later hospital admission and
higher deep focus occurrence among CA-SAB patients. Further support for this interpreta-
tion is the similarity in occurrence of unstable haemodynamic status and ICU surveillance
between CA-SAB and HA-SAB; thus, severity of illness has not influenced the mortality
trend. This observation of Study I is in contradiction with many previous studies associating
CA-SAB with more severe illness at S. aureus-positive blood culture with higher occurrence
of septic shock [2,28], ARDS [2,28], DIC [2,28], ICU need [2], mechanical ventilation [2]
and renal failure [2,28].
6.2. Cell-free DNA as a biomarker in Staphylococcus aureus bacteraemia
Cell-free DNA (cf-DNA) is formed from DNA fragments released into the circulation from
apoptotic cells [415].  Cf-DNA has been observed to serve as a biomarker for fatal outcome
in septic and critically ill patients [402,409,410,411,412,413,414,422]. However, only two
reports have evaluated the predictive value of cf-DNA in bacteraemic patients [412,414],
and no studies with S. aureus as the only causative bacteraemia pathogen have been per-
formed. High cf-DNA values in ICU-treated patients were reported in a previous study that
included solely bacteraemic patients with various causative pathogens (S. aureus, Strepto-
coccus pneumoniae, ß-haemolytic streptococcae or Escherichia coli). However, in this
study, separate prognostic cf-DNA cut-off values were not evaluated for individual patho-
gens and no specific comparison of predictive values of cf-DNA between ICU and non-ICU
patients on outcome was performed [412].
We investigated the prognostic value of cf-DNA among SAB patients treated in the general
ward and in ICU (Study II).  Plasma cf-DNA levels were found to be significantly higher at
both day 3 and day 5 among ICU patients than among non-ICU patients, and the high cf-
DNA levels predicted fatal outcome, especially in ICU patients, during the first week, 28
days or three months, i.e. irrespective of death time. When accounting for all prognostic
markers, Pitt bacteraemia scores ?4 points, the day 3 cf-DNA cut-off value and McCabe’s
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healthy or non-fatal classification were observed to have the strongest association with fa-
tal outcome among ICU patients. However, day 5 plasma cf-DNA was not a significant
prognostic marker and was more dependent on patients age and underlying diseases.
In Study II, in 99 ICU patients cf-DNA predicted fatal outcome with a sensitivity of 67% and
a specificity of 77% and AUC of 0.71 in ROC analysis at day 3 from positive blood culture.
These results are comparable with those seen in studies with other types of patient co-
horts, but are clearly lower than the highest reported ones [402,409,411,412,413,422]. In
previous studies, cf-DNA as a predictor of mortality has been determined within 0 - 72
hours of ICU admission and the sensitivity and specificity have ranged from 60% to 92%
and 67% to 93%, with ROC analysis AUC values of 0.70 - 0.97 [409,411,414,422]. It
seems that larger studies may reveal a lower specificity and sensitivity since cf-DNA de-
termined at admission and at 48 hours in 580 mechanically ventilated critically ill patients
had a predictive value for fatal outcome with sensitivity of 53% and specificity of 69% and a
ROC analysis AUC of 0.62 [413]. Furthermore, in a recent study, cf-DNA predicted the
presence of infection among febrile patients with AUC of 0.99 and 95% sensitivity and 96%
specificity and among sepsis patients with AUC of 0.95 and 77% sensitivity and 94% speci-
ficity [402].
The lower sensitivity and specificity observed in Study II relative to earlier studies maybe
explained by several factors. Most previous cf-DNA studies have determined cf-DNA at
ICU admission or subsequent to ICU admission, whereas in Study II cf-DNA was measured
in relation to positive blood culture [409,411,413,414,422]. As Study II correlated cf-DNA
measurement with a specific time-point of disease progression, and not with clinical dete-
rioration (i.e. ICU admission), the patients who deteriorated later certainly presented with
lower cf-DNA levels. In Study II, only 4% of ICU patients presented with severe sepsis,
whereas in previous studies much higher percentages of severe sepsis have been re-
ported, with one study reporting 100% of patients suffering from severe sepsis with high
APACHE points and high sensitivity and specificity for the prognostic value of cf-DNA [414].
Thus, it is evident that some of the most severely ill SAB patients have been missed, which
is substantiated by a 28-day mortality of 12%, a much lower figure than in previous SAB
studies and clearly lower than the mortality of 25-34% in ICU studies only [51,137,184,
409,422]. Furthermore, 24% of the SAB patients in Study II required ICU surveillance within
one week and 8% of these ICU patients did not survive. Although these factors clearly re-
duced the prognostic value of cf-DNA in our study, the cut-off value of day 3 cf-DNA to-
gether with Pitt bacteraemia scores ?4 points were the strongest factors predicting fatal
outcome among ICU patients when all prognostic markers were accounted for. The results
of Study II suggest that early apoptosis in SAB patients requiring ICU surveillance might
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contribute to fatal outcome, as ICU non-survivors had significantly higher cf-DNA levels at
day 3, although non-significant differences were observed at day 5.
More studies on the use of cf-DNA as a biomarker in serious infections and in septic pa-
tients are needed before it can be used in everyday clinical practice. Different cf-DNA
measurement scales applied in various reports complicates the clinical usefulness of cf-
DNA, with some authors using cf-DNA qPCR quantification with results presented as ge-
nome equivalents per millilitre (GE/mL) [402,411,413,422] and others measuring cf-DNA
straight from plasma in micro- or nanograms per millilitre (?g/mL or ng/mL) [409,412].
6.3. Bedside and telephone infectious diseases specialist consultation in
Staphylococcus aureus bacteraemia
Several studies with varying study settings and study populations have demonstrated a
positive impact of IDSC on SAB management and prognosis [2,3,12,16,18,56,57,58,
184,257,353]. IDSC and especially informal IDSC have become more common as a result
of the ever-deepening specialization in clinical medicine [340,345,346,347], and IDSs are
among the specialities most frequently consulted [344]. The value of informal consultations
in SAB was investigated in one study with a power of only six informal consultations out of
all 233 studied IDSC. This study came to the conclusion that informal consultations were
not associated with more SAB relapses or lower survival rate [353]. Furthermore, a pro-
spective post hoc study of 627 patients with various infections observed no significant dif-
ference between formal and informal IDSC regarding compliance with recommendations
for treatment, performing of diagnostic or monitoring tests, early clinical improvement, in-
hospital mortality or length of hospital stay. However, only 3% of the patients had received
ICU treatment and only 7% were defined as bacteraemic or septic. No causative pathogens
were reported for the bacteraemic or septic patients [343].
In Study III, the impact of formal bedside IDSC, informal telephone IDSC and no IDSC on
disease progression and prognosis of MSSA bacteremia was investigated. The main result
was a significantly poorer prognosis of SAB patients treated with informal telephone IDSC
as compared with formal bedside IDSC. Informal telephone IDSC was associated with an
over twofold higher mortality than formal bedside IDSC when all prognostic factors were
adjusted for. Altogether, informal telephone IDSC, as compared with formal bedside IDSC,
was associated with less frequently performed radiological investigations, fewer deep infec-
tion focus localized, fewer patients with proper duration of antibiotic therapy, prolonged du-
ration of fever and shorter hospitalization time. Moreover, the poorer outcome among in-
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formal telephone IDSC patients was not explainable by differences in underlying conditions
or severity of illness as compared with patients provided with formal bedside IDSC.
Delayed onset of appropriate antibiotic therapy impairs prognosis in both MSSA and MRSA
bacteraemia [40,50,188,437]. MRSA bacteraemia has been connected to poorer prognosis
and delayed onset of correct antibiotic therapy [49,51,52,58]. Vancomycin, the first-line
drug for MRSA infections, has been associated with higher occurrence of persistent and
recurrent SAB than the staphylococcal penicillin cloxacillin [53]. However, invasive and
bacteraemic MRSA infections are rare in Finland, with a recent prevalence below 3% [54],
and no MRSA cases were included in Study III. Moreover, effective empiric antibiotic ther-
apy was provided to each patient on the day of first positive blood culture, and only 3% of
SAB patients were treated with vancomycin. Hence, the study setting enabled analyses of
impact of various IDSC types on disease progression and prognosis without any bias or
disturbance from MRSA or differences in antibiotic selection prior to the IDSC.
The nature of Study II was retrospective, which has been linked to risk for various biases,
such as failing to detect serious S. aureus cases, as compared with prospective studies
[183]. In Study III, no significant difference was observed in underlying diseases (McCabe’s
classification) or severe sepsis at S. aureus-positive blood culture in patients receiving for-
mal bedside IDCS and informal telephone IDSC. Thus, underlying diseases and severity of
illness at S. aureus-positive blood culture have most probably not influenced the results be-
tween formal bedside and informal telephone IDSC.
Factors associated with poor prognosis that were identified in Study III have been reported
previously: need for ICU surveillance [3,18], corticosteroid therapy (>10 mg/day for > 1
month) [58] and pneumonia [7,12,51]. Informal telephone IDSC was linked more often to
ICU treatment within the first three days, but not within the first week, than formal bedside
IDSC. This might have contributed to a higher mortality rate in the informal telephone IDSC
group. ICU treatment within the first three days was significantly more common among pa-
tients presenting with other factors associated with poor prognosis, such as severe sepsis
at S. aureus-positive blood culture (OR 10.2, p <0.001) and acute congestive heart failure
(OR 5.94, p <0.001), than among patients managed outside the ICU. When the patients
with ICU treatment were analysed separately, informal telephone IDSC remained one of
the strongest prognostic factors for poor outcome (OR 4.87, p=0.001).
IDSC has been observed to result in more diagnosed endocarditis and deep infection focus
[3,56,57,184,257] and improved selection and duration of antibiotic therapy. Furthermore,
IDSC has resulted in more appropriate timing of MRSA therapy and in use of ?-lactam an-
tibiotics whenever possible [3,18,56,57,58,257,353], longer mean duration of therapy [16,
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257] and longer hospital treatment than non-IDSC cases [57]. Interestingly, these differ-
ences were observed also between formal bedside and informal telephone IDSC in our
study. Formal bedside IDSC resulted more often in proper duration of antibiotic therapy and
longer hospitalization duration than informal telephone IDSC. However, in multinomial lo-
gistic regression analysis, when the various prognostic factors were adjusted for, no differ-
ences were seen between formal bedside and informal telephone IDSC with regard to
proper duration of antibiotic treatment or duration of hospitalization. The presence of deep
infection foci was linked to proper length of antibiotic therapy. Less radiological examina-
tions were made based on informal telephone IDSC, which resulted in fewer deep infection
foci localized. Therefore, one key factor behind better outcome among formal bedside
IDSC than among informal telephone IDSC seemed to be the more thorough search for
deep infection foci.
Previous reports have concluded that IDSC results in more radiological investigations, in-
cluding both echocardiography and bone scans [3,18,56,257]. Study III presented, surpris-
ingly, leukocyte indium-111 scintigraphy as an independent positive prognostic factor,
which has not been reported previously. Leukocyte indium-111 scintigraphy is uncommon
in the clinical management of bacteraemic infections, but it was provided significantly more
often to formal bedside IDSC patients than to the other two SAB patient groups. Despite
the independent nature in statistical analysis, the independent prognostic nature of leuko-
cyte indium-111 scintigraphy must be considered carefully and further validation and inves-
tigation of its prognostic nature are needed.
The number of potentially missed informal telephone IDSC cases was low as only 10% of
all SAB patients had no mention of any IDSC in their patient records and all S. aureus
blood culture isolates could be linked to patient identification, verifying that no SAB patients
were missed. Furthermore, patient records were unavailable for only seven patients. During
office hours the same IDS consultant performed informal telephone and formal bedside
IDSC. However, outside office hours and on weekends, the IDS or resident on call received
the informal telephone consultation calls. The specific time-point of the consultations could
not be retrieved from the patient records and might potentially explain the high number of
informal telephone IDSCs among ICU patients, and to some extent also provide a reason
for the improved outcome of formal bedside IDSC relative to informal telephone IDSC. The
risk of insufficient information being provided or important information being missed in in-
formal consultations [344] or inaccurate or incomplete information being presented in in-
formal consultations resulting in inappropriate management advice [350] has been reported
previously. Hence, it is advisable that informal telephone IDSC in SAB should be comple-
mented by formal bedside IDSC as soon as possible.
89
Study III demonstrated that formal bedside IDSC, compared with informal telephone IDSC,
associated with improved outcome. This trend was observed also in Study IV, as telephone
IDSC patients had higher risk for fatal outcome in univariate analysis, but not in Cox re-
gression analysis. However, Study IV analysed a much larger patient number than Study III
(617 vs. 342), and patients with a fatal outcome within 14 days were excluded to allow for a
fatal outcome before completing at least 14 days of rifampicin therapy. When Cox regres-
sion analysis was performed excluding only patients with a fatal outcome within 3 days as
in Study III, the negative prognostic value of telephone consultation became significant (OR
1.72, p<0.05) (data not shown).
Hospital-related temporary differences in treatment or personnel practices are factors diffi-
cult to control for in retrospective studies, and thus, to exclude the effect of unidentified dif-
ferences, two different time periods for data collection were included in Study III. Moreover,
two study periods were regarded as mandatory, as most patients from the first study period
had participated in our previous prospective study [15]. When the two study periods were
analysed separately, no significant difference in the results was observed. The electronic
patient records available in the later study period enabled retrieval of patient records and
laboratory results during the ongoing informal telephone IDSC. However, the degree to
which electronic patient records were retrieved during consultations could not be assessed
and further investigations on possible benefits of electronic patient records during the con-
sultation process are necessary.
The results of Study III differ from those of an earlier study [353] and are completely oppo-
site to those demonstrated by another study [343], in which no significant difference was
observed between formal and informal IDSC. However, only 7% of the patients were bacte-
raemic or septic and only 3% required ICU in the latter report. Hence, it is reasonable to
assume that a positive prognostic impact of formal IDSC, as compared with informal IDSC,
is not observed until the patient population reaches a considerable size and a certain de-
gree of severity of illness.
6.4. Rifampicin in Staphylococcus aureus bacteraemia with deep infection
foci
Few clinical studies have evaluated the impact of rifampicin combination therapy on dis-
ease progression and prognosis in SAB and S. aureus-related deep infection foci. In gen-
eral, studies with low MRSA bacteraemia occurrence have reported some degree of im-
proved clinical outcome due to rifampicin combination therapy [15,66,75,76,77,78,
79,80,176]. Studies with high MRSA occurrence, however, have reported such adverse ef-
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fects as prolonged bacteraemia, rifampicin resistance development and negative prognos-
tic impact to be associated with rifampicin combination therapy [82,83,84,329]. Rifampicin
resistance development in S. aureus infections has been well-characterized [67,68] and
has especially been described in studies with high (76-100%) MRSA prevalence, where ri-
fampicin resistance has developed in 5-56% of cases [82,83,84,329,465]. Most authors
conclude that initiation of rifampicin therapy during the MRSA bacteraemic phase [82,329]
and especially with suboptimal vancomycin effect creates a setting resembling rifampicin
monotherapy against MRSA [83,465].
The Infectious Diseases Society of America guidelines regarding management of MRSA in-
fections recommend rifampicin and vancomycin combination therapy with level A-II evi-
dence for device-related osteoarticular infections, level B-III evidence for prosthetic valve
infective endocarditis, osteomyelitis, meningitis and abscesses and level C-III evidence for
recurrent skin and soft tissue infections [36]. Recently, rifampicin-vancomycin combination
therapy was associated with higher cure rates than vancomycin alone for HA MRSA pneu-
monia [330].
However, no studies have evaluated the optimal onset time-point for rifampicin therapy in
MRSA bacteraemia. Some studies recommend rifampicin initiation after clearance of bacte-
raemia based on observations that rifampicin onset during ongoing MRSA bacteraemia re-
sults in significantly prolonged bacteraemia and significantly poorer outcome [82]. No re-
ports are available regarding the optimal rifampicin therapy onset time-point for MSSA bac-
teremia.
Study IV included only MSSA bacteraemia cases, and 99% of patients had appropriate
empirical antibiotic therapy initiated at blood culture collection. Vancomycin therapy was
received by only 2% of patients. MRSA has been associated with delayed effective antim-
icrobial therapy, which in turn has been identified as a major risk factor for poor prognosis
[49,50,51,52]. In Study IV, the impact of rifampicin adjunctive therapy on disease progres-
sion and prognosis could be evaluated without disturbance from delayed empirical antibi-
otic therapy.
Study IV investigated the optimal time-point for onset of adjunctive rifampicin therapy and
the minimal rifampicin therapy duration needed for a positive impact on prognosis in 475
patients. Originally, the patient cohort included 617 patients, however, after taking into ac-
count exclusion criteria, 475 patients were included in the study. The primary finding of this
study was the positive prognostic impact of rifampicin adjunctive therapy on SAB patients
with a deep infection focus. The positive impact was seen when rifampicin was initiated
within one week of S. aureus-positive blood culture and continued for at least 14 days. As a
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result of early adjunctive rifampicin therapy for at least 14 days, the risk of fatal outcome
decreased (OR 0.38) in the whole patient population and this positive prognostic impact
was further accentuated in patients with a deep infection focus (OR 0.29). Study IV is the
first to demonstrate a positive prognostic impact of early initiation of rifampicin adjunctive
therapy on MSSA bacteraemia.
Adjunctive rifampicin therapy has had a positive impact on disease progression and prog-
nosis in SAB patients with a deep infection focus and a low (0-13%) MRSA prevalence
[15,66,75,76,77,78,79,80,176,308]. In two prospective studies, a mainly orally given com-
bination of a fluoroquinolone, ciprofloxacin, together with rifampicin has been compared
with intravenous conventional antistaphylococcal therapy (oxacillin, flucloxacillin or vanco-
mycin) [79,80]. In these studies, a tendency for less clinical failures in endocarditis (5% vs.
12%, non-significant) [80] and a higher cure rate in foreign body infection (100% vs. 58%,
p<0.05) [79] were observed with the combination therapy. However, the cure rate was not
significantly different in a prospective randomized trial with a fleroxacin-rifampicin combina-
tion compared with conventional intravenous monotherapy in patients with mostly MSSA
bacteraemia and a high number of deep infection foci [308]. Recently, a retrospective re-
port that included patients with total hip or knee prosthetic infections and 17% MRSA asso-
ciated rifampicin-fluoroquinolone therapy with improved outcome relative to other antim-
icrobial regimens, with no outcome difference between MSSA and MRSA infections [176].
No prospective studies with rifampicin as an adjunctive therapy to standard ?-lactam-based
intravenous therapy in MSSA bacteraemia have been done. We observed in a post hoc
analysis of our previous prospective study in MSSA bacteraemia that patients with a deep
infection focus who also received rifampicin had lower three-month mortality than patients
treated without rifampicin. However, no randomization for rifampicin was performed and the
rifampicin therapy onset time-point was not analysed [15].
Most commonly, the combination of vancomycin and rifampicin has been investigated.
Many studies involving a high MRSA prevalence (76-100%) have reported poorer clinical
outcome due to rifampicin combination therapy in endocarditis, various deep infection foci
or persistent bacteraemia [81,82,83,84,329]. A retrospective randomized cohort study of 42
native valve endocarditis patients compared rifampicin-vancomycin with vancomycin only;
the combination treatment group demonstrated prolonged bacteraemia [81]. Resistance
development to rifampicin is a common finding, occurring in 56% of cases in a retrospec-
tive study in 2008 that investigated the benefit of rifampicin adjunctive therapy in native
valve infective endocarditis with high (76%) MRSA prevalence and showed prolonged bac-
teraemia with rifampicin treatment [82]. Another retrospective report followed rifampicin-
vancomycin therapy in MRSA and hVISA bacteraemia patients and demonstrated pro-
longed bacteraemia and higher rifampicin resistance development (5% vs. 44%) for hVISA
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cases [83]. A recent study investigated prolonged MRSA bacteraemia in elderly (> 65
years) patients and demonstrated rifampicin resistance in 36% of cases due to glycopep-
tide-rifampicin combination therapy and patients with rifampicin resistance presented
higher, although not significant, MRSA-related and 30-day mortality [329]. Thus, it is rea-
sonable to assume that resistance development to rifampicin may de due to prolonged bac-
teraemia during vancomycin therapy rather than to the methicillin resistance of the staphy-
lococcal strain [53]. No prospective studies evaluating the optimal onset of rifampicin ther-
apy in SAB are available in the literature. Some reports recommend onset of rifampicin ad-
junctive therapy after clearance of bacteraemia [36,82]. These recommendations, however,
are based on reports including high MRSA occurrence. No guidelines exist regarding ad-
junctive rifampicin therapy in MSSA bacteraemia.
In Study IV, the median time from blood culture to clinical report of S. aureus as the
causative bacteraemic pathogen was three days. Hence, rifampicin adjunctive therapy was
initiated at the earliest at three days subsequent to onset of appropriate empirical antibiotic
therapy, i.e. mostly a ?-lactam antibiotic. As Study IV did not observe a single case of
rifampicin resistance during follow-up, it is reasonable to assume that the three days of
appropriate ?-lactam antibiotic therapy prior to rifampicin onset prevented resistance
development among the MSSA bacteraemia patients. Moreover, only 1% of patients
experienced a SAB relapse during the three-month follow-up, which is far lower than
reported in previous studies of 2-16% of SAB patients suffering from SAB recurrence,
reinfection or relapse [3,19,22,41,121,123]. The low SAB relapse percentage supports the
observation of successful antimicrobial therapy for each SAB patient and the lack of any
rifampicin resistance development. However, repeated blood culture during antimicrobial
therapy is not a routine procedure in Finland, and thus, some cases of prolonged
bacteraemia or even rifampicin resistance might have been missed.
Study IV clearly indicates that rifampicin adjunctive therapy should be initiated within the
first week of positive blood culture. A subanalysis (Study IV; Table 3) included 26 SAB
patients with various deep infection foci with adjunctive rifampicin therapy initiated 7 days
after S. aureus-positive blood culture and with rifampicin therapy duration for at least 14
days. Interestingly, no positive impact on prognosis was observed among these patients as
a result of rifampicin adjunctive therapy. Rifampicin adjunctive therapy is recommended to
be continued for several weeks [36]. Study IV did not investigate the optimal duration of
rifampicin treatment, however, patients with < 14 days of rifampicin therapy received
rifampicin with a mean treatment period of 7.68 ± 3.8 days (mean ±SD). This short
rifampicin treatment was not associated with improved prognosis.
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Patients with a history of alcoholism or patients suffering from acute or chronic liver
diseases were excluded in Study IV. These exclusion criteria reduced the patient number
by 128 cases. Alcoholism and acute or chronic liver failure were viewed as
contraindications for rifampicin therapy as the risk for liver failure, as a complication of
rifampicin therapy, is accentuated in patients with these conditions. Patients with
alcoholism and liver diseases unavoidably contributes to a statistical bias due to the fact
that patients with these conditions are unlike to be treated with rifampicin.
When comparing age, gender, underlying conditions, severity of illness at blood culture
time point and antibiotic therapy, no difference was seen between patients with rifampicin ?
14 days and patients with rifampicin < 14 days with the exception of male sex associating
to longer rifampicin therapy. Similar patterns were seen when comparing the patient groups
receiving shorter duration of rifampicin therapy. Thus, rifampicin therapy duration could be
compared without disturbance from confounding differences in age, underlying diseases,
severity of illness or standard antibiotic therapy. These are parameters difficult to control for
in statistical analyses.
It is well documented that rifampicin is a potent CYP3A4 liver enzyme inducer (including
other hepatic CYP- liver enzymes such as CYP2C8, CYP2C9 and 2C19 as well). Thus, the
metabolism of drugs administered simultaneously may be enhanced. Furthermore,
rifampicin carries the risk of hepatitis and this risk is increased by alcoholism [61,62].
Underlying conditions (as well as rapidly fatal McCabe´s classification), did not differ
between patients receiving shorter and longer rifampicin therapy, and thus, it may be
assumed that background medication of the different patient groups were approximately
the same. Hence, the risk and possibility for pharmacological interactions with rifampicin as
a potential contraindication for rifampicin therapy was not accentuated in any patient group.
Several factors associated with poor prognosis in Study IV have been reported earlier, e.g.
McCabe’s healthy or non-fatal diseases [3,7], high age [7,12,19] and pneumonia [7,12].
Rifampicin adjunctive therapy for at least 14 days with early onset within one week of
bacteraemia remained a favourable prognostic factor with lower likelihood for fatal outcome
(OR 0.38, 95% CI 0.23-0.64) (p<0.01) when controlling for all of these factors. Furthermore,
when only patients with a diagnosed deep infection focus were included, the positive
prognostic value was intensified (OR 0.29, 95% CI 0.17-0.52) (p<0.01).
The overall mortality in Study IV was 13% at 30 days and 17% at three months, which is at
the lower end compared to the mortality of 14-32% reported in several recent studies from
the 2000s and 2010s [2,3,12,13,14,16,17,18]. The power to detect a positive prognostic
effect of rifampicin has most probably been reduced by the low overall mortality rate.
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6.5. Limitations due to designs in Studies III and IV
Several notable limitations in the designs of Study III and IV warrant discussion.
Study III
Study III lacked documentation of the precise timing and content of the telephone IDSC
provided. The study design could not determine the extent to which the informal IDSC was
telephone-based or an informal sidewalk discussion between the treating physician and the
IDS. However, outside office hours and during the weekend, the on-call IDS is physically
located at the Division for Infectious Diseases at Aurora Hospital, which is located
separately from Helsinki University Central Hospital in Meilahti - this setting enables only
telephone consultations outside office hours, and thus, it is reasonable to assume that the
vast majority of informal IDSCs were in fact telephone-based. We could not document I)
whether the advice given by the IDS via the telephone conversation was correct, II)
whether the treating physician requesting advice understood the advice received and III)
whether the advice received was properly documented by the treating physician. Hence,
misconceptions taking place during the telephone conversation were not documented.
Moreover, Study III did not document the type of physician requesting an informal IDSC,
and thus, we do not know the proportions of internists, neurologists, surgeons and
intensivists requesting informal IDSC. This information would have been valuable as it
might have enlightened the fact that ICU patients, during the initial 3 days, received more
telephone IDSCs.
In Study III, rigorous adjustments were made for confounding factors, however, the
adjustments may have been insufficient. High age [12,22,23,156,168,431,432,433,434,
435], ultimately or rapidly fatal underlying diseases [3,22,188] and severe sepsis at S.
aureus-positive blood culture [25,183,445] were associated independently with higher
mortality. When comparing background patient characteristics and severity of illness at S.
aureus-positive blood culture in patients who received bedside and telephone IDSC, the
differences regarding age, McCabe’s classification and severe sepsis were statistically
non-significant. However, the telephone IDSC patients were somewhat older (54.8 ± 16.5
vs. 53.2 ± 17.7 years, mean ±SD), had somewhat more ultimately or rapidly fatal underlying
diseases (42% vs. 29%) and slightly more severe sepsis at S. aureus-positive blood culture
(10% vs. 7%).
Moreover, telephone IDSC patients, as compared with bedside IDSC patients, received
significantly more ICU treatment (34% vs. 21%) during the initial 3 days. Previous reports
have independently associated need for ICU treatment [3,25,188,436] and ICU admission
[3,443] with weaker outcome relative to non-ICU patients. However, when analysing
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separately patients treated in the ICU by survival rate, telephone IDSC was one of the most
important prognostic markers for fatal outcome, with an OR of 4.87 (p=001).
Study III was retrospective. Retrospective design, compared with prospective design, may
fail to detect serious S. aureus cases [183]. A prospective study could have been designed
to document the time, content and type of treating physician requesting a consultation, and
thus, many of the limitations discussed above would have been avoided.
The limitations of Study III, especially the lack of documentation of exact timing, content
and possible misconceptions about informal IDSC, make it difficult to understand the
precise reason for the poorer outcome of informal telephone IDSC patients. However,
these limitations do not invalidate the major finding of Study III, the significantly better
prognosis of bedside IDSC, relative to telephone IDSC, in the management of SAB. This
conclusion was reached also by Chu and Sexton in the editorial commentary connected to
Study III [466].
Study IV
The major limitation of Study IV was its retrospective design. Randomized controlled trials
are viewed as the gold standard for clinical trials and medical interventions. Hence, the
patient cohort in Study IV could not be randomized and controlled with respect to
rifampicin.
Study IV applied dichotomization of rifampicin therapy duration, according to rifampicin
therapy ? 14 days or < 14 days, which may appear artificial and arbitrary. However,
approximately on third of the patients received no rifampicin therapy and more than half of
patients received rifampicin ? 14 days. Few received rifampicin for only a few days.
Categorization of rifampicin therapy, according to duration ? 14 days or < 14 days, in the
present study was performed enable statistical analyses. A valid continuous statistical
analysis estimating specific cut-off values (in days) after which rifampicin therapy would
impact the prognosis positively was not possible with the present patient cohort. The
present study, however, shows a positive prognostic impact in Cox regression for patients
with early onset of rifampicin therapy for at least 14 days. This observation was not seen
among patients receiving shorter durations of rifampicin therapy.
Study IV excluded cases with a fatal outcome within three days. This was made to allow for
death prior to positive blood culture results and the possibility for rifampicin therapy. One
may argue that patients with early death (e.g. within 14 days) were sicker and thus more
likely to be treated without rifampicin. Thus, a parallel analysis was performed by excluding
patients with a fatal outcome within 14 days - with results very similar to those reported
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above. When excluding patients with a fatal outcome within 14 days, early onset of
rifampicin therapy for at least 14 days was associated to a positive prognostic impact in
Cox regression when taking into account only patients with a deep infection foci (OR 0.54,
p <0.01).
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7. CONCLUSIONS
Results of Studies I - IV summarized as follows:
Study I
The community-associated (CA) SAB patients, compared with the health care-associated
(HA) SAB patients, were younger and more often classified as healthy or non-fatal due to
underlying conditions (88% vs. 59%, p <0.0001). Regarding underlying conditions, only al-
coholism, IDU and chronic liver disease were significantly more common among CA-SAB
than among HA-SAB. Deep infection foci were more common than reported in previous
studies, and they were diagnosed more frequently in CA-SAB than in HA-SAB both within
three days (84% vs. 69%, p <0.0001) and at three months (87% vs. 80%, p <0.05). At 28
days, no difference was present in mortality between CA- and HA-SAB (11% vs. 14%), but
at three months the mortality among HA-SAB patients was significant higher (13% vs. 22%,
p <0.05). Factors independently predicting outcome were higher age, alcoholism, immuno-
suppressive treatment, ultimate or rapidly fatal underlying diseases, severe sepsis at S.
aureus-positive blood culture, S. aureus pneumonia and endocarditis. The prospective
study design and infectious disease specialist (IDS) surveillance of each patient and the in-
tensive deep infection focus search resulted in a high percentage of SAB patients having
deep infection focus diagnosed already within three days of S. aureus-positive blood cul-
ture and overall low mortality rates.
Study II
SAB patients with high Pitt bacteraemia scores and need for ICU surveillance had signifi-
cantly higher plasma cf-DNA levels at both day 3 and day 5 after positive blood culture as
compared with non-ICU SAB patients. Moreover, significantly higher cf-DNA values among
ICU non-survivors than among ICU survivors were observed at days 3 and 5. When all
prognostic factors were controlled for, Pitt bacteraemia scores ? 4 and day 3 cf-DNA were
the strongest mortality predictors among ICU patients, whereas day 5 cf-DNA was not a
significant prognostic marker and it depended more on patients age and underlying dis-
eases.
Study  III
Formal bedside IDSC significantly improved patient outcome in SAB as compared with in-
formal (telephone) IDSC. Patients treated according to formal bedside IDSC more often
had proper length of antibiotic treatment, more often radiological investigations performed,
more frequently localized deep infection focus (78% vs. 53%) and shorter duration of fever.
Formal bedside IDSC was associated with significantly lower mortality at seven days (1%
vs. 8%), 28 days (5% vs. 16%) and three months (9% vs. 29%). When all prognostic mark-
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ers were noted, patients receiving informal telephone IDSC had over twofold higher odd ra-
tio of fatal outcome relative to formal bedside IDSC. Our results indicate that informal tele-
phone IDSC was inferior to formal bedside IDSC and that it might be reasonable to com-
plement and complete informal telephone IDSC either with thorough patient record retrieval
or formal bedside consultation.
Study IV
Adjunctive rifampicin therapy initiated within seven days of S. aureus-positive blood culture
and continued for at least 14 days had a significant positive prognostic impact on SAB pa-
tients and this positive impact was further accentuated when taking into account only pa-
tients with a deep infection focus. As a result of early rifampicin adjunctive therapy for at
least 14 days, the risk of a fatal outcome was more than halved in the whole patient popu-
lation. When continued for less than 14 days or, initiated seven days past S. aureus-
positive blood culture, adjunctive rifampicin therapy demonstrated no positive impact on
prognosis.
The results of Study IV encourage a recommendation of rifampicin adjunctive therapy al-
ready during the first week in bacteraemia due to MSSA and with a suspicion of a deep in-
fection focus. However, these recommendations apply solely to MSSA bacteraemia and
are not applicable to MRSA bacteraemia and MRSA infections.
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